Agile Therapeutics (AGXRW) 10-K 22 Mar 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 14, 2023	Jun. 30, 2022
Document and Entity Information
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-36464
Entity Registrant Name	AGILE THERAPEUTICS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-2936302
Entity Address, Address Line One	500 College Road East, Suite 310
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	609
Local Phone Number	683-1880
Title of 12(b) Security	Common stock
Trading Symbol	AGRX
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 14.4
Entity Common Stock, Shares Outstanding		46,538,250
Entity Central Index Key	0001261249
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Iselin, New Jersey

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 5,246	$ 6,145	$ 13,027	$ 3,743	$ 19,143
Accounts receivable, net	3,377	3,711	2,087	1,665	1,533
Inventory, net	1,332	1,797	2,340	2,693	966
Prepaid expenses and other current assets	1,403	3,834	1,016	1,576	2,283
Total current assets	11,358	15,487	18,470	14,352	23,925
Property and equipment, net	177	203	11,524	12,047	12,447
Right of use asset	695	761	825	888	949
Other non-current assets	2,012	2,012	2,012	2,012	2,012
Total assets	14,242	18,463	32,831	29,299	39,333
Current liabilities:
Long-term debt, current portion	1,426	1,318	12,630	12,252	16,833
Accounts payable	7,734	4,906	12,036	9,537	8,707
Accrued expenses	3,908	5,152	3,877	3,828	3,563
Lease liability, current portion	319	277	239	231	175
Total current liabilities	13,387	11,653	28,782	25,848	29,278
Lease liabilities, long-term	466	550	630	708	784
Warrant liability	5,934	9,285	1,050	8,101	5,356
Total liabilities	19,787	21,488	30,462	34,657	35,418
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021
Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued and outstanding at December 31, 2022 and December 31, 2021, respectively	4	4	1
Additional paid-in capital	403,153	401,744	401,211	388,317	387,205
Accumulated deficit	(408,702)	(404,773)	(398,843)	(393,675)	(383,290)
Total stockholders' equity	(5,545)	(3,025)	2,369	(5,358)	3,915	$ 49,328	$ 45,745
Total liabilities and stockholders' equity	$ 14,242	$ 18,463	$ 32,831	$ 29,299	$ 39,333

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Jan. 07, 2022	Jan. 06, 2022	Dec. 31, 2021	Jan. 06, 2020
Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Preferred stock, authorized (in shares)	10,000,000			10,000,000
Preferred stock, issued (in shares)	4,850			0
Preferred stock, outstanding (in shares)	0			0
Common stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Common stock, authorized (in shares)	300,000,000	300,000,000	150,000,000	300,000,000	300,000,000
Common stock, issued (in shares)	42,970,134			3,034,901
Common stock, outstanding (in shares)	42,970,134			3,034,901

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statements of Operations and Comprehensive Loss
Revenues, net	$ 3,002	$ 2,126	$ 1,761	$ 3,887	$ 6,888	$ 10,884	$ 4,101	$ 749
Cost of product revenues	1,425	2,231	1,527	3,758	5,183	6,836	10,718	282
Gross profit (loss)	1,577	(105)	234	129	1,705	4,048	(6,617)	467
Operating expenses:
Research and development	788	856	1,257	2,113	2,901	3,253	6,246	13,500
Selling and marketing	5,560	7,411	10,553	17,964	23,523	30,369	43,444	23,285
General and administrative	2,815	3,026	3,997	7,023	9,837	11,860	14,698	12,735
Loss on disposition of assets	11,122				11,122	11,122
Total operating expenses	20,285	11,293	15,807	27,100	47,383	56,604	64,388	49,520
Loss from operations	(18,708)	(11,398)	(15,573)	(26,971)	(45,678)	(52,556)	(71,005)	(49,053)
Other income (expense)
Interest income	46	2	1	3	50	80	25	309
Interest expense	(1,004)	(823)	(872)	(1,695)	(2,699)	(3,131)	(3,914)	(3,109)
Unrealized gain on warrant liability	13,736	7,051	1,384	8,435	22,171	25,520	3,827
Total other income (expense), net	12,778	6,230	513	6,743	19,522	22,469	(62)	(2,800)
Loss before benefit from income taxes	(5,930)	(5,168)	(15,060)	(20,228)	(26,156)	(30,087)	(71,067)	(51,853)
Benefit from income taxes			4,675	4,675	4,675	4,675
Net loss	$ (5,930)	$ (5,168)	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Net loss per share (basic) (in dollars per share)	$ (0.16)	$ (1.15)	$ (3.33)	$ (4.08)	$ (1.43)	$ (1.18)	$ (29.28)	$ (24.40)
Net loss per share (diluted) (in dollars per share)	$ (0.16)	$ (1.15)	$ (3.33)	$ (4.08)	$ (1.43)	$ (1.18)	$ (29.28)	$ (24.40)
Weighted-average common shares (basic) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534	21,610,947	2,426,821	2,117,077
Weighted-average common shares (diluted) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534	21,610,947	2,426,821	2,117,077
Comprehensive loss:
Net loss	$ (5,930)	$ (5,168)	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Other comprehensive income:
Unrealized (loss) gain on marketable securities							(3)	3
Comprehensive loss	$ (5,930)	$ (5,168)	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,070)	$ (51,850)

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock Series A Convertible Preferred Stock	Preferred Stock Series B Convertible Preferred Stock	Preferred Stock Series A and B Convertible Preferred Stock	Preferred Stock	Common stock Public offering	Common stock At-the-market sales	Common stock Series A Convertible Preferred Stock	Common stock Series B Convertible Preferred Stock	Common stock	Additional Paid in Capital. Public offering	Additional Paid in Capital. At-the-market sales	Additional Paid in Capital.	Accumulated Other Comprehensive Income	Accumulated Deficit	Public offering	At-the-market sales	Total
Balance at Dec. 31, 2019												$ 306,115,000		$ (260,370,000)			$ 45,745,000
Balance (in shares) at Dec. 31, 2019									1,745,264
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												2,818,000					2,818,000
Issuance of common stock										$ 48,435,000					$ 48,435,000
Issuance of common stock (in shares)					431,250
Issuance of common stock upon exercise of options												610,000					610,000
Issuance of common stock upon exercise of options (in shares)									12,586
Warrants issued in connection with long-term debt												3,570,000					3,570,000
Unrealized net gain on marketable securities													$ 3,000				3,000
Net loss														(51,853,000)			(51,853,000)
Balance at Dec. 31, 2020												361,548,000	3,000	(312,223,000)			49,328,000
Balance (in shares) at Dec. 31, 2020									2,189,100
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												3,338,000					3,338,000
Issuance of common stock										$ 11,898,000	$ 9,266,000				11,898,000	$ 9,266,000
Issuance of common stock (in shares)					666,666	172,879
Issuance of common stock upon exercise of options												75,000					75,000
Issuance of common stock upon exercise of options (in shares)									3,160
Vesting of RSUs (in shares)									3,096
Warrants issued in connection with long-term debt												1,080,000					1,080,000
Unrealized net gain on marketable securities													$ (3,000)				(3,000)
Net loss														(71,067,000)			(71,067,000)
Balance at Dec. 31, 2021												387,205,000		(383,290,000)			3,915,000
Balance (in shares) at Dec. 31, 2021									3,034,901
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												764,000					764,000
Issuance of common stock											348,000					348,000
Issuance of common stock (in shares)						25,623
Conversion of convertible preferred stock (in shares)	(2,425)		4,850				303,125
Vesting of RSUs (in shares)									1,773
Net loss														(10,385,000)			(10,385,000)
Balance at Mar. 31, 2022												388,317,000		(393,675,000)			(5,358,000)
Balance (in shares) at Mar. 31, 2022				2,425					3,365,422
Balance at Dec. 31, 2021												387,205,000		(383,290,000)			3,915,000
Balance (in shares) at Dec. 31, 2021									3,034,901
Increase (decrease) in stockholders' equity
Net loss																	(15,553,000)
Balance at Jun. 30, 2022									$ 1,000			401,211,000		(398,843,000)			2,369,000
Balance (in shares) at Jun. 30, 2022									12,360,157
Balance at Dec. 31, 2021												387,205,000		(383,290,000)			3,915,000
Balance (in shares) at Dec. 31, 2021									3,034,901
Increase (decrease) in stockholders' equity
Net loss																	(21,481,000)
Balance at Sep. 30, 2022									$ 4,000			401,744,000					(3,025,000)
Balance (in shares) at Sep. 30, 2022									39,026,823
Balance at Dec. 31, 2021												387,205,000		(383,290,000)			3,915,000
Balance (in shares) at Dec. 31, 2021									3,034,901
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												2,492,000					2,492,000
Fractional shares retired as a result of reverse split									(11)
Issuance of common stock					$ 3,000	$ 1,000					13,456,000				$ 3,000	13,457,000
Issuance of common stock (in shares)					26,666,666	12,655,773
Conversion of convertible preferred stock (in shares)	(2,425)	(2,425)	4,850				303,125	303,125
Vesting of RSUs (in shares)									6,555
Net loss														(25,412,000)			(25,412,000)
Balance at Dec. 31, 2022									$ 4,000			403,153,000		(408,702,000)			(5,545,000)
Balance (in shares) at Dec. 31, 2022									42,970,134
Balance at Mar. 31, 2022												388,317,000		(393,675,000)			(5,358,000)
Balance (in shares) at Mar. 31, 2022				2,425					3,365,422
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												669,000					669,000
Fractional shares retired as a result of reverse split									(10)
Issuance of common stock						$ 1,000					12,225,000					$ 12,226,000
Issuance of common stock (in shares)						8,687,502
Conversion of convertible preferred stock		$ (2,425)
Conversion of convertible preferred stock (in shares)								303,125
Vesting of RSUs (in shares)									4,118
Net loss														(5,168,000)			(5,168,000)
Balance at Jun. 30, 2022									$ 1,000			401,211,000		$ (398,843,000)			2,369,000
Balance (in shares) at Jun. 30, 2022									12,360,157
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												536,000
Issuance of common stock						$ 3,000					$ (3,000)
Issuance of common stock (in shares)						26,666,666
Net loss																	(5,930,000)
Balance at Sep. 30, 2022									$ 4,000			$ 401,744,000					$ (3,025,000)
Balance (in shares) at Sep. 30, 2022									39,026,823

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash inventory reserve					5,323
Depreciation	527	1,057	1,255	1,280	2,064	105
Amortization	61	124	188	254	159	171
Loss on disposition of assets			11,122	11,122
Noncash stock-based compensation	764	1,433	1,969	2,493	3,338	2,818
Noncash amortization of deferred financing costs	419	797	1,635	1,969	1,661	1,341
Unrealized gain on warrants	(1,384)	(8,435)	(22,171)	(25,520)	(3,827)
Changes in operating assets and liabilities:
Accounts receivable	(132)	(554)	(2,178)	(1,844)	(668)	(865)
Income taxes receivable	(4,675)
Inventory	(1,727)	(1,374)	(831)	(366)	(6,289)
Prepaid expenses and other assets	707	1,267	(1,551)	880	(967)	(2,485)
Accounts payable and accrued expenses	1,095	3,643	(2,213)	(628)	5,202	3,641
Lease liability	(21)	(90)	(132)	(175)	(131)	(184)
Net cash used in operating activities	(14,751)	(17,685)	(34,388)	(35,947)	(65,202)	(47,311)
Cash flows from investing activities:
Purchases of marketable securities						(54,837)
Sales and maturities of marketable securities					39,729	14,500
Acquisition of property and equipment	(126)	(133)	(133)	(133)	(269)	(353)
Net cash (used in) provided by investing activities	(126)	(133)	(133)	(133)	39,460	(40,690)
Cash flows from financing activities:
Proceeds from issuance of common stock in public offering, net of offering costs			21,971	21,936	21,081	48,434
Proceeds from issuance of long-term debt						20,000
Repayments of long-term debt	(5,000)	(5,000)	(17,150)	(17,375)
Debt financing costs paid						(1,059)
Proceeds from exercise of stock options					75	610
Net cash provided by financing activities	(523)	11,702	21,523	22,183	30,422	67,985
Net (decrease) increase in cash and cash equivalents	(15,400)	(6,116)	(12,998)	(13,897)	4,680	(20,016)
Cash and cash equivalents, beginning of period	19,143	19,143	19,143	19,143	14,463	34,479
Cash and cash equivalents, end of period	3,743	13,027	6,145	5,246	19,143	14,463
Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt					1,080	3,570
Operating right-of-use assets obtained in exchange for new operating lease liabilities					969
Supplemental cash flow information
Interest paid	452	898	1,078	1,162	2,383	$ 2,099
Public offering
Cash flows from financing activities:
Proceeds from issuance of preferred stock in registered direct offering, net of offering costs	4,129	4,129	4,129	4,128
At-the-market sales
Cash flows from financing activities:
Proceeds from At-the-Market sales of common stock, net of offering costs	$ 348	$ 12,573	$ 12,573	$ 13,494	$ 9,266

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2022
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business Nature of Operations Agile Therapeutics, Inc. (“Agile” or the “Company”) was incorporated in Delaware on December 22, 1997. Agile is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. The Company’s activities since inception have consisted principally of raising capital, performing research and development, including development of the Company’s lead product, Twirla ® The Company’s sole approved product, Twirla, also known prior to its approval as AG200-15, is a once-weekly prescription contraceptive patch that received approval from the U.S. Food and Drug Administration, or FDA, in February 2020 and was commercially launched in early December 2020. Substantially all of the Company’s resources are currently dedicated to commercializing Twirla in the United States. The Company has generated minimal product revenue to date and is subject to a number of risks similar to those of other early stage commercial companies, including, but not limited to, dependence on key individuals, the difficulties and uncertainties inherent in the development of commercially usable products, market acceptance of products, protection of proprietary technology, the potential need to obtain additional capital necessary to fund the development of its products, reliance on a consistent supply chain both for Twirla and in general, macroeconomic factors such as inflation, competition from larger companies, and compliance with FDA and other government regulations. If the Company does not successfully commercialize Twirla, it will be unable to generate recurring product revenue or achieve profitability. The Company has incurred operating losses and negative cash flows from operating activities each year since inception. As of December 31, 2022, the Company had an accumulated deficit of approximately $408 million. The Company expects to continue to incur significant operating expenses for the foreseeable future in connection with its ongoing activities, as the Company: ● maintains a sales and marketing infrastructure to support the continued commercialization of Twirla in the United States; ● continues to commercialize Twirla and seek increased uptake of Twirla in the United States; ● continues to evaluate additional line extensions for Twirla and initiates development of potential product candidates in addition to Twirla; ● maintains, leverages and expands the Company’s intellectual property portfolio; and ● maintains operational, financial and management information systems and personnel, including personnel to support the Company’s product development and future commercialization efforts. ​ The Company has financed its operations to date primarily through the issuance and sale of its common stock in both public and private offerings (see Note 10), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. Going Concern As of December 31, 2022, the Company had cash and cash equivalents of $5.2 million and a $2.0 million working capital deficit. The Company’s current liquidity is sufficient to fund operations only into the second quarter of 2023. The Company closely monitors its cash and cash equivalents and will need to raise additional funds to meet its projected operating requirements, including the continued commercialization of Twirla, and exploring the advancement of its existing pipeline and its possible expansion through business development activities. The Company has generated losses since inception, used substantial cash in operations, has a working capital deficit at December 31, 2022 and anticipates it will continue to incur net losses for the foreseeable future. The Company’s future success depends on its ability to obtain additional capital and/or implement various strategic alternatives, and there can be no assurance that any financing can be realized by the Company, or if realized, what the terms of any such financing may be, or that any amount that the Company is able to raise will be adequate. Based upon the foregoing, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern through the 12 months following the date on which this Annual Report on Form 10-K is filed. The Company continues to analyze various alternatives, including refinancing alternatives, asset sales and mergers and acquisitions. The Company’s future success depends on its ability to raise additional capital as discussed above. The Company cannot be certain that these initiatives or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current stockholders will experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company then may be unable to continue the commercialization of Twirla, and may also be required to cut operating costs, and forego future development and other opportunities. The audited financial statements as of December 31, 2022 have been prepared under the assumption that the Company will continue as a going concern for the next 12 months. The Company’s ability to continue as a going concern is dependent upon its uncertain ability to obtain additional capital, reduce expenditures and/or execute on its business plan and successfully launch Twirla. The audited financial statements as of December 31, 2022 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements.

Restatement of Previously Issue

Restatement of Previously Issued Financial Statements	12 Months Ended
	Dec. 31, 2022
Restatement of Previously Issued Financial Statements
Restatement of Previously Issued Financial Statements	2. Restatement of Previously Issued Financial Statements ​ In February 2023, the Company concluded that it incorrectly classified certain warrants (the “Warrants”) that were issued to investors in connection with a public offering of the Company’s common stock (“Common Stock”) in October 2021, a registered direct offering of the Company’s preferred stock (“Preferred Stock”) in March 2022 and a public offering of the Company’s Common Stock in July 2022. ​ Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants. The Company reassessed its accounting for the Warrants and determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company Statement of Operations each reporting period. ​ ​ Impact of the Restatement ​ The Company has restated herein its audited financial statements at December 31, 2022 for the year ended December 31, 2021. We have also restated interim financial statement periods for the first, second and third quarters of 2022, see Note 14. The following tables represent the restated balance sheet, restated statements of operations and comprehensive loss, statements of changes in stockholders’ equity and statement of cash flows for the year ended December 31, 2021. These tables also present a reconciliation from the prior period as previously reported to the restated amounts. The amounts as previously reported for fiscal year 2021 was derived from the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 30, 2022. ​ Balance Sheet ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ Reported Adjustment ​ As Restated Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ ​ $ 19,143 Accounts receivable, net ​ ​ 1,533 ​ ​ — ​ ​ ​ 1,533 Inventory, net ​ ​ 966 ​ ​ — ​ ​ ​ 966 Prepaid expenses and other current assets ​ 2,283 ​ ​ — ​ ​ 2,283 Total current assets ​ 23,925 ​ ​ — ​ ​ 23,925 Property and equipment, net ​ 12,447 ​ ​ — ​ ​ 12,447 Right of use asset ​ ​ 949 ​ ​ — ​ ​ ​ 949 Other non-current assets ​ 2,012 ​ ​ — ​ ​ 2,012 Total assets ​ $ 39,333 ​ $ — ​ ​ $ 39,333 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities and stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term debt, current portion ​ $ 16,833 ​ ​ — ​ ​ $ 16,833 Accounts payable ​ ​ 8,707 ​ ​ — ​ ​ ​ 8,707 Accrued expenses ​ 3,563 ​ ​ — ​ ​ 3,563 Lease liability, current portion ​ 175 ​ ​ — ​ ​ 175 Total current liabilities ​ 29,278 ​ ​ — ​ ​ 29,278 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liabilities, long-term ​ ​ 784 ​ ​ — ​ ​ ​ 784 Warrant liability ​ ​ — ​ ​ 5,356 ​ ​ ​ 5,356 Total liabilities ​ ​ 30,062 ​ ​ 5,356 ​ ​ ​ 35,418 Commitments and contingencies (Note 13) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding ​ ​ — ​ ​ — ​ ​ ​ — Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued outstanding ​ — ​ ​ — ​ ​ — Additional paid-in capital * ​ 396,388 ​ ​ (9,183) ​ ​ 387,205 Accumulated deficit ​ (387,117) ​ ​ 3,827 ​ ​ (383,290) Total stockholders’ equity ​ 9,271 ​ ​ (5,356) ​ ​ 3,915 Total liabilities and stockholders’ equity ​ $ 39,333 ​ $ — ​ ​ $ 39,333 ​ * Adjustment reflected as a result of the 1 ​ Statement of Operations and Comprehensive Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ As Previously Reported Adjustment As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, net ​ $ 4,101 ​ $ — ​ $ 4,101 Cost of product revenues ​ ​ 10,718 ​ ​ — ​ ​ 10,718 Gross profit (loss) ​ ​ (6,617) ​ ​ — ​ ​ (6,617) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 6,246 ​ $ — ​ $ 6,246 Selling and marketing ​ ​ 43,444 ​ ​ — ​ ​ 43,444 General and administrative ​ 14,698 ​ — ​ 14,698 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — Total operating expenses ​ 64,388 ​ — ​ 64,388 Loss from operations ​ (71,005) ​ — ​ (71,005) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ 25 ​ — ​ 25 Interest expense ​ ​ (3,914) ​ ​ — ​ ​ (3,914) Unrealized gain on warrant liability ​ ​ — ​ ​ 3,827 ​ ​ 3,827 Total other income (expense), net ​ ​ (3,889) ​ ​ 3,827 ​ ​ (62) Loss before benefit from income taxes ​ ​ (74,894) ​ ​ 3,827 ​ ​ (71,067) Benefit from income taxes ​ ​ — ​ ​ — ​ ​ — Net loss ​ $ (74,894) ​ $ 3,827 ​ $ (71,067) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share (basic and diluted)* ​ $ (30.86) ​ $ 1.58 ​ $ (29.28) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average common shares (basic and diluted) ​ ​ 2,426,821 ​ 2,426,821 ​ 2,426,821 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (74,894) ​ $ 3,827 ​ $ (71,067) Other comprehensive income: ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized (loss) gain on marketable securities ​ ​ (3) ​ ​ — ​ ​ (3) Comprehensive loss ​ $ (74,897) ​ $ 3,827 ​ $ (71,070) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * Adjustment reflected as a result of the 1-for-40 reverse stock split effectuated on April 26, 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Changes in Stockholders’ Equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common Stock ​ Additional ​ Accumulated ​ ​ ​ ​ Net ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ ​ Shares * Amount Capital * Income Deficit Equity As Previoulsy Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2020 ​ ​ 2,189,100 ​ $ — ​ $ 361,548 ​ $ 3 ​ $ (312,223) ​ $ 49,328 Share-based compensation - stock options and RSUs ​ ​ — ​ ​ — ​ ​ 3,338 ​ ​ — ​ ​ — ​ ​ 3,338 Issuance of common stock pursuant to at‑the‑market stock sales, net of expenses ​ ​ 172,879 ​ ​ — ​ ​ 9,266 ​ ​ — ​ ​ — ​ ​ 9,266 Issuance of common stock in public offering, net of expenses ​ ​ 666,666 ​ ​ — ​ ​ 21,081 ​ ​ — ​ ​ — ​ ​ 21,081 Issuance of common stock upon exercise of stock options ​ ​ 3,160 ​ ​ — ​ ​ 75 ​ ​ — ​ ​ — ​ ​ 75 Vesting of RSUs ​ ​ 3,096 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with long-term debt ​ ​ — ​ ​ — ​ ​ 1,080 ​ ​ — ​ ​ — ​ ​ 1,080 Unrealized net gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ (3) ​ ​ — ​ ​ (3) Net loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (74,894) ​ ​ (74,894) Balance December 31, 2021 ​ ​ 3,034,901 ​ $ — ​ $ 396,388 ​ $ — ​ $ (387,117) ​ $ 9,271 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2020 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Share-based compensation - stock options and RSUs ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at‑the‑market stock sales, net of expenses ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock in public offering, net of expenses ​ ​ — ​ ​ — ​ ​ (9,183) ​ ​ — ​ ​ — ​ ​ (9,183) Issuance of common stock upon exercise of stock options ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with long-term debt ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Unrealized net gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 3,827 ​ ​ 3,827 Total adjustment December 31, 2021 ​ ​ — ​ $ — ​ $ (9,183) ​ $ — ​ $ 3,827 ​ $ (5,356) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2020 ​ ​ 2,189,100 ​ $ — ​ $ 361,548 ​ $ 3 ​ $ (312,223) ​ $ 49,328 Share-based compensation - stock options and RSUs ​ ​ — ​ ​ — ​ ​ 3,338 ​ ​ — ​ ​ — ​ ​ 3,338 Issuance of common stock pursuant to at‑the‑market stock sales, net of expenses ​ ​ 172,879 ​ ​ — ​ ​ 9,266 ​ ​ — ​ ​ — ​ ​ 9,266 Issuance of common stock in public offering, net of expenses ​ ​ 666,666 ​ ​ — ​ ​ 11,898 ​ ​ — ​ ​ — ​ ​ 11,898 Issuance of common stock upon exercise of stock options ​ ​ 3,160 ​ ​ — ​ ​ 75 ​ ​ — ​ ​ — ​ ​ 75 Vesting of RSUs ​ ​ 3,096 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with long-term debt ​ ​ — ​ ​ — ​ ​ 1,080 ​ ​ — ​ ​ — ​ ​ 1,080 Unrealized net gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ (3) ​ ​ — ​ ​ (3) Net loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (71,067) ​ ​ (71,067) Balance December 31, 2021 (Restated) ​ ​ 3,034,901 ​ $ — ​ $ 387,205 ​ $ — ​ $ (383,290) ​ $ 3,915 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * Adjustment reflected as a result of the 1 -for-40 reverse stock split effectuated on April 26, 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flows ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2021 ​ As Previously Reported Adjustment As Restated Cash flows from operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (74,894) ​ $ 3,827 ​ $ (71,067) Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Noncash inventory reserve ​ ​ 5,323 ​ ​ — ​ ​ 5,323 Depreciation ​ 2,064 ​ — ​ 2,064 Amortization ​ 159 ​ — ​ 159 Noncash stock-based compensation ​ 3,338 ​ — ​ 3,338 Noncash amortization of deferred financing costs ​ ​ 1,661 ​ ​ — ​ ​ 1,661 Unrealized gain on warrants ​ ​ — ​ ​ (3,827) ​ ​ (3,827) Changes in operating assets and liabilities: ​ ​ ​ ​ ​ ​ Accounts receivable ​ ​ (668) ​ ​ — ​ ​ (668) Inventory ​ ​ (6,289) ​ ​ — ​ ​ (6,289) Prepaid expenses and other assets ​ ​ (967) ​ ​ — ​ ​ (967) Accounts payable and accrued expenses ​ 5,202 ​ — ​ 5,202 Lease liability ​ ​ (131) ​ ​ — ​ ​ (131) Net cash used in operating activities ​ (65,202) ​ — ​ (65,202) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchases of marketable securities ​ ​ — ​ ​ — ​ ​ — Sales and maturities of marketable securities ​ ​ 39,729 ​ ​ — ​ ​ 39,729 Acquisition of property and equipment ​ (269) ​ — ​ (269) Net cash provided by investing activities ​ 39,460 ​ — ​ 39,460 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from issuance of preferred stock in registered direct offering, net of offering costs ​ ​ — ​ ​ — ​ ​ — Proceeds from issuance of common stock in public offering, net of offering costs ​ ​ 21,081 ​ ​ — ​ ​ 21,081 Proceeds from At-the-Market sales of common stock, net of offering costs ​ ​ 9,266 ​ ​ — ​ ​ 9,266 Proceeds from exercise of stock options ​ 75 ​ — ​ 75 Net cash provided by financing activities ​ ​ 30,422 ​ ​ — ​ ​ 30,422 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net (decrease) increase in cash and cash equivalents ​ 4,680 ​ — ​ 4,680 Cash and cash equivalents, beginning of period ​ 14,463 ​ — ​ 14,463 Cash and cash equivalents, end of period ​ $ 19,143 ​ $ — ​ $ 19,143 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental disclosure of noncash financing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants issued in connection with long-term debt ​ $ 1,080 ​ $ — ​ $ 1,080 Operating right-of-use assets obtained in exchange for new operating lease liabilities ​ ​ 969 ​ ​ — ​ ​ 969 Supplemental cash flow information ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest paid ​ $ 2,383 ​ $ — ​ $ 2,383 ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Polices ​ Basis of Presentation The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented. ​ Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, costs of product revenues, the accounting for common stock warrants, stock-based compensation, and accounting for research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. ​ Risks and Uncertainties While Twirla has been approved by the FDA, other potential product candidates developed by the Company will require approval from the FDA prior to commercial sales. There can be no assurance that the Company’s other product candidates will receive the required approval. If the Company is denied approval or such approval is delayed, or is unable to obtain the necessary financing to complete development and approval, there could be a material adverse impact on the Company’s financial condition and results of operations. ​ It should be noted that current public health threats could adversely affect the Company’s ongoing or planned business operations. In particular, the ongoing COVID-19 pandemic has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The effect of these orders, government imposed quarantines and measures the Company has taken, such as implementing work-at-home policies, may negatively impact productivity, disrupt the Company’s business and could delay the Company’s commercialization timeline. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties with whom it engages, including personnel at third-party manufacturing facilities and other third parties with whom the Company conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct its business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on the Company. While to date we have been able to continue to execute our overall business plan, some of our business activities have been slowed and taken longer to complete and we continue to adjust to the challenges of operating in a largely remote setting with our employees. We have only recently launched our commercial activities for Twirla and begun engaging with healthcare providers to promote Twirla. We expect that, as we broaden our sales detailing activities, in some instances our sales force may encounter challenges engaging with healthcare providers during this on-going pandemic. Although many areas of the United States have begun to re-open access to offices and other commercial facilities, there continue to be areas where restrictions remain in place, which may have the potential to affect our ability to conduct our business. Further, new variants, including those which are more easily transmissible or resistant to existing vaccines, may lead to new shutdowns or business disruptions in the future. The Company will continue to closely monitor events as they develop and evaluate alternative, mitigating measures it can implement if needed. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations. The Company maintains balances with financial institutions in excess of the Federal Deposit Insurance Corporation limit. ​ Trade Accounts Receivable and Allowances Trade accounts receivable are amounts owed to the Company by its customers for product that has been delivered. The trade accounts receivable are recorded at the invoice amount, less prompt pay and other discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company’s estimate of losses over the life of the receivables. The Company evaluates forward looking economic factors and uses professional judgment to determine the allowance for credit losses. The credit loss reserves are reviewed and adjusted periodically. Credit loss reserves were not material as of December 31, 2022 and 2021, respectively. ​ Trade accounts receivable are aged based on the contractual payment terms. When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts receivable, accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature. Inventory Inventory is valued utilizing the weighted average costing method. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management’s current knowledge with respect to inventory levels, planned production and sales volume assumptions. During the year ended December 31, 2021, the Company established a reserve of approximately million for inventory not expected to be sold prior to its shelf-life date. As of December 31, 2022 inventory reserves approximated $0.6 million. ​ ​ Property and Equipment Property and equipment, consisting of office equipment, computer equipment and manufacturing equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight- line method over the estimated useful lives of the assets. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred. Improvements and additions are capitalized in accordance with Company policy. In the third quarter of 2022, the Company transferred manufacturing equipment with a book value of $11.1 million to Corium in exchange for relief from minimum material purchase requirements. The Company recorded a loss of Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment ​ Research and Development Expense Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees and support services used in drug development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received. ​ Advertising Costs The Company has elected to expense advertising costs when incurred. Advertising costs totaled Deferred Financing Costs Costs directly attributable to the Company’s term loan (see Note 9) are deferred and reported as a reduction of the related term loan. These costs represent legal fees and other costs related to the term loan and are being amortized utilizing the straight-line method over the term of the loan. Amortization of deferred financing costs charged to interest expense was approximately $342,000, $277,000 and $231,000 for the years ended December 31, 2022, 2021 and 2020, respectively. ​ Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist principally of cash, cash equivalents and marketable securities. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has no financial instruments with off balance sheet risk of accounting loss. Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In 2022, the Company had sales to customers that individually accounted for more than 10% of its total revenue. These customers had sales of of total revenues in the aggregate. In 2021, the Company had sales to Revenue Recognition The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, Revenue from Contracts with Customers ​ In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable and Allowance policy. ​ The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. ​ Twirla is sold to customers at the wholesale acquisition cost (WAC). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following: ​ ● Distribution services fees ● Prompt pay and other discounts ● Product returns ● Chargebacks ● Rebates ● Co-payment assistance ​ An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period. ​ In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relied on industry standard data and trend analysis since historical sales data was not available as Twirla was launched in December 2020. As historical data becomes available, the Company will incorporate that data into its estimates of variable consideration. ​ The specific considerations that the Company uses in estimating these amounts related to variable considerations are as follows. ​ Distribution services fees – The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount. The Company records these fees as contra trade accounts receivable on the balance sheet. ​ Prompt pay and other discount Prompt pay discounts are typically taken by the Company’s customers, so an estimate of the discount is recorded at the time of sale based on the WAC. Prompt pay discount estimates are recorded as contra trade accounts receivable on the balance sheet. ​ The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded. ​ Product returns ​ Chargebacks ​ Rebates ​ Co-payment assistance ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Allowances for ​ Payments & ​ December 31, ​ 2021 current period sales credits 2022 Customer credits, discounts and allowances (contra accounts receivable) ​ $ 371 ​ $ 5,891 ​ $ (3,268) ​ $ 2,994 Rebates and co-pay assistance (accrued expenses) ​ ​ 669 ​ ​ 4,434 ​ ​ (2,771) ​ ​ 2,332 Total ​ $ 1,040 ​ $ 10,325 ​ $ (6,039) ​ $ 5,326 ​ Warrants The Company accounts for its warrants to purchase common stock in accordance with ASC 480, Distinguishing Liabilities from Equity . shares of its common stock to the lender, Perceptive Credit Holdings III, L.P. (“Perceptive”). In connection with an amendment to that facility in February 2021, the Company issued warrants to purchase shares of the Company’s common stock (collectively, the “Perceptive Warrants”). The Perceptive Warrants qualify for equity classification and have been allocated based upon the relative fair value of the base instrument and the warrant. The Perceptive Warrants were subject to repricing in the event of an offering of securities at a price lower than the existing strike price before December 31, 2022. In connection with the Sixth Amendment, we amended and restated the Perceptive Warrants to reset the strike price of the Perceptive Warrants. See Notes 9 and 10 for additional information. ​ In connection with an underwritten public offering completed in October 2021, the Company issued warrants to purchase 333,333 shares of its common stock. This offering also triggered an adjustment to the exercise price of the Perceptive Warrants, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. See Notes 9 and 10 for additional information. ​ In connection with a registered direct offering completed in March 2022, the Company issued warrants to purchase 1,242,813 shares of its common stock. This offering also triggered an adjustment to the exercise price of the Perceptive Warrants, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. See Notes 9 and 10 for additional information. ​ In connection with a letter agreement and waiver entered into with an investor on April 2022, the Company issued warrants to purchase 212,188 shares of common stock. See Note 10 for additional information. ​ In connection with a public offering completed in July 2022, the Company issued warrants to purchase 54,666,665 shares of its common stock. This offering also triggered an adjustment to the exercise price of the Perceptive Warrants, which resulted in a reduction of the strike price for these warrants. ​ Income Taxes The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no uncertain tax positions as of December 31, 2022 that qualify for either recognition or disclosure in the financial statements under this guidance. ​ Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation . The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital. The Company also awards restricted stock units (“RSUs”) to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. Cost associated with performance-based restricted stock units with a performance condition which affects the vesting is recognized only if the performance condition is probable of being satisfied. ​ Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting ​ Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the years ended December 31, 2022, 2021 and 2020, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Common stock warrants ​ 56,501,249 379,583 35,000 Unvested restricted stock units ​ 6,461 8,325 3,995 Common stock options ​ 397,818 259,145 212,977 Total ​ 56,905,528 647,053 251,972 ​ Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 was adopted by the Company on January 1, 2020 and had no current impact on the Company as the Company did not have any financial instruments covered by the topic on the date of adoption. Subsequent to the adoption date, the allowance for credit losses is immaterial. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). This guidance simplifies the accounting for income taxes by, among other things, reducing complexity in the interim-period accounting for year-to-date loss limitations and changes in tax laws. The adoption of this standard did not have a material impact on its financial statements. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), an expansion of ASU 2020-04: Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2021-01”). This guidance permits entities to elect certain optional expedients and exceptions when accounting for derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, for computing variation margin settlements, and for calculating price alignment interest) in connection with reference rate reform activities under way in global financial markets (the “discounting transition”). The guidance was effective immediately and did not have an impact on our consolidated financial statements. ​ Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Fair Value Measurements
Fair Value Measurements	4. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: ● Level 1—Quoted prices in active markets for identical assets and liabilities. The Company’s Level 1 assets consist of cash and cash equivalents. The Company has no Level 1 liabilities. ● Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities. ● Level 3—Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participants price the fair value of the assets or liabilities. The Company’s level 3 liabilities consist of warrant liability. The Company has no level 3 assets. The following tables set forth the Company’s financial instruments measured at fair value by level within the fair value hierarchy as of December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 5,246 ​ $ — ​ $ — Total assets at fair value ​ $ 5,246 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability ​ $ — ​ $ — ​ $ 5,934 Total assets at fair value ​ $ — ​ $ — ​ $ 5,934 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 (Restated) December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ $ — Total assets at fair value ​ $ 19,143 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability (Restated) ​ $ — ​ $ — ​ $ 5,356 Total assets at fair value ​ $ — ​ $ — ​ $ 5,356 ​ The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of December 31, 2022 include (i) volatility 136.8% - 137.4%, (ii) risk-free interest rate 4.2%, (iii) strike price for the common warrants $0.90, (iv) strike price for the preferred warrants (10.40), (v) fair value of common stock $0.23, and (vi) expected life 4.3 – 4.5 years. The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of December 31, 2021 include (i) volatility ​ The following is a roll forward of the fair value of Level 3 warrants: ​ ​ ​ ​ ​ ​ Beginning balance at December 31, 2020 $ — Warrants issued ​ ​ 9,183 Change in fair value ​ (3,827) Ending balance at December 31, 2021 (Restated) ​ 5,356 Warrants issued ​ ​ 26,098 Change in fair value ​ (25,520) Ending balance at December 31, 2022 ​ $ 5,934 ​ There were no transfers between Level 1, 2 or 3 during 2022 or 2021.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses
Prepaid Expenses	5. Prepaid Expenses Prepaid expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Prepaid insurance ​ $ 628 ​ $ 775 Other ​ 775 ​ 1,508 Total prepaid expenses and other current assets ​ $ 1,403 ​ $ 2,283 ​

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Property and Equipment	6. Property and Equipment Property and equipment, consisting of manufacturing, office and computer equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Property and equipment consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Estimated ​ 2022 2021 Life Office equipment ​ $ 132 ​ $ 7 5 years Computer equipment ​ 121 ​ 113 3 Years Manufacturing equipment ​ — ​ 14,477 7 years ​ ​ 253 ​ 14,597 ​ ​ Less: accumulated depreciation ​ (76) ​ (2,150) Property and equipment ​ $ 177 ​ $ 12,447 ​ Upon successful completion of the validation of the commercial manufacturing process for Twirla by the Company’s contract manufacturer, Corium, and the announcement of the commercial launch of Twirla in December 2020, manufacturing equipment with a cost of $14.3 million was placed into service and started being depreciated. ​ In accordance with Amendment No. 1 to the Corium Agreement (the “Amendment”), the Company transferred all of its manufacturing equipment to Corium during the third quarter of 2022.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2022
Accrued Liabilities
Accrued Liabilities	7. Accrued Liabilities Accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Gross to net accruals ​ $ 2,332 ​ $ 670 Accrued compensation ​ ​ 833 ​ ​ 2,086 Accrued professional fees and other ​ 743 ​ 807 Total accrued liabilities ​ $ 3,908 ​ $ 3,563 ​

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	8. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases . The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the statement of operations. The Company adopted ASU No. 2016-02 on January 1, 2019 for leases that existed on that date. The Company has elected to apply the provisions of ASC 842 modified retrospectively at January 1, 2019 through a cumulative-effect adjustment. Prior period results continue to be presented under ASC 840 based on the accounting standards originally in effect for such periods. The Company has no finance leases and one operating lease for its corporate headquarters in Princeton, NJ. The current lease commenced on December 1, 2021 and terminates on March 31, 2025. The lease provides the Company with an . Under the terms of the lease, the Company pays base annual rent subject to a fixed dollar amount increase each year, a fixed monthly charge for electricity, and other normal operating expenses such as taxes, repairs, and maintenance. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require variable lease payments, residual value guarantees or restrictive covenants. The lease does not provide an implicit rate, therefore the Company used its incremental borrowing rate as the discount rate when measuring the operating lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease. Operating lease expense was for the years ended December 31, 2022 and 2021, respectively. Operating cash flows used for operating leases during the years ended December 31, 2022 and 2021 were respectively. As of December 31, 2022, the weighted-average remaining lease term was Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows: ​ ​ ​ ​ 2023 ​ $ 391 2024 ​ ​ 397 2025 ​ 101 Total ​ $ 889 Less: Interest ​ (104) Present value of lease liability ​ $ 785 ​

Credit Agreement and Guaranty

Credit Agreement and Guaranty	12 Months Ended
	Dec. 31, 2022
Credit Agreement and Guaranty
Credit Agreement and Guaranty	9. Credit Agreement and Guaranty million tranche was to be available to the Company based on the achievement of a revenue milestone by December 31, 2021, which was not achieved. The other tranches of debt under the Amended Perceptive Credit Agreement are The facility will mature on February 10, 2024 (“Maturity Date”). Pursuant to the Fifth Amendment, beginning August 31, 2022, the Company began making monthly principal payments in an amount equal to Borrowings under the Fifth Amendment will accrue interest at an annual rate equal to the London Interbank Offered Rate for one-month deposits (“LIBOR”) plus The Company may prepay any outstanding loans in whole or in part. Any such prepayment of the loans is subject to a prepayment premium of All of the Company’s obligations under the Fifth Amendment are secured by a first-priority lien and security interest in substantially all of the Company’s tangible and intangible assets, including intellectual property. The Amended Perceptive Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customary for similar financings. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Amended Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company’s business activities; make certain investments or restricted payments (each as defined in the Amended Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company’s ability to make loan repayments under the Amended Perceptive Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of million for the fiscal quarter ending December 31, 2023. Pursuant to the Waiver and Sixth Amendment to the Perceptive Credit Agreement (the “Sixth Amendment”), the Company has received a waiver of certain financial covenants through the second quarter of 2023. In the event the Company does not pay off the remainder of the outstanding principal under the facility, the Company will need to negotiate for a waiver of its obligations to comply with the covenants relating to revenue for Twirla in the second quarter of 2023. In connection with the Perceptive Credit Agreement, the Company issued to Perceptive two warrants to purchase an aggregate of 35,000 shares of the Company’s common stock (together, the “2020 Perceptive Warrants”). The first warrant is exercisable for 17,500 shares of common stock at an exercise price of $149.60 per share. The second warrant is exercisable for 17,500 shares of common stock at an exercise price of $186.80 per share. The 2020 Perceptive Warrants expire on February 10, 2027. In connection with the Amended Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase 11,250 shares of the Company’s common stock (the “2021 Perceptive Warrant” and, together with the 2020 Perceptive Warrants, the “Perceptive Warrants”) at an exercise price of $114.80 per share. The 2021 Perceptive Warrant expires on February 26, 2028. The Perceptive Warrants contain anti-dilution provisions that expired on December 31, 2022 and other warrant holder protections and are not exercisable to the extent that Perceptive would beneficially own more than 19.99% of the Company’s common stock as a result of the exercise. In connection with the Sixth Amendment, we amended and restated the Perceptive Warrants to reset the strike price of the Perceptive Warrants. As a result of the public offering of the Company’s common stock completed in October 2021 (see Note 10), the antidilution provision of the Perceptive Warrants was triggered, resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase 17,500 shares of common stock that had an exercise price of $186.80 per share were reduced to $141.60 per share, warrants to purchase 17,500 shares of common stock that had an exercise price of $149.60 per share were reduced to $115.20 per share, and warrants to purchase 11,250 shares of common stock that had an exercise price of $114.80 per share were reduced to $90.80 per share. As a result of the registered direct offering completed in March 2022 (see Note 10), the anti-dilution provision of the Perceptive Warrants was again triggered resulting in a further reduction of the strike price for the Perceptive Warrants. Warrants to purchase 17,500 shares of common stock that had an adjusted exercise price of $141.60 per share were reduced to $105.52 per share, warrants to purchase 17,500 shares of common stock that had an adjusted exercise price of $115.20 per share were reduced to $86.61 per share, and warrants to purchase 11,250 shares of common stock that had an adjusted exercise price of $90.80 per share were reduced to $69.13 per share. As a result of the public offering of the Company’s common stock completed in July 2022 (see Note 10), the antidilution provision of the Perceptive Warrants was again triggered resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase 17,500 shares of common stock that had an exercise price of $105.52 per share were reduced to $14.90 per share, warrants to purchase 17,500 shares of common stock that had an exercise price of $86.61 per share were reduced to $12.37 per share, and warrants to purchase 11,250 shares of common stock that had an exercise price of $69.13 per share were reduced to $10.03 per share. The Company allocated the proceeds of ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Notes payable $ 2,625 ​ $ 20,000 Debt issuance costs ​ ​ (209) ​ ​ (550) Warrant discount ​ ​ (990) ​ ​ (2,617) Total debt ​ $ 1,426 ​ $ 16,833 Less, current portion ​ ​ 1,426 ​ ​ 16,833 Long-term debt, less current portion ​ $ — ​ $ — ​ ​ The fair value of the warrants and the debt issue costs are being amortized utilizing the effective interest method over the term of the loan. The Company recorded interest expense for the amortization of the fair value of the warrants and debt issue costs of $1,969,000, $1,661,000 and $1,341,000 for the years ended December 31, 2022, 2021, and 2020 respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity
Stockholders' Equity	10. Stockholders’ Equity The Company’s Certificate of Incorporation, as amended, among other things: (i) authorizes 300,000,000 shares of common stock; (ii) authorizes 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; (iii) provides that the Board be divided into three classes with staggered three-year terms, with one class of directors to be elected at each annual meeting of the Company’s stockholders; (iv) provides that directors may only be removed with cause and only upon the affirmative vote of holders of at least 75% of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally in the election of directors; (v) provides that only the Board, the chairman of the Board or the chief executive officer may call a special meeting of stockholders; and (vi) requires that any action instituted against the Company’s officers or directors in connection with their service to the Company be brought in the State of Delaware. On January 7, 2022, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 150,000,000 shares to 300,000,000 shares. Shelf Registration Statement On October 2, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate amount of $200.0 million (the “2020 Shelf Registration Statement”). On October 14, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC. In the future, the Company may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered. At the time any of the securities covered by the 2020 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering. Public Offerings In October 2021, the Company completed a public offering of 666,666 shares of its common stock and warrants to purchase 333,333 shares of its common stock at a combined price of $34.00 per share of common stock and one-half of a warrant to purchase one share of common stock. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $21.1 million. In July 2022, the Company completed a public offering of (1) 19,148,332 shares of its common stock and warrants to purchase 38,296,664 shares of its common stock at a combined price of $0.90 per share of common stock and warrants and (2) 7,518,334 pre-funded warrants to purchase 7,518,334 shares of its common stock and warrants to purchase 15,036,668 shares of its common stock at a combined price of $0.8999 per share of common stock and pre-funded warrant. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $22.0 million. ATM Sales Agreements In March 2021, the Company entered into a common stock sales agreement (the “2021 ATM Agreement”) under which the Company may sell up to an aggregate of $50.0 million in gross proceeds through the sale of shares of common stock from time to time in “at-the-market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under the 2021 ATM Agreement. During the year ended December 31, 2021, the Company issued and sold 172,879 shares of common stock under the 2021 ATM Agreement resulting in net proceeds to the Company of approximately $9.3 million. On January 10, 2022, the Company filed a prospectus supplement to its 2020 Shelf Registration Statement registering an at-the-market offering program (the “January 2022 ATM”) the Company entered into for the sale of up to $50.0 million of shares of its common stock. The Company agreed to pay a commission of up to million. On April 26, 2022, the Company terminated the January 2022 ATM. On April 27, 2022, the Company entered into a new at-the-market offering program (“April 2022 ATM”) with H.C. Wainwright LLC and Co. (the “Sales Agent”), under which the Company may, from time to time in its sole discretion, issue and sell through or to the Sales Agent, acting as the Company’s agent, up to $12,841,000 of shares of the Company’s common stock (the “Placement Shares”). The Company agreed to pay the Sales Agent a commission of up to 3.0% of the gross sales proceeds of any Placement Shares sold under the April 2022 ATM. Through September 30, 2022, the Company issued and sold a total of million. On August 22, 2022, the Company increased the April 2022 ATM (“August 2022 ATM”). As increased, the Company may now offer and sell, from time to time through the Sales Agent, shares of the Company’s common stock having an aggregate offering price of up to$75.0 million. During the year ended December 31, 2022, the Company issued and sold 3,942,648 shares of common stock under the August 2022 ATM resulting in net proceeds to the Company of approximately $0.9 million. Registered Direct Offering On March 14, 2022, the Company filed a prospectus supplement to its 2020 Shelf Registration Statement registering a direct offering (the “2022 Preferred Stock Offering”) of 2,425 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) and 2,425 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) and Series A warrants (the “Series A Warrants”) to purchase up to an aggregate of 606,250 shares of the common stock of the Company and Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of 606,250 shares of common Stock. Each share of Series A Preferred Stock and Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of $8.00 per share. The shares of preferred stock issued in the 2022 Preferred Stock Offering are convertible into an aggregate of 606,250 shares of common stock. The Series A Warrants have an exercise price of one -half years following the initial exercise date. Proceeds from the 2022 Preferred Stock Offering, net of the placement agent’s fees and offering expenses were approximately million. A portion of the placement agent’s fees included warrants to purchase On March 15, 2022, 2,425 shares of the Series A Preferred Stock were converted into 303,125 shares of the Company’s common stock. On April 4, 2022, 2,425 shares of the Series B Preferred Stock were converted into 303,125 shares of the Company’s common stock. On April 25, 2022, the Company entered into a letter agreement and waiver (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), pursuant to which Armistice consented to the Company entering into and effecting an at-the-market (“ATM”) offering facility. On March 14, 2022, the Company entered into the 2022 Preferred Stock Offering with Armistice, under which agreement, the Company was restricted from entering into and effecting an ATM offering facility until the 180-day conditions as the Series A Warrants, provided that such New Warrant shall be exercisable into 212,188 warrant shares. The Series A Warrants have an exercise price of $10.40 per share, and will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The New Warrant is exercisable 6 months after the date of the Letter Agreement. On July 6, 2022, the Company completed a best efforts public offering (the “Offering”) in which the Company raised net proceeds of $22.0 million through the sale of 19,148,332 shares of common stock and 7,518,334 pre-funded warrants (“Series B pre-funded warrants”) to purchase 7,518,334 shares of common stock. Both the sales of shares of common stock and pre-funded warrants were accompanied by Series A-1 and Series A-2 warrants (together the “Series A warrants”) to purchase shares of common stock. The Series A-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series A-2 warrants are exercisable immediately and will expire thirteen months from the date of issuance. H.C. Wainwright acted as the exclusive placement agent in connection with the Offering and, as compensation, received a cash fee of 7% of the aggregate proceeds raised in the Offering. The Company also issued to certain designees of H.C. Wainwright warrants to purchase up to Common Stock Warrants shares of its common stock. These warrants contain antidilution provisions that were triggered upon the Company’s public offering that was completed in October 2021. As a result of the offering, warrants to purchase 17,500 shares of common stock that had an exercise price of $186.80 per share were reduced to $141.60 per share, warrants to purchase 17,500 shares of common stock that had an exercise price of $149.60 per share were reduced to $115.20 per share, and warrants to purchase 11,250 shares of common stock that had an exercise price of $114.80 per share were reduced to $90.80 per share. These repricing’s resulted in an immaterial increase to additional paid-in-capital. As a result of the registered direct offering completed in March 2022, the anti-dilution provision of the Perceptive Warrants was again triggered resulting in a further reduction of the strike price for the Perceptive Warrants. Warrants to purchase per share. As a result of the public offering of the Company’s common stock completed in July 2022, the antidilution provision of the Perceptive Warrants was again triggered resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase per share. All Perceptive Warrants are accounted for in equity, whereas all warrants associated with our various financings are accounted for as liabilities. In accordance with ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity, these liabilities are measured at fair value upon issuance, with subsequent changes in fair value reported in the Statement of Operations each reporting period. ​

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Dec. 31, 2022
Equity Incentive Plans
Equity Incentive Plans	11. Equity Incentive Plans Stock options The Company had granted stock options under an amended and restated 1997 Equity Incentive Plan (the “1997 Plan”) and a 2008 Equity Incentive Plan (the “2008 Plan”). The plans provided for the granting of incentive and non-statutory options and stock awards to consultants, directors, officers and employees. Such options are exercisable for a period of ten years and generally vest over a four-year period. In conjunction with the adoption of the 2008 Plan in April 2008, no additional grants were made from the 1997 Plan and issued options from the 1997 Plan remain outstanding. In 2014, the Board approved the 2014 Incentive Compensation Plan (the “2014 Plan”). The 2014 Plan is the successor to the Company’s 2008 Plan and 1997 Plan. In conjunction with the adoption of the 2014 Plan in 2014, no additional grants were made from the 2008 Plan and options from the 1997 Plan and the 2008 Plan remain outstanding. In June 2018, the 2014 Plan was amended and restated, and the Amended and Restated 2014 Incentive Compensation Plan is now referred to as the Amended 2014 Plan. As of December 31, 2022, there were Through December 31, 2022, the Company granted options to certain employees and non-employees to purchase shares of common stock at exercise prices ranging from $0.20 to $430.00 per share. The Company recorded noncash stock-based compensation expense for the years ended December 31, 2022, 2021 and 2020 based on the fair market value of the options and shares granted at the grant date. Stock-based compensation expense was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, ​ 2022 2021 2020 Cost of goods sold ​ $ 133 ​ $ 271 ​ $ 14 Research and development ​ ​ 372 ​ ​ 490 ​ ​ 651 Selling and marketing ​ ​ 155 ​ ​ 148 ​ ​ 108 General and administrative ​ 1,833 ​ 2,429 ​ 2,045 Total ​ $ 2,493 ​ $ 3,338 ​ $ 2,818 ​ The following assumptions were used to compute employee stock-based compensation under the Black-Scholes option pricing model: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2020 Risk‑free interest rate 1.71% - 4.22 % .66% - 1.51 % .40% - 1.68 % Expective volatility 107% ‑ 118 % 105% ‑ 106 % 65% ‑ 106 % Expected dividend yield 0 % 0 % 0 % Expected life (in years) 6.25 6.25 6.25 ​ ​ Risk-free interest rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the stock option grants. Expected dividend yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends. Expected volatility. The expected volatility assumption was based on volatilities of a peer group of similar companies whose share prices are publicly available until August 2020. The peer group was developed based on comparable companies in the biotechnology and pharmaceutical industries. In August 2020, the Company transitioned to its own expected volatility based on sufficient historical data. Expected term. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historic exercise behavior, management determined the expected life assumption using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period. Forfeitures. As of December 31, 2022, the unrecorded deferred stock-based compensation balance related to stock options was approximately $3.3 million and will be recognized over an estimated weighted-average amortization period of 2.8 years. The weighted average grant date fair value of options granted during the year ended December 31, 2022 was The following table summarizes the options outstanding, options vested and the options exercisable as of December 31, 2022, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ Average Remaining ​ ​ ​ ​ ​ ​ Exercise Contractual ​ Aggregate ​ ​ Options ​ Price Life (Years) ​ Intrinsic Value Options outstanding at December 31, 2020 212,946 125.29 6.3 ​ Options granted 64,528 105.00 ​ Options exercised (3,159) 23.80 ​ Options cancelled/forfeited (15,170) 264.46 ​ Options outstanding at December 31, 2021 259,145 113.33 6.1 ​ Options granted 187,454 3.97 ​ Options exercised — — ​ Options cancelled/forfeited (48,781) 97.44 ​ Options outstanding at December 31, 2022 397,818 63.75 7.7 ​ $ 6 Options exercisable at December 31, 2022 182,667 113.54 5.7 ​ $ — Vested and expected to vest at December 31, 2022 397,818 ​ $ 6 ​ Intrinsic value in the tables was calculated as the difference between the Company's stock price at December 31, 2022, of $0.23 per share, and the exercise price, multiplied by the number of options. Restricted Stock Units During the year ended December 31, 2021, the Company granted a total of 1,774 RSUs to certain employees of the Company. These RSUs vested on the anniversary of the grant date. During the year ended December 31, 2021, the Company granted a total of RSUs to directors of the Company. These RSUs vest ratably over one . During the year ended December 31, 2022, the Company granted a total of 4,690 RSUs to directors of the Company. These RSUs vest ratably over . As of December 31, 2022, the unrecorded deferred stock-based compensation balance related to RSUs was approximately $68,000 and will be recognized over an estimated weighted-average amortization period of 0.7 years. The following table shows the Company's restricted stock unit activity during the years ended December 31, 2022, and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Aggregate ​ ​ Shares Grant Date Fair Value Intrinsic Value Restricted stock units outstanding at December 31, 2020 3,988 ​ $ 458 Granted 7,433 67.27 ​ ​ ​ Vested ​ (3,096) ​ 112.73 ​ ​ ​ Restricted stock units outstanding at December 31, 2021 8,325 — ​ $ 163 Granted ​ 4,690 ​ 1.05 ​ ​ ​ Vested (6,554) 76.30 ​ ​ ​ Restricted stock units outstanding at December 31, 2022 6,461 ​ ​ $ 2 ​

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income Taxes	12. Income Taxes On March 27, 2020 the US government enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which includes numerous modifications to income tax provisions, including a limitation on business interest expense and net operating loss provisions and the acceleration of alternative minimum tax credits. Given the Company’s history of losses, the CARES Act did not have a material impact on its tax provision. As of December 31, 2022, the Company had available net operating loss carryforwards (“NOLs”) of approximately $390.6 million for federal and $79.9 million for state income tax reporting purposes. Under the TCJA, the federal NOLs generated after 2017, approximately $201.7 million, can be carried forward indefinitely, while the NOLs generated through taxable years ending December 31, 2017, approximately $188.9 million, are available to offset future federal taxable income, if any, through 2037. The Company also has research and development tax credit carryforwards of approximately $6.4 million and $0.9 million for federal and state income tax reporting purposes, respectively, which are available to reduce federal income taxes, if any, through 2042 and state income taxes, if any, through 2037. The Internal Revenue Code of 1986, as amended (the “Code”) provides for a limitation on the annual use of NOLs and other tax attributes (such as research and development tax credit carryforwards) following certain ownership changes, as defined by the Code that could significantly limit the Company’s ability to utilize these carryforwards. At this time, the Company has not completed a study to assess whether an ownership change under Section 382 of the Code has occurred, or whether there have been multiple ownership changes since the Company’s formation, due to the costs and complexities associated with such a study. The Company is likely to have experienced various ownership changes, as defined by the Code, as a result of past financings. Accordingly, the Company’s ability to utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may be applied against future taxes. Therefore, the Company may not be able to take full advantage of these carryforwards for federal and state income tax purposes. The Company does not have any significant unrecognized tax benefits. As of December 31, 2022, the Company has not accrued interest or penalties related to uncertain tax positions. The Company’s tax returns for the years ended December 31, 2019 through December 31, 2021 are still subject to examination by major tax jurisdictions. However, the Internal Revenue Service (“IRS”) and state tax jurisdictions can audit the NOLs generated in prior years in the years that those NOLs are utilized. For all years through December 31, 2022, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment in known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforwards and the valuation allowance. The tax effects of temporary differences that give rise to significant portions of the deferred tax assets are presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Deferred tax assets: ​ ​ Net operating loss carryforwards ​ $ 87,216 ​ $ 81,102 Research credit carryforward ​ 7,071 ​ 7,943 Stock options and other ​ 2,297 ​ 2,114 Total gross deferred tax assets ​ 96,584 ​ 91,159 Valuation allowance for deferred tax assets ​ (96,584) ​ (91,159) Net deferred tax assets ​ $ — ​ $ — ​ The net change in the valuation allowance for the years ended December 31, 2022 and 2021 was an increase of $5.4 million and an increase of $14.4 million, respectively. A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 (Restated) 2020 Federal income tax at statutory rate 21.0 % 21.0 % 21.0 % State income tax benefit, net of federal benefit 0.1 % 0.2 % 1.0 % Unrealized gain on warrants ​ 18.8 % 1.1 % — % Research and development tax credits 0.1 % 0.2 % 0.7 % Other (5.6) % (2.2) % (2.0) % Increase to valuation allowance (18.5) % (20.3) % (20.7) % Effective income tax rate 15.9 % 0.0 % 0.0 % ​ Sale of New Jersey Net Operating Losses The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by The New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused NOLs and unused research and development credits to sell these tax benefits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The Program is administered by The New Jersey Economic Development Authority and the New Jersey Department of the Treasury’s Division of Taxation. The Company had previously reached the maximum lifetime benefit of $15.0 million under the historical Program, however in January 2021 the Program was amended to extend the maximum lifetime benefit to $20.0 million. In March 2022, the Company completed the sale of NOLs totaling approximately

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	13. Commitments and Contingencies The Company has several firm purchase commitments, primarily related to the manufacture and supply of Twirla and the supply of a field force of sales representatives to provide certain detailing services, sales operation services, compliance services, and training services. Future firm purchase commitments under these agreements, the last of which ends in 2033, total million. This amount does not represent all of the Company’s anticipated purchases in the future, but instead represents only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend in 2023 or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment. In April 2020, the Company entered into a manufacturing and commercialization agreement with Corium, (the “Corium Agreement”). Under the Corium Agreement, the Company has a requirement to order quarterly minimum volumes of approximately million of product. In the event that the Company does not order the minimum volume, the Company is required to pay an additional fee equal to twenty-five percent ( per unit fee as a penalty for all units ordered during the period. Based on current demand expectations for Twirla, the Company did not expect to meet the minimum volume order for the balance of 2022 and would be subject to the additional fee on future purchases. On July 25, 2022 the Company and Corium entered into Amendment No. 1 to the Corium Agreement (the “Amendment”) that is designed to restructure the contract minimums applicable to the purchase of manufactured Twirla and other services provided by Corium, transfer equipment ownership to Corium to support the manufacture of Twirla and extend the term of the Corium Agreement. Pursuant to the Amendment, the parties agreed to adjust the process for the Company providing Corium certain binding and non-binding forecasts required under the Corium Agreement. Additionally, Corium will not enforce the original quantity minimums in the Corium Agreement, which are waived and replaced by new minimums that are based on Corium’s revenue for product purchased by the Company, expiring raw materials, and other services billed by Corium to support batch production and release. The guaranteed minimum revenue requirement for 2022 is million for 2024 and each year thereafter. In the event that the Company does not meet the guaranteed minimum revenue requirements in any given year, the Company will be required to make additional payments to Corium for the shortfall. The Company agreed to make certain monthly supplemental payments to Corium through December 2023, which payments are eligible to be retroactively reduced based upon product orders placed by the Company during 2022 and 2023 meeting certain designated thresholds. In connection with the supplemental payments, Corium will retain the proceeds for the sale of certain raw materials to which the Company would otherwise have economic right to offset such supplemental payments. Further, the Company agreed to reimburse Corium for any unused raw materials in the event the Company’s actual product requirements are lower than initially forecasted. Pursuant to the Amendment, the term of the Corium Agreement was extended to December 31, 2033. Pursuant to the Amendment, the parties agreed to transfer ownership of certain manufacturing equipment used in the manufacture of Twirla from the Company to Corium under a Bill of Sale dated July 25, 2022. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial position. As of December 31, 2022, the Company has not recorded a provision for any contingent losses.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information (Unaudited)
Quarterly Financial Information (Unaudited)	14. Quarterly Financial Information (Unaudited) ​ As further described in Note 2, the previously reported financial information for the three months ended March 31, 2022, the three and six months ended June 30, 2022 and the three and nine months ended September 30, 2022, have been restated. Relevant restated financial information for each relevant period is included in this Annual Report on Form 10-K in the tables that follow. As part of the restatement, the Company recorded adjustments to correct the misstatements in the impacted periods. Descriptions of the restatement can be found in Note 2. The unaudited interim financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. Restated amounts are computed independently each quarter; therefore, the sum of the quarterly amounts may not equal the total amount for the respective year due to rounding. ​ Balance Sheets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 (unaudited) ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ ​ As Previously ​ ​ ​ ​ ​ ​ As Previously ​ ​ ​ ​ ​ ​ As Previously ​ ​ ​ ​ ​ ​ Reported Adjustment As Restated Reported Adjustment As Restated Reported Adjustment As Restated Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 3,743 ​ $ — ​ $ 3,743 ​ $ 13,027 ​ $ — ​ $ 13,027 ​ $ 6,145 ​ $ — ​ $ 6,145 Accounts receivable, net ​ ​ 1,665 ​ ​ — ​ ​ 1,665 ​ ​ 2,087 ​ ​ — ​ ​ 2,087 ​ ​ 3,711 ​ ​ — ​ ​ 3,711 Income taxes receivable ​ ​ 4,675 ​ ​ — ​ ​ 4,675 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Inventory, net ​ ​ 2,693 ​ ​ — ​ ​ 2,693 ​ ​ 2,340 ​ ​ — ​ ​ 2,340 ​ ​ 1,797 ​ ​ — ​ ​ 1,797 Prepaid expenses and other current assets ​ 1,576 ​ ​ — ​ 1,576 ​ 1,016 ​ ​ — ​ 1,016 ​ 3,834 ​ ​ — ​ 3,834 Total current assets ​ 14,352 ​ ​ — ​ 14,352 ​ 18,470 ​ ​ — ​ 18,470 ​ 15,487 ​ ​ — ​ 15,487 Property and equipment, net ​ 12,047 ​ ​ — ​ 12,047 ​ 11,524 ​ ​ — ​ 11,524 ​ 203 ​ ​ — ​ 203 Right of use asset ​ ​ 888 ​ ​ — ​ ​ 888 ​ ​ 825 ​ ​ — ​ ​ 825 ​ ​ 761 ​ ​ — ​ ​ 761 Other non-current assets ​ 2,012 ​ ​ — ​ 2,012 ​ 2,012 ​ ​ — ​ 2,012 ​ 2,012 ​ ​ — ​ 2,012 Total assets ​ $ 29,299 ​ $ — ​ $ 29,299 ​ $ 32,831 ​ $ — ​ $ 32,831 ​ $ 18,463 ​ $ — ​ $ 18,463 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities and stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term debt, current portion ​ $ 12,252 ​ ​ — ​ $ 12,252 ​ $ 12,630 ​ ​ — ​ $ 12,630 ​ $ 1,318 ​ ​ — ​ $ 1,318 Accounts payable ​ ​ 9,537 ​ ​ — ​ ​ 9,537 ​ ​ 12,036 ​ ​ — ​ ​ 12,036 ​ ​ 4,906 ​ ​ — ​ ​ 4,906 Accrued expenses ​ 3,828 ​ ​ — ​ 3,828 ​ 3,877 ​ ​ — ​ 3,877 ​ 5,152 ​ ​ — ​ 5,152 Lease liability, current portion ​ 231 ​ ​ — ​ 231 ​ 239 ​ ​ — ​ 239 ​ 277 ​ ​ — ​ 277 Total current liabilities ​ 25,848 ​ ​ — ​ 25,848 ​ 28,782 ​ ​ — ​ 28,782 ​ 11,653 ​ ​ — ​ 11,653 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liabilities, long-term ​ ​ 708 ​ ​ — ​ ​ 708 ​ ​ 630 ​ ​ — ​ ​ 630 ​ ​ 550 ​ ​ — ​ ​ 550 Warrant liability ​ ​ — ​ ​ 8,101 ​ ​ 8,101 ​ ​ — ​ ​ 1,050 ​ ​ 1,050 ​ ​ — ​ ​ 9,285 ​ ​ 9,285 Total liabilities ​ ​ 26,556 ​ ​ 8,101 ​ ​ 34,657 ​ ​ 29,412 ​ ​ 1,050 ​ ​ 30,462 ​ ​ 12,203 ​ ​ 9,285 ​ ​ 21,488 Commitments and contingencies (Note 13) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021 ​ ​ 887 ​ ​ (887) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued and outstanding at December 31, 2022 and December 31, 2021, respectively * ​ — ​ ​ — ​ — ​ 1 ​ ​ — ​ 1 ​ 4 ​ ​ — ​ 4 Additional paid-in capital * ​ 400,742 ​ ​ (12,425) ​ 388,317 ​ 414,523 ​ ​ (13,312) ​ 401,211 ​ 437,027 ​ ​ (35,283) ​ 401,744 Accumulated deficit ​ (398,886) ​ ​ 5,211 ​ (393,675) ​ (411,105) ​ ​ 12,262 ​ (398,843) ​ (430,771) ​ ​ 25,998 ​ (404,773) Total stockholders’ equity ​ 2,743 ​ ​ (8,101) ​ (5,358) ​ 3,419 ​ ​ (1,050) ​ 2,369 ​ 6,260 ​ ​ (9,285) ​ (3,025) Total liabilities and stockholders’ equity ​ $ 29,299 ​ $ — ​ $ 29,299 ​ $ 32,831 ​ $ — ​ $ 32,831 ​ $ 18,463 ​ $ — ​ $ 18,463 ​ * Adjustment reflected as a result of the 1 Quarterly and Year to Date Statements of Operations and Comprehensive Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Three Months Ended ​ Three Months Ended ​ ​ March 31, 2022 (unaudited) ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ As Previously Reported Adjustment As Restated As Previously Reported Adjustment As Restated As Previously Reported Adjustment As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, net ​ $ 1,761 ​ $ — ​ $ 1,761 ​ $ 2,126 ​ $ — ​ $ 2,126 ​ $ 3,002 ​ $ — ​ $ 3,002 Cost of product revenues ​ ​ 1,527 ​ ​ — ​ ​ 1,527 ​ ​ 2,231 ​ ​ — ​ ​ 2,231 ​ ​ 1,425 ​ ​ — ​ ​ 1,425 Gross profit (loss) ​ ​ 234 ​ ​ — ​ ​ 234 ​ ​ (105) ​ ​ — ​ ​ (105) ​ ​ 1,577 ​ ​ — ​ ​ 1,577 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 1,257 ​ $ — ​ $ 1,257 ​ $ 856 ​ $ — ​ $ 856 ​ $ 788 ​ $ — ​ $ 788 Selling and marketing ​ ​ 10,553 ​ ​ — ​ ​ 10,553 ​ ​ 7,411 ​ ​ — ​ ​ 7,411 ​ ​ 5,560 ​ ​ — ​ ​ 5,560 General and administrative ​ 3,997 ​ — ​ 3,997 ​ 3,026 ​ — ​ 3,026 ​ 2,815 ​ — ​ 2,815 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 11,122 ​ ​ — ​ ​ 11,122 Total operating expenses ​ 15,807 ​ — ​ 15,807 ​ 11,293 ​ — ​ 11,293 ​ 20,285 ​ — ​ 20,285 Loss from operations ​ (15,573) ​ — ​ (15,573) ​ (11,398) ​ — ​ (11,398) ​ (18,708) ​ — ​ (18,708) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ 1 ​ — ​ 1 ​ 2 ​ — ​ 2 ​ 46 ​ — ​ 46 Interest expense ​ ​ (872) ​ ​ — ​ ​ (872) ​ ​ (823) ​ ​ — ​ ​ (823) ​ ​ (1,004) ​ ​ — ​ ​ (1,004) Unrealized gain on warrant liability ​ ​ — ​ ​ 1,384 ​ ​ 1,384 ​ ​ — ​ ​ 7,051 ​ ​ 7,051 ​ ​ — ​ ​ 13,736 ​ ​ 13,736 Total other income (expense), net ​ ​ (871) ​ ​ 1,384 ​ ​ 513 ​ ​ (821) ​ ​ 7,051 ​ ​ 6,230 ​ ​ (958) ​ ​ 13,736 ​ ​ 12,778 Loss before benefit from income taxes ​ ​ (16,444) ​ ​ 1,384 ​ ​ (15,060) ​ ​ (12,219) ​ ​ 7,051 ​ ​ (5,168) ​ ​ (19,666) ​ ​ 13,736 ​ ​ (5,930) Benefit from income taxes ​ ​ 4,675 ​ ​ — ​ ​ 4,675 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (12,219) ​ $ 7,051 ​ $ (5,168) ​ $ (19,666) ​ $ 13,736 ​ $ (5,930) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share (basic and diluted) ​ $ (3.78) ​ $ 0.44 ​ $ (3.33) ​ $ (2.71) ​ $ 1.56 ​ $ (1.15) ​ $ (0.53) ​ $ 0.37 ​ $ (0.16) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average common shares (basic and diluted) ​ ​ 3,115,211 ​ 3,115,211 ​ 3,115,211 ​ ​ 4,510,219 ​ 4,510,219 ​ 4,510,219 ​ ​ 36,997,836 ​ 36,997,836 ​ 36,997,836 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (12,219) ​ $ 7,051 ​ $ (5,168) ​ $ (19,666) ​ $ 13,736 ​ $ (5,930) Other comprehensive income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized (loss) gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Comprehensive loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (12,219) ​ $ 7,051 ​ $ (5,168) ​ $ (19,666) ​ $ 13,736 ​ $ (5,930) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ Nine Months Ended ​ ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ As Previously Reported Adjustment As Restated As Previously Reported Adjustment As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, net ​ $ 3,887 ​ $ — ​ $ 3,887 ​ $ 6,888 ​ $ — ​ $ 6,888 Cost of product revenues ​ ​ 3,758 ​ ​ — ​ ​ 3,758 ​ ​ 5,183 ​ ​ — ​ ​ 5,183 Gross profit (loss) ​ ​ 129 ​ ​ — ​ ​ 129 ​ ​ 1,705 ​ ​ — ​ ​ 1,705 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 2,113 ​ $ — ​ $ 2,113 ​ $ 2,901 ​ $ — ​ $ 2,901 Selling and marketing ​ ​ 17,964 ​ ​ — ​ ​ 17,964 ​ ​ 23,523 ​ ​ — ​ ​ 23,523 General and administrative ​ 7,023 ​ — ​ 7,023 ​ 9,837 ​ — ​ 9,837 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — ​ ​ 11,122 ​ ​ — ​ ​ 11,122 Total operating expenses ​ 27,100 ​ — ​ 27,100 ​ 47,383 ​ — ​ 47,383 Loss from operations ​ (26,971) ​ — ​ (26,971) ​ (45,678) ​ — ​ (45,678) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ 3 ​ — ​ 3 ​ 50 ​ — ​ 50 Interest expense ​ ​ (1,695) ​ ​ — ​ ​ (1,695) ​ ​ (2,699) ​ ​ — ​ ​ (2,699) Unrealized gain on warrant liability ​ ​ — ​ ​ 8,435 ​ ​ 8,435 ​ ​ — ​ ​ 22,171 ​ ​ 22,171 Total other income (expense), net ​ ​ (1,692) ​ ​ 8,435 ​ ​ 6,743 ​ ​ (2,649) ​ ​ 22,171 ​ ​ 19,522 Loss before benefit from income taxes ​ ​ (28,663) ​ ​ 8,435 ​ ​ (20,228) ​ ​ (48,327) ​ ​ 22,171 ​ ​ (26,156) Benefit from income taxes ​ ​ 4,675 ​ ​ — ​ ​ 4,675 ​ ​ 4,675 ​ ​ — ​ ​ 4,675 Net loss ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share (basic and diluted) ​ $ (6.29) ​ $ 2.21 ​ $ (4.08) ​ $ (2.91) ​ $ 1.48 ​ $ (1.43) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average common shares (basic and diluted) ​ ​ 3,816,569 ​ 3,816,569 ​ 3,816,569 ​ ​ 14,998,534 ​ 14,998,534 ​ 14,998,534 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) Other comprehensive income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized (loss) gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Comprehensive loss ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) ​ ​ Statements of Changes in Stockholders’ Equity (Unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock ​ ​ Common Stock ​ Additional ​ Accumulated ​ ​ ​ Total ​ ​ Number of ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ Shares Amount ​ Shares * Amount Capital * Income Deficit Equity As Previously Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2021 ​ — ​ $ — ​ ​ 3,034,901 ​ $ — ​ $ 396,388 ​ $ — ​ $ (387,117) ​ $ 9,271 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 764 ​ ​ — ​ ​ — ​ ​ 764 Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 25,623 ​ ​ — ​ ​ 348 ​ ​ — ​ ​ — ​ ​ 348 Issuance of series A and B convertible preferred stock in a registered direct offering (Note 8) ​ 4,850 ​ ​ 4,850 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 4,850 Registered direct financing costs, inclusive of warrants ​ — ​ ​ (965) ​ ​ — ​ ​ — ​ ​ 244 ​ ​ — ​ ​ — ​ ​ (721) Conversion of series A convertible preferred stock ​ (2,425) ​ ​ (897) ​ ​ 303,125 ​ ​ — ​ ​ 897 ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 1,773 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with registered direct offering ​ — ​ ​ (2,101) ​ ​ — ​ ​ — ​ ​ 2,101 ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (11,769) ​ ​ (11,769) Balance March 31, 2022 ​ 2,425 ​ $ 887 ​ ​ 3,365,422 ​ $ — ​ $ 400,742 ​ $ — ​ $ (398,886) ​ $ 2,743 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2021 ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (9,183) ​ ​ — ​ ​ 3,827 ​ ​ (5,356) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of series A and B convertible preferred stock in a registered direct offering (Note 8) ​ — ​ ​ (4,850) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (4,850) Registered direct financing costs, inclusive of warrants ​ — ​ ​ 965 ​ ​ — ​ ​ — ​ ​ (244) ​ ​ — ​ ​ — ​ ​ 721 Conversion of series A convertible preferred stock ​ — ​ ​ 897 ​ ​ — ​ ​ — ​ ​ (897) ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with registered direct offering ​ — ​ ​ 2,101 ​ ​ — ​ ​ — ​ ​ (2,101) ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 1,384 ​ ​ 1,384 Total Adjustment March 31, 2022 ​ — ​ $ (887) ​ ​ — ​ $ — ​ $ (12,425) ​ $ — ​ $ 5,211 ​ $ (8,101) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2021 ​ — ​ $ — ​ ​ 3,034,901 ​ $ — ​ $ 387,205 ​ $ — ​ $ (383,290) ​ $ 3,915 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 764 ​ ​ — ​ ​ — ​ ​ 764 Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 25,623 ​ ​ — ​ ​ 348 ​ ​ — ​ ​ — ​ ​ 348 Issuance of series A and B convertible preferred stock in a registered direct offering (Note 8) ​ 4,850 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Registered direct financing costs, inclusive of warrants ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Conversion of series A convertible preferred stock ​ (2,425) ​ ​ — ​ ​ 303,125 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 1,773 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with registered direct offering ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (10,385) ​ ​ (10,385) Balance March 31, 2022 ​ 2,425 ​ $ — ​ ​ 3,365,422 ​ $ — ​ $ 388,317 ​ $ — ​ $ (393,675) ​ $ (5,358) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statements of Changes in Stockholders’ Equity (Unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock ​ ​ Common Stock ​ Additional ​ Accumulated ​ ​ ​ Total ​ ​ Number of ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ Shares Amount ​ Shares * Amount Capital * Income Deficit Equity As Previously Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance March 31, 2022 ​ 2,425 ​ $ 887 ​ ​ 3,365,422 ​ $ — ​ $ 400,742 ​ $ — ​ $ (398,886) ​ $ 2,743 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 669 ​ ​ — ​ ​ — ​ ​ 669 Fractional shares retired as a result of reverse split ​ — ​ ​ — ​ ​ (10) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 8,687,502 ​ ​ 1 ​ ​ 12,225 ​ ​ — ​ ​ — ​ ​ 12,226 Conversion of series B convertible preferred stock ​ (2,425) ​ ​ (887) ​ ​ 303,125 ​ ​ — ​ ​ 887 ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 4,118 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (12,219) ​ ​ (12,219) Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 414,523 ​ $ — ​ $ (411,105) ​ $ 3,419 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance March 31, 2022 ​ — ​ ​ (887) ​ ​ — ​ ​ — ​ ​ (12,425) ​ ​ — ​ ​ 5,211 ​ ​ (8,101) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Fractional shares retired as a result of reverse split ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Conversion of series B convertible preferred stock ​ — ​ ​ 887 ​ ​ — ​ ​ — ​ ​ (887) ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 7,051 ​ ​ 7,051 Balance June 30, 2022 ​ — ​ $ — ​ ​ — ​ $ — ​ $ (13,312) ​ $ — ​ $ 12,262 ​ $ (1,050) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance March 31, 2022 ​ 2,425 ​ $ — ​ ​ 3,365,422 ​ $ — ​ $ 388,317 ​ $ — ​ $ (393,675) ​ $ (5,358) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 669 ​ ​ — ​ ​ — ​ ​ 669 Fractional shares retired as a result of reverse split ​ — ​ ​ — ​ ​ (10) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 8,687,502 ​ ​ 1 ​ ​ 12,225 ​ ​ — ​ ​ — ​ ​ 12,226 Conversion of series B convertible preferred stock ​ (2,425) ​ ​ — ​ ​ 303,125 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 4,118 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (5,168) ​ ​ (5,168) Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 401,211 ​ $ — ​ $ (398,843) ​ $ 2,369 * Adjustment reflected as a result of the 1 . Statements of Changes in Stockholders’ Equity (Unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock ​ ​ Common Stock ​ Additional ​ ​ Accumulated ​ ​ ​ Total ​ ​ Number of ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ Shares Amount ​ Shares * Amount Capital * ​ Income Deficit Equity As Previously Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 414,523 ​ ​ $ — ​ $ (411,105) ​ $ 3,419 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 536 ​ ​ ​ — ​ ​ — ​ ​ 536 Issuance of common stock pursuant to a public offering, net of expenses ​ — ​ ​ — ​ ​ 26,666,666 ​ ​ 3 ​ ​ 21,968 ​ ​ ​ — ​ ​ — ​ ​ 21,971 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ (19,666) ​ ​ (19,666) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance September 30, 2022 ​ — ​ ​ — ​ ​ 39,026,823 ​ $ 4 ​ $ 437,027 ​ ​ $ — ​ $ (430,771) ​ $ 6,260 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance June 30, 2022 ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (13,312) ​ ​ ​ — ​ ​ 12,262 ​ ​ (1,050) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to a public offering, net of expenses ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (21,971) ​ ​ ​ — ​ ​ — ​ ​ (21,971) Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ 13,736 ​ ​ 13,736 Balance September 30, 2022 ​ — ​ ​ — ​ ​ — ​ $ — ​ $ (35,283) ​ ​ $ — ​ $ 25,998 ​ $ (9,285) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 401,211 ​ ​ $ — ​ $ (398,843) ​ $ 2,369 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 536 ​ ​ ​ — ​ ​ — ​ ​ 536 Issuance of common stock pursuant to a public offering, net of expenses ​ — ​ ​ — ​ ​ 26,666,666 ​ ​ 3 ​ ​ (3) ​ ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ (5,930) ​ ​ (5,930) Balance September 30, 2022 ​ — ​ ​ — ​ ​ 39,026,823 ​ $ 4 ​ $ 401,744 ​ ​ $ — ​ $ (404,773) ​ $ (3,025) * Adjustment reflected as a result of the 1 ​ Statements of Cash Flows ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Six Months Ended ​ Nine Months Ended ​ ​ March 31, 2022 (unaudited) ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ As Previoulsy Reported Adjustment As Restated As Previoulsy Reported Adjustment As Restated ​ As Previoulsy Reported Adjustment As Restated Cash flows from operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Noncash inventory reserve ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Depreciation ​ 527 ​ — ​ 527 ​ 1,057 ​ — ​ 1,057 ​ 1,255 ​ — ​ 1,255 Amortization ​ 61 ​ — ​ 61 ​ 124 ​ — ​ 124 ​ 188 ​ — ​ 188 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ ​ ​ — ​ ​ — ​ ​ 11,122 ​ ​ — ​ ​ 11,122 Noncash stock-based compensation ​ 764 ​ — ​ 764 ​ 1,433 ​ — ​ 1,433 ​ 1,969 ​ — ​ 1,969 Noncash amortization of deferred financing costs ​ ​ 419 ​ ​ — ​ ​ 419 ​ ​ 797 ​ ​ — ​ ​ 797 ​ ​ 1,635 ​ ​ — ​ ​ 1,635 Unrealized gain on warrants ​ ​ — ​ ​ (1,384) ​ ​ (1,384) ​ ​ — ​ ​ (8,435) ​ ​ (8,435) ​ ​ ​ ​ ​ (22,171) ​ ​ (22,171) Changes in operating assets and liabilities: ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts receivable ​ ​ (132) ​ ​ — ​ ​ (132) ​ ​ (554) ​ ​ — ​ ​ (554) ​ ​ (2,178) ​ ​ — ​ ​ (2,178) Income taxes receivable ​ ​ (4,675) ​ ​ ​ ​ ​ (4,675) ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ — Inventory ​ ​ (1,727) ​ ​ — ​ ​ (1,727) ​ ​ (1,374) ​ ​ — ​ ​ (1,374) ​ ​ (831) ​ ​ — ​ ​ (831) Prepaid expenses and other assets ​ ​ 707 ​ ​ — ​ ​ 707 ​ ​ 1,267 ​ ​ — ​ ​ 1,267 ​ ​ (1,551) ​ ​ — ​ ​ (1,551) Accounts payable and accrued expenses ​ 1,095 ​ — ​ 1,095 ​ 3,643 ​ — ​ 3,643 ​ (2,213) ​ — ​ (2,213) Lease liability ​ ​ (21) ​ ​ — ​ ​ (21) ​ ​ (90) ​ ​ — ​ ​ (90) ​ ​ (132) ​ ​ — ​ ​ (132) Net cash used in operating activities ​ (14,751) ​ — ​ (14,751) ​ (17,685) ​ — ​ (17,685) ​ (34,388) ​ — ​ (34,388) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchases of marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Sales and maturities of marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Acquisition of property and equipment ​ (126) ​ — ​ (126) ​ (133) ​ — ​ (133) ​ (133) ​ — ​ (133) Net cash (used in) provided by investing activities ​ (126) ​ — ​ (126) ​ (133) ​ — ​ (133) ​ (133) ​ — ​ (133) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from issuance of preferred stock in registered direct offering, net of offering costs ​ ​ 4,129 ​ ​ — ​ ​ 4,129 ​ ​ 4,129 ​ ​ — ​ ​ 4,129 ​ ​ 4,129 ​ ​ — ​ ​ 4,129 Proceeds from issuance of common stock in public offering, net of offering costs ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ ​ ​ — ​ ​ — ​ ​ 21,971 ​ ​ — ​ ​ 21,971 Proceeds from At-the-Market sales of common stock, net of offering costs ​ ​ 348 ​ ​ — ​ ​ 348 ​ ​ 12,573 ​ ​ — ​ ​ 12,573 ​ ​ 12,573 ​ ​ — ​ ​ 12,573 Proceeds from issuance of long-term debt ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Repayments of long-term debt ​ ​ (5,000) ​ ​ — ​ ​ (5,000) ​ ​ (5,000) ​ ​ — ​ ​ (5,000) ​ ​ (17,150) ​ ​ — ​ ​ (17,150) Debt financing costs paid ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Proceeds from exercise of stock options ​ — ​ — ​ — ​ — ​ — ​ — ​ — ​ — ​ — Net cash provided by financing activities ​ ​ (523) ​ ​ — ​ ​ (523) ​ ​ 11,702 ​ ​ — ​ ​ 11,702 ​ ​ 21,523 ​ ​ — ​ ​ 21,523 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net (decrease) increase in cash and cash equivalents ​ (15,400) ​ — ​ (15,400) ​ (6,116) ​ — ​ (6,116) ​ (12,998) ​ — ​ (12,998) Cash and cash equivalents, beginning of period ​ 19,143 ​ — ​ 19,143 ​ 19,143 ​ — ​ 19,143 ​ 19,143 ​ — ​ 19,143 Cash and cash equivalents, end of period ​ $ 3,743 ​ $ — ​ $ 3,743 ​ $ 13,027 ​ $ — ​ $ 13,027 ​ $ 6,145 ​ $ — ​ $ 6,145 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental cash flow information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest paid ​ $ 452 ​ $ — ​ $ 452 ​ $ 898 ​ $ — ​ $ 898 ​ $ 1,078 ​ $ — ​ $ 1,078 ​

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent Events	15. Subsequent Events On January 25, 2023, the Board declared a dividend of one one-thousandth ( 1/1,000th ​ All shares of Series C Preferred Stock that were not present in person or by proxy at the Special Meeting as of immediately prior to the opening of the polls at the Special Meeting were automatically redeemed (the “Initial Redemption”). The outstanding shares of Series C Preferred Stock that were not redeemed pursuant to the Initial Redemption were redeemed automatically upon the approval by the Company’s stockholders of the Reverse Stock Split Proposal. ​ On March 9, 2023, we conducted the Special Meeting where the vote on the Reverse Stock Split Proposal was approved. We have been notified by Nasdaq that we have until June 30, 2023 to effectuate the reverse stock split and regain compliance. ​ On March 21, 2023, the Company and Perceptive entered into the Sixth Amendment. The Sixth Amendment waived the Company’s obligations to (1) comply with certain financial covenants relating to minimum revenue requirements and minimum liquidity through June 30, 2023, and (2) file financial statements along with its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 that are not subject to any “going concern” qualification. In connection with the Sixth Amendment to the Perceptive Agreement, we amended and restated the Perceptive Warrants to reset the strike price of the Perceptive Warrants. ​ ​ ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, costs of product revenues, the accounting for common stock warrants, stock-based compensation, and accounting for research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. ​
Risks and Uncertainties	Risks and Uncertainties While Twirla has been approved by the FDA, other potential product candidates developed by the Company will require approval from the FDA prior to commercial sales. There can be no assurance that the Company’s other product candidates will receive the required approval. If the Company is denied approval or such approval is delayed, or is unable to obtain the necessary financing to complete development and approval, there could be a material adverse impact on the Company’s financial condition and results of operations. ​ It should be noted that current public health threats could adversely affect the Company’s ongoing or planned business operations. In particular, the ongoing COVID-19 pandemic has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The effect of these orders, government imposed quarantines and measures the Company has taken, such as implementing work-at-home policies, may negatively impact productivity, disrupt the Company’s business and could delay the Company’s commercialization timeline. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties with whom it engages, including personnel at third-party manufacturing facilities and other third parties with whom the Company conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct its business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on the Company. While to date we have been able to continue to execute our overall business plan, some of our business activities have been slowed and taken longer to complete and we continue to adjust to the challenges of operating in a largely remote setting with our employees. We have only recently launched our commercial activities for Twirla and begun engaging with healthcare providers to promote Twirla. We expect that, as we broaden our sales detailing activities, in some instances our sales force may encounter challenges engaging with healthcare providers during this on-going pandemic. Although many areas of the United States have begun to re-open access to offices and other commercial facilities, there continue to be areas where restrictions remain in place, which may have the potential to affect our ability to conduct our business. Further, new variants, including those which are more easily transmissible or resistant to existing vaccines, may lead to new shutdowns or business disruptions in the future. The Company will continue to closely monitor events as they develop and evaluate alternative, mitigating measures it can implement if needed.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations. The Company maintains balances with financial institutions in excess of the Federal Deposit Insurance Corporation limit.
Trade Accounts Receivable and Allowances	Trade Accounts Receivable and Allowances Trade accounts receivable are amounts owed to the Company by its customers for product that has been delivered. The trade accounts receivable are recorded at the invoice amount, less prompt pay and other discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses is the Company’s estimate of losses over the life of the receivables. The Company evaluates forward looking economic factors and uses professional judgment to determine the allowance for credit losses. The credit loss reserves are reviewed and adjusted periodically. Credit loss reserves were not material as of December 31, 2022 and 2021, respectively. ​ Trade accounts receivable are aged based on the contractual payment terms. When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts receivable, accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.
Inventory	Inventory Inventory is valued utilizing the weighted average costing method. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management’s current knowledge with respect to inventory levels, planned production and sales volume assumptions. During the year ended December 31, 2021, the Company established a reserve of approximately million for inventory not expected to be sold prior to its shelf-life date. As of December 31, 2022 inventory reserves approximated $0.6 million. ​ ​
Property and Equipment	Property and Equipment Property and equipment, consisting of office equipment, computer equipment and manufacturing equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight- line method over the estimated useful lives of the assets. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred. Improvements and additions are capitalized in accordance with Company policy. In the third quarter of 2022, the Company transferred manufacturing equipment with a book value of $11.1 million to Corium in exchange for relief from minimum material purchase requirements. The Company recorded a loss of
Long-Lived Assets	Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment ​
Research and Development Expense	Research and Development Expense Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees and support services used in drug development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received. ​
Advertising Costs	Advertising Costs The Company has elected to expense advertising costs when incurred. Advertising costs totaled
Deferred Financing Costs	Deferred Financing Costs Costs directly attributable to the Company’s term loan (see Note 9) are deferred and reported as a reduction of the related term loan. These costs represent legal fees and other costs related to the term loan and are being amortized utilizing the straight-line method over the term of the loan. Amortization of deferred financing costs charged to interest expense was approximately $342,000, $277,000 and $231,000 for the years ended December 31, 2022, 2021 and 2020, respectively. ​
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist principally of cash, cash equivalents and marketable securities. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has no financial instruments with off balance sheet risk of accounting loss. Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In 2022, the Company had sales to customers that individually accounted for more than 10% of its total revenue. These customers had sales of of total revenues in the aggregate. In 2021, the Company had sales to
Revenue Recognition	Revenue Recognition The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, Revenue from Contracts with Customers ​ In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable and Allowance policy. ​ The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. ​ Twirla is sold to customers at the wholesale acquisition cost (WAC). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following: ​ ● Distribution services fees ● Prompt pay and other discounts ● Product returns ● Chargebacks ● Rebates ● Co-payment assistance ​ An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period. ​ In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relied on industry standard data and trend analysis since historical sales data was not available as Twirla was launched in December 2020. As historical data becomes available, the Company will incorporate that data into its estimates of variable consideration. ​ The specific considerations that the Company uses in estimating these amounts related to variable considerations are as follows. ​ Distribution services fees – The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount. The Company records these fees as contra trade accounts receivable on the balance sheet. ​ Prompt pay and other discount Prompt pay discounts are typically taken by the Company’s customers, so an estimate of the discount is recorded at the time of sale based on the WAC. Prompt pay discount estimates are recorded as contra trade accounts receivable on the balance sheet. ​ The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded. ​ Product returns ​ Chargebacks ​ Rebates ​ Co-payment assistance ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Allowances for ​ Payments & ​ December 31, ​ 2021 current period sales credits 2022 Customer credits, discounts and allowances (contra accounts receivable) ​ $ 371 ​ $ 5,891 ​ $ (3,268) ​ $ 2,994 Rebates and co-pay assistance (accrued expenses) ​ ​ 669 ​ ​ 4,434 ​ ​ (2,771) ​ ​ 2,332 Total ​ $ 1,040 ​ $ 10,325 ​ $ (6,039) ​ $ 5,326 ​
Warrants	Warrants The Company accounts for its warrants to purchase common stock in accordance with ASC 480, Distinguishing Liabilities from Equity . shares of its common stock to the lender, Perceptive Credit Holdings III, L.P. (“Perceptive”). In connection with an amendment to that facility in February 2021, the Company issued warrants to purchase shares of the Company’s common stock (collectively, the “Perceptive Warrants”). The Perceptive Warrants qualify for equity classification and have been allocated based upon the relative fair value of the base instrument and the warrant. The Perceptive Warrants were subject to repricing in the event of an offering of securities at a price lower than the existing strike price before December 31, 2022. In connection with the Sixth Amendment, we amended and restated the Perceptive Warrants to reset the strike price of the Perceptive Warrants. See Notes 9 and 10 for additional information. ​ In connection with an underwritten public offering completed in October 2021, the Company issued warrants to purchase 333,333 shares of its common stock. This offering also triggered an adjustment to the exercise price of the Perceptive Warrants, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. See Notes 9 and 10 for additional information. ​ In connection with a registered direct offering completed in March 2022, the Company issued warrants to purchase 1,242,813 shares of its common stock. This offering also triggered an adjustment to the exercise price of the Perceptive Warrants, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. See Notes 9 and 10 for additional information. ​ In connection with a letter agreement and waiver entered into with an investor on April 2022, the Company issued warrants to purchase 212,188 shares of common stock. See Note 10 for additional information. ​ In connection with a public offering completed in July 2022, the Company issued warrants to purchase 54,666,665 shares of its common stock. This offering also triggered an adjustment to the exercise price of the Perceptive Warrants, which resulted in a reduction of the strike price for these warrants.
Income Taxes	Income Taxes The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no uncertain tax positions as of December 31, 2022 that qualify for either recognition or disclosure in the financial statements under this guidance.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation . The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital. The Company also awards restricted stock units (“RSUs”) to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. Cost associated with performance-based restricted stock units with a performance condition which affects the vesting is recognized only if the performance condition is probable of being satisfied. ​
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating and reporting ​
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the years ended December 31, 2022, 2021 and 2020, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Common stock warrants ​ 56,501,249 379,583 35,000 Unvested restricted stock units ​ 6,461 8,325 3,995 Common stock options ​ 397,818 259,145 212,977 Total ​ 56,905,528 647,053 251,972 ​
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. ASU 2016-13 was adopted by the Company on January 1, 2020 and had no current impact on the Company as the Company did not have any financial instruments covered by the topic on the date of adoption. Subsequent to the adoption date, the allowance for credit losses is immaterial. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). This guidance simplifies the accounting for income taxes by, among other things, reducing complexity in the interim-period accounting for year-to-date loss limitations and changes in tax laws. The adoption of this standard did not have a material impact on its financial statements. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848), an expansion of ASU 2020-04: Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2021-01”). This guidance permits entities to elect certain optional expedients and exceptions when accounting for derivative contracts and certain hedging relationships affected by changes in the interest rates used for discounting cash flows, for computing variation margin settlements, and for calculating price alignment interest) in connection with reference rate reform activities under way in global financial markets (the “discounting transition”). The guidance was effective immediately and did not have an impact on our consolidated financial statements. ​ Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Restatement of Previously Iss_2

Restatement of Previously Issued Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2022
Restatement of Previously Issued Financial Statements
Schedule of impact of the restatement on the balance sheets, operations and comprehensive loss, equity and cash flow statements for the affected periods	The following tables represent the restated balance sheet, restated statements of operations and comprehensive loss, statements of changes in stockholders’ equity and statement of cash flows for the year ended December 31, 2021. These tables also present a reconciliation from the prior period as previously reported to the restated amounts. The amounts as previously reported for fiscal year 2021 was derived from the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed on March 30, 2022. ​ Balance Sheet ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2021 ​ ​ As Previously ​ ​ ​ ​ ​ ​ ​ Reported Adjustment ​ As Restated Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ ​ $ 19,143 Accounts receivable, net ​ ​ 1,533 ​ ​ — ​ ​ ​ 1,533 Inventory, net ​ ​ 966 ​ ​ — ​ ​ ​ 966 Prepaid expenses and other current assets ​ 2,283 ​ ​ — ​ ​ 2,283 Total current assets ​ 23,925 ​ ​ — ​ ​ 23,925 Property and equipment, net ​ 12,447 ​ ​ — ​ ​ 12,447 Right of use asset ​ ​ 949 ​ ​ — ​ ​ ​ 949 Other non-current assets ​ 2,012 ​ ​ — ​ ​ 2,012 Total assets ​ $ 39,333 ​ $ — ​ ​ $ 39,333 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities and stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term debt, current portion ​ $ 16,833 ​ ​ — ​ ​ $ 16,833 Accounts payable ​ ​ 8,707 ​ ​ — ​ ​ ​ 8,707 Accrued expenses ​ 3,563 ​ ​ — ​ ​ 3,563 Lease liability, current portion ​ 175 ​ ​ — ​ ​ 175 Total current liabilities ​ 29,278 ​ ​ — ​ ​ 29,278 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liabilities, long-term ​ ​ 784 ​ ​ — ​ ​ ​ 784 Warrant liability ​ ​ — ​ ​ 5,356 ​ ​ ​ 5,356 Total liabilities ​ ​ 30,062 ​ ​ 5,356 ​ ​ ​ 35,418 Commitments and contingencies (Note 13) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding ​ ​ — ​ ​ — ​ ​ ​ — Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued outstanding ​ — ​ ​ — ​ ​ — Additional paid-in capital * ​ 396,388 ​ ​ (9,183) ​ ​ 387,205 Accumulated deficit ​ (387,117) ​ ​ 3,827 ​ ​ (383,290) Total stockholders’ equity ​ 9,271 ​ ​ (5,356) ​ ​ 3,915 Total liabilities and stockholders’ equity ​ $ 39,333 ​ $ — ​ ​ $ 39,333 ​ * Adjustment reflected as a result of the 1 ​ Statement of Operations and Comprehensive Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ As Previously Reported Adjustment As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, net ​ $ 4,101 ​ $ — ​ $ 4,101 Cost of product revenues ​ ​ 10,718 ​ ​ — ​ ​ 10,718 Gross profit (loss) ​ ​ (6,617) ​ ​ — ​ ​ (6,617) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 6,246 ​ $ — ​ $ 6,246 Selling and marketing ​ ​ 43,444 ​ ​ — ​ ​ 43,444 General and administrative ​ 14,698 ​ — ​ 14,698 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — Total operating expenses ​ 64,388 ​ — ​ 64,388 Loss from operations ​ (71,005) ​ — ​ (71,005) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ 25 ​ — ​ 25 Interest expense ​ ​ (3,914) ​ ​ — ​ ​ (3,914) Unrealized gain on warrant liability ​ ​ — ​ ​ 3,827 ​ ​ 3,827 Total other income (expense), net ​ ​ (3,889) ​ ​ 3,827 ​ ​ (62) Loss before benefit from income taxes ​ ​ (74,894) ​ ​ 3,827 ​ ​ (71,067) Benefit from income taxes ​ ​ — ​ ​ — ​ ​ — Net loss ​ $ (74,894) ​ $ 3,827 ​ $ (71,067) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share (basic and diluted)* ​ $ (30.86) ​ $ 1.58 ​ $ (29.28) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average common shares (basic and diluted) ​ ​ 2,426,821 ​ 2,426,821 ​ 2,426,821 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (74,894) ​ $ 3,827 ​ $ (71,067) Other comprehensive income: ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized (loss) gain on marketable securities ​ ​ (3) ​ ​ — ​ ​ (3) Comprehensive loss ​ $ (74,897) ​ $ 3,827 ​ $ (71,070) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * Adjustment reflected as a result of the 1-for-40 reverse stock split effectuated on April 26, 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Changes in Stockholders’ Equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Common Stock ​ Additional ​ Accumulated ​ ​ ​ ​ Net ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ ​ Shares * Amount Capital * Income Deficit Equity As Previoulsy Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2020 ​ ​ 2,189,100 ​ $ — ​ $ 361,548 ​ $ 3 ​ $ (312,223) ​ $ 49,328 Share-based compensation - stock options and RSUs ​ ​ — ​ ​ — ​ ​ 3,338 ​ ​ — ​ ​ — ​ ​ 3,338 Issuance of common stock pursuant to at‑the‑market stock sales, net of expenses ​ ​ 172,879 ​ ​ — ​ ​ 9,266 ​ ​ — ​ ​ — ​ ​ 9,266 Issuance of common stock in public offering, net of expenses ​ ​ 666,666 ​ ​ — ​ ​ 21,081 ​ ​ — ​ ​ — ​ ​ 21,081 Issuance of common stock upon exercise of stock options ​ ​ 3,160 ​ ​ — ​ ​ 75 ​ ​ — ​ ​ — ​ ​ 75 Vesting of RSUs ​ ​ 3,096 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with long-term debt ​ ​ — ​ ​ — ​ ​ 1,080 ​ ​ — ​ ​ — ​ ​ 1,080 Unrealized net gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ (3) ​ ​ — ​ ​ (3) Net loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (74,894) ​ ​ (74,894) Balance December 31, 2021 ​ ​ 3,034,901 ​ $ — ​ $ 396,388 ​ $ — ​ $ (387,117) ​ $ 9,271 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2020 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Share-based compensation - stock options and RSUs ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at‑the‑market stock sales, net of expenses ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock in public offering, net of expenses ​ ​ — ​ ​ — ​ ​ (9,183) ​ ​ — ​ ​ — ​ ​ (9,183) Issuance of common stock upon exercise of stock options ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with long-term debt ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Unrealized net gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 3,827 ​ ​ 3,827 Total adjustment December 31, 2021 ​ ​ — ​ $ — ​ $ (9,183) ​ $ — ​ $ 3,827 ​ $ (5,356) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2020 ​ ​ 2,189,100 ​ $ — ​ $ 361,548 ​ $ 3 ​ $ (312,223) ​ $ 49,328 Share-based compensation - stock options and RSUs ​ ​ — ​ ​ — ​ ​ 3,338 ​ ​ — ​ ​ — ​ ​ 3,338 Issuance of common stock pursuant to at‑the‑market stock sales, net of expenses ​ ​ 172,879 ​ ​ — ​ ​ 9,266 ​ ​ — ​ ​ — ​ ​ 9,266 Issuance of common stock in public offering, net of expenses ​ ​ 666,666 ​ ​ — ​ ​ 11,898 ​ ​ — ​ ​ — ​ ​ 11,898 Issuance of common stock upon exercise of stock options ​ ​ 3,160 ​ ​ — ​ ​ 75 ​ ​ — ​ ​ — ​ ​ 75 Vesting of RSUs ​ ​ 3,096 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with long-term debt ​ ​ — ​ ​ — ​ ​ 1,080 ​ ​ — ​ ​ — ​ ​ 1,080 Unrealized net gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ (3) ​ ​ — ​ ​ (3) Net loss ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (71,067) ​ ​ (71,067) Balance December 31, 2021 (Restated) ​ ​ 3,034,901 ​ $ — ​ $ 387,205 ​ $ — ​ $ (383,290) ​ $ 3,915 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * Adjustment reflected as a result of the 1 -for-40 reverse stock split effectuated on April 26, 2022. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statement of Cash Flows ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2021 ​ As Previously Reported Adjustment As Restated Cash flows from operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (74,894) ​ $ 3,827 ​ $ (71,067) Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Noncash inventory reserve ​ ​ 5,323 ​ ​ — ​ ​ 5,323 Depreciation ​ 2,064 ​ — ​ 2,064 Amortization ​ 159 ​ — ​ 159 Noncash stock-based compensation ​ 3,338 ​ — ​ 3,338 Noncash amortization of deferred financing costs ​ ​ 1,661 ​ ​ — ​ ​ 1,661 Unrealized gain on warrants ​ ​ — ​ ​ (3,827) ​ ​ (3,827) Changes in operating assets and liabilities: ​ ​ ​ ​ ​ ​ Accounts receivable ​ ​ (668) ​ ​ — ​ ​ (668) Inventory ​ ​ (6,289) ​ ​ — ​ ​ (6,289) Prepaid expenses and other assets ​ ​ (967) ​ ​ — ​ ​ (967) Accounts payable and accrued expenses ​ 5,202 ​ — ​ 5,202 Lease liability ​ ​ (131) ​ ​ — ​ ​ (131) Net cash used in operating activities ​ (65,202) ​ — ​ (65,202) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchases of marketable securities ​ ​ — ​ ​ — ​ ​ — Sales and maturities of marketable securities ​ ​ 39,729 ​ ​ — ​ ​ 39,729 Acquisition of property and equipment ​ (269) ​ — ​ (269) Net cash provided by investing activities ​ 39,460 ​ — ​ 39,460 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from issuance of preferred stock in registered direct offering, net of offering costs ​ ​ — ​ ​ — ​ ​ — Proceeds from issuance of common stock in public offering, net of offering costs ​ ​ 21,081 ​ ​ — ​ ​ 21,081 Proceeds from At-the-Market sales of common stock, net of offering costs ​ ​ 9,266 ​ ​ — ​ ​ 9,266 Proceeds from exercise of stock options ​ 75 ​ — ​ 75 Net cash provided by financing activities ​ ​ 30,422 ​ ​ — ​ ​ 30,422 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net (decrease) increase in cash and cash equivalents ​ 4,680 ​ — ​ 4,680 Cash and cash equivalents, beginning of period ​ 14,463 ​ — ​ 14,463 Cash and cash equivalents, end of period ​ $ 19,143 ​ $ — ​ $ 19,143 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental disclosure of noncash financing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants issued in connection with long-term debt ​ $ 1,080 ​ $ — ​ $ 1,080 Operating right-of-use assets obtained in exchange for new operating lease liabilities ​ ​ 969 ​ ​ — ​ ​ 969 Supplemental cash flow information ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest paid ​ $ 2,383 ​ $ — ​ $ 2,383

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of sales allowances and related accruals	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Allowances for ​ Payments & ​ December 31, ​ 2021 current period sales credits 2022 Customer credits, discounts and allowances (contra accounts receivable) ​ $ 371 ​ $ 5,891 ​ $ (3,268) ​ $ 2,994 Rebates and co-pay assistance (accrued expenses) ​ ​ 669 ​ ​ 4,434 ​ ​ (2,771) ​ ​ 2,332 Total ​ $ 1,040 ​ $ 10,325 ​ $ (6,039) ​ $ 5,326
Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for the years ended December 31, 2022, 2021 and 2020, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 2020 Common stock warrants ​ 56,501,249 379,583 35,000 Unvested restricted stock units ​ 6,461 8,325 3,995 Common stock options ​ 397,818 259,145 212,977 Total ​ 56,905,528 647,053 251,972 ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Measurements
Schedule of financial instruments measured at fair value by level within the fair value hierarchy	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 5,246 ​ $ — ​ $ — Total assets at fair value ​ $ 5,246 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability ​ $ — ​ $ — ​ $ 5,934 Total assets at fair value ​ $ — ​ $ — ​ $ 5,934 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 (Restated) December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ $ — Total assets at fair value ​ $ 19,143 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrant Liability (Restated) ​ $ — ​ $ — ​ $ 5,356 Total assets at fair value ​ $ — ​ $ — ​ $ 5,356 ​
Schedule of rollforward of the fair value of Level 3 warrants	​ ​ ​ ​ ​ Beginning balance at December 31, 2020 $ — Warrants issued ​ ​ 9,183 Change in fair value ​ (3,827) Ending balance at December 31, 2021 (Restated) ​ 5,356 Warrants issued ​ ​ 26,098 Change in fair value ​ (25,520) Ending balance at December 31, 2022 ​ $ 5,934 ​

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses
Schedule of prepaid expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Prepaid insurance ​ $ 628 ​ $ 775 Other ​ 775 ​ 1,508 Total prepaid expenses and other current assets ​ $ 1,403 ​ $ 2,283

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Schedule of components of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Estimated ​ 2022 2021 Life Office equipment ​ $ 132 ​ $ 7 5 years Computer equipment ​ 121 ​ 113 3 Years Manufacturing equipment ​ — ​ 14,477 7 years ​ ​ 253 ​ 14,597 ​ ​ Less: accumulated depreciation ​ (76) ​ (2,150) Property and equipment ​ $ 177 ​ $ 12,447 ​

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Accrued Liabilities
Schedule of accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Gross to net accruals ​ $ 2,332 ​ $ 670 Accrued compensation ​ ​ 833 ​ ​ 2,086 Accrued professional fees and other ​ 743 ​ 807 Total accrued liabilities ​ $ 3,908 ​ $ 3,563

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Maturity of lease liabilities	Future minimum lease payments under non-cancellable leases as of December 31, 2022 were as follows: ​ ​ ​ ​ 2023 ​ $ 391 2024 ​ ​ 397 2025 ​ 101 Total ​ $ 889 Less: Interest ​ (104) Present value of lease liability ​ $ 785

Credit Agreement and Guaranty (

Credit Agreement and Guaranty (Tables)	12 Months Ended
	Dec. 31, 2022
Credit Agreement and Guaranty
Schedule of carrying amount of term loan	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Notes payable $ 2,625 ​ $ 20,000 Debt issuance costs ​ ​ (209) ​ ​ (550) Warrant discount ​ ​ (990) ​ ​ (2,617) Total debt ​ $ 1,426 ​ $ 16,833 Less, current portion ​ ​ 1,426 ​ ​ 16,833 Long-term debt, less current portion ​ $ — ​ $ — ​

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2022
Equity Incentive Plans
Schedule of stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, ​ 2022 2021 2020 Cost of goods sold ​ $ 133 ​ $ 271 ​ $ 14 Research and development ​ ​ 372 ​ ​ 490 ​ ​ 651 Selling and marketing ​ ​ 155 ​ ​ 148 ​ ​ 108 General and administrative ​ 1,833 ​ 2,429 ​ 2,045 Total ​ $ 2,493 ​ $ 3,338 ​ $ 2,818 ​
Schedule of assumptions used to compute employee stock-based compensation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 2020 Risk‑free interest rate 1.71% - 4.22 % .66% - 1.51 % .40% - 1.68 % Expective volatility 107% ‑ 118 % 105% ‑ 106 % 65% ‑ 106 % Expected dividend yield 0 % 0 % 0 % Expected life (in years) 6.25 6.25 6.25 ​ ​
Summary of options outstanding, vested and exercisable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ Average Remaining ​ ​ ​ ​ ​ ​ Exercise Contractual ​ Aggregate ​ ​ Options ​ Price Life (Years) ​ Intrinsic Value Options outstanding at December 31, 2020 212,946 125.29 6.3 ​ Options granted 64,528 105.00 ​ Options exercised (3,159) 23.80 ​ Options cancelled/forfeited (15,170) 264.46 ​ Options outstanding at December 31, 2021 259,145 113.33 6.1 ​ Options granted 187,454 3.97 ​ Options exercised — — ​ Options cancelled/forfeited (48,781) 97.44 ​ Options outstanding at December 31, 2022 397,818 63.75 7.7 ​ $ 6 Options exercisable at December 31, 2022 182,667 113.54 5.7 ​ $ — Vested and expected to vest at December 31, 2022 397,818 ​ $ 6 ​
Schedule of restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average Aggregate ​ ​ Shares Grant Date Fair Value Intrinsic Value Restricted stock units outstanding at December 31, 2020 3,988 ​ $ 458 Granted 7,433 67.27 ​ ​ ​ Vested ​ (3,096) ​ 112.73 ​ ​ ​ Restricted stock units outstanding at December 31, 2021 8,325 — ​ $ 163 Granted ​ 4,690 ​ 1.05 ​ ​ ​ Vested (6,554) 76.30 ​ ​ ​ Restricted stock units outstanding at December 31, 2022 6,461 ​ ​ $ 2

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Schedule of tax effects of temporary differences that give rise to significant portions of deferred tax assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Deferred tax assets: ​ ​ Net operating loss carryforwards ​ $ 87,216 ​ $ 81,102 Research credit carryforward ​ 7,071 ​ 7,943 Stock options and other ​ 2,297 ​ 2,114 Total gross deferred tax assets ​ 96,584 ​ 91,159 Valuation allowance for deferred tax assets ​ (96,584) ​ (91,159) Net deferred tax assets ​ $ — ​ $ — ​
Schedule of reconciliation of U.S. statutory income tax rate to effective tax rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 (Restated) 2020 Federal income tax at statutory rate 21.0 % 21.0 % 21.0 % State income tax benefit, net of federal benefit 0.1 % 0.2 % 1.0 % Unrealized gain on warrants ​ 18.8 % 1.1 % — % Research and development tax credits 0.1 % 0.2 % 0.7 % Other (5.6) % (2.2) % (2.0) % Increase to valuation allowance (18.5) % (20.3) % (20.7) % Effective income tax rate 15.9 % 0.0 % 0.0 % ​

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information (Unaudited)
Summary of quarterly financial information	Balance Sheets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 (unaudited) ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ ​ As Previously ​ ​ ​ ​ ​ ​ As Previously ​ ​ ​ ​ ​ ​ As Previously ​ ​ ​ ​ ​ ​ Reported Adjustment As Restated Reported Adjustment As Restated Reported Adjustment As Restated Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 3,743 ​ $ — ​ $ 3,743 ​ $ 13,027 ​ $ — ​ $ 13,027 ​ $ 6,145 ​ $ — ​ $ 6,145 Accounts receivable, net ​ ​ 1,665 ​ ​ — ​ ​ 1,665 ​ ​ 2,087 ​ ​ — ​ ​ 2,087 ​ ​ 3,711 ​ ​ — ​ ​ 3,711 Income taxes receivable ​ ​ 4,675 ​ ​ — ​ ​ 4,675 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Inventory, net ​ ​ 2,693 ​ ​ — ​ ​ 2,693 ​ ​ 2,340 ​ ​ — ​ ​ 2,340 ​ ​ 1,797 ​ ​ — ​ ​ 1,797 Prepaid expenses and other current assets ​ 1,576 ​ ​ — ​ 1,576 ​ 1,016 ​ ​ — ​ 1,016 ​ 3,834 ​ ​ — ​ 3,834 Total current assets ​ 14,352 ​ ​ — ​ 14,352 ​ 18,470 ​ ​ — ​ 18,470 ​ 15,487 ​ ​ — ​ 15,487 Property and equipment, net ​ 12,047 ​ ​ — ​ 12,047 ​ 11,524 ​ ​ — ​ 11,524 ​ 203 ​ ​ — ​ 203 Right of use asset ​ ​ 888 ​ ​ — ​ ​ 888 ​ ​ 825 ​ ​ — ​ ​ 825 ​ ​ 761 ​ ​ — ​ ​ 761 Other non-current assets ​ 2,012 ​ ​ — ​ 2,012 ​ 2,012 ​ ​ — ​ 2,012 ​ 2,012 ​ ​ — ​ 2,012 Total assets ​ $ 29,299 ​ $ — ​ $ 29,299 ​ $ 32,831 ​ $ — ​ $ 32,831 ​ $ 18,463 ​ $ — ​ $ 18,463 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities and stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Long-term debt, current portion ​ $ 12,252 ​ ​ — ​ $ 12,252 ​ $ 12,630 ​ ​ — ​ $ 12,630 ​ $ 1,318 ​ ​ — ​ $ 1,318 Accounts payable ​ ​ 9,537 ​ ​ — ​ ​ 9,537 ​ ​ 12,036 ​ ​ — ​ ​ 12,036 ​ ​ 4,906 ​ ​ — ​ ​ 4,906 Accrued expenses ​ 3,828 ​ ​ — ​ 3,828 ​ 3,877 ​ ​ — ​ 3,877 ​ 5,152 ​ ​ — ​ 5,152 Lease liability, current portion ​ 231 ​ ​ — ​ 231 ​ 239 ​ ​ — ​ 239 ​ 277 ​ ​ — ​ 277 Total current liabilities ​ 25,848 ​ ​ — ​ 25,848 ​ 28,782 ​ ​ — ​ 28,782 ​ 11,653 ​ ​ — ​ 11,653 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Lease liabilities, long-term ​ ​ 708 ​ ​ — ​ ​ 708 ​ ​ 630 ​ ​ — ​ ​ 630 ​ ​ 550 ​ ​ — ​ ​ 550 Warrant liability ​ ​ — ​ ​ 8,101 ​ ​ 8,101 ​ ​ — ​ ​ 1,050 ​ ​ 1,050 ​ ​ — ​ ​ 9,285 ​ ​ 9,285 Total liabilities ​ ​ 26,556 ​ ​ 8,101 ​ ​ 34,657 ​ ​ 29,412 ​ ​ 1,050 ​ ​ 30,462 ​ ​ 12,203 ​ ​ 9,285 ​ ​ 21,488 Commitments and contingencies (Note 13) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stockholders’ equity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021 ​ ​ 887 ​ ​ (887) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued and outstanding at December 31, 2022 and December 31, 2021, respectively * ​ — ​ ​ — ​ — ​ 1 ​ ​ — ​ 1 ​ 4 ​ ​ — ​ 4 Additional paid-in capital * ​ 400,742 ​ ​ (12,425) ​ 388,317 ​ 414,523 ​ ​ (13,312) ​ 401,211 ​ 437,027 ​ ​ (35,283) ​ 401,744 Accumulated deficit ​ (398,886) ​ ​ 5,211 ​ (393,675) ​ (411,105) ​ ​ 12,262 ​ (398,843) ​ (430,771) ​ ​ 25,998 ​ (404,773) Total stockholders’ equity ​ 2,743 ​ ​ (8,101) ​ (5,358) ​ 3,419 ​ ​ (1,050) ​ 2,369 ​ 6,260 ​ ​ (9,285) ​ (3,025) Total liabilities and stockholders’ equity ​ $ 29,299 ​ $ — ​ $ 29,299 ​ $ 32,831 ​ $ — ​ $ 32,831 ​ $ 18,463 ​ $ — ​ $ 18,463 ​ * Adjustment reflected as a result of the 1 Quarterly and Year to Date Statements of Operations and Comprehensive Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Three Months Ended ​ Three Months Ended ​ ​ March 31, 2022 (unaudited) ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ As Previously Reported Adjustment As Restated As Previously Reported Adjustment As Restated As Previously Reported Adjustment As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, net ​ $ 1,761 ​ $ — ​ $ 1,761 ​ $ 2,126 ​ $ — ​ $ 2,126 ​ $ 3,002 ​ $ — ​ $ 3,002 Cost of product revenues ​ ​ 1,527 ​ ​ — ​ ​ 1,527 ​ ​ 2,231 ​ ​ — ​ ​ 2,231 ​ ​ 1,425 ​ ​ — ​ ​ 1,425 Gross profit (loss) ​ ​ 234 ​ ​ — ​ ​ 234 ​ ​ (105) ​ ​ — ​ ​ (105) ​ ​ 1,577 ​ ​ — ​ ​ 1,577 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 1,257 ​ $ — ​ $ 1,257 ​ $ 856 ​ $ — ​ $ 856 ​ $ 788 ​ $ — ​ $ 788 Selling and marketing ​ ​ 10,553 ​ ​ — ​ ​ 10,553 ​ ​ 7,411 ​ ​ — ​ ​ 7,411 ​ ​ 5,560 ​ ​ — ​ ​ 5,560 General and administrative ​ 3,997 ​ — ​ 3,997 ​ 3,026 ​ — ​ 3,026 ​ 2,815 ​ — ​ 2,815 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 11,122 ​ ​ — ​ ​ 11,122 Total operating expenses ​ 15,807 ​ — ​ 15,807 ​ 11,293 ​ — ​ 11,293 ​ 20,285 ​ — ​ 20,285 Loss from operations ​ (15,573) ​ — ​ (15,573) ​ (11,398) ​ — ​ (11,398) ​ (18,708) ​ — ​ (18,708) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ 1 ​ — ​ 1 ​ 2 ​ — ​ 2 ​ 46 ​ — ​ 46 Interest expense ​ ​ (872) ​ ​ — ​ ​ (872) ​ ​ (823) ​ ​ — ​ ​ (823) ​ ​ (1,004) ​ ​ — ​ ​ (1,004) Unrealized gain on warrant liability ​ ​ — ​ ​ 1,384 ​ ​ 1,384 ​ ​ — ​ ​ 7,051 ​ ​ 7,051 ​ ​ — ​ ​ 13,736 ​ ​ 13,736 Total other income (expense), net ​ ​ (871) ​ ​ 1,384 ​ ​ 513 ​ ​ (821) ​ ​ 7,051 ​ ​ 6,230 ​ ​ (958) ​ ​ 13,736 ​ ​ 12,778 Loss before benefit from income taxes ​ ​ (16,444) ​ ​ 1,384 ​ ​ (15,060) ​ ​ (12,219) ​ ​ 7,051 ​ ​ (5,168) ​ ​ (19,666) ​ ​ 13,736 ​ ​ (5,930) Benefit from income taxes ​ ​ 4,675 ​ ​ — ​ ​ 4,675 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (12,219) ​ $ 7,051 ​ $ (5,168) ​ $ (19,666) ​ $ 13,736 ​ $ (5,930) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share (basic and diluted) ​ $ (3.78) ​ $ 0.44 ​ $ (3.33) ​ $ (2.71) ​ $ 1.56 ​ $ (1.15) ​ $ (0.53) ​ $ 0.37 ​ $ (0.16) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average common shares (basic and diluted) ​ ​ 3,115,211 ​ 3,115,211 ​ 3,115,211 ​ ​ 4,510,219 ​ 4,510,219 ​ 4,510,219 ​ ​ 36,997,836 ​ 36,997,836 ​ 36,997,836 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (12,219) ​ $ 7,051 ​ $ (5,168) ​ $ (19,666) ​ $ 13,736 ​ $ (5,930) Other comprehensive income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized (loss) gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Comprehensive loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (12,219) ​ $ 7,051 ​ $ (5,168) ​ $ (19,666) ​ $ 13,736 ​ $ (5,930) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ Nine Months Ended ​ ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ As Previously Reported Adjustment As Restated As Previously Reported Adjustment As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, net ​ $ 3,887 ​ $ — ​ $ 3,887 ​ $ 6,888 ​ $ — ​ $ 6,888 Cost of product revenues ​ ​ 3,758 ​ ​ — ​ ​ 3,758 ​ ​ 5,183 ​ ​ — ​ ​ 5,183 Gross profit (loss) ​ ​ 129 ​ ​ — ​ ​ 129 ​ ​ 1,705 ​ ​ — ​ ​ 1,705 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 2,113 ​ $ — ​ $ 2,113 ​ $ 2,901 ​ $ — ​ $ 2,901 Selling and marketing ​ ​ 17,964 ​ ​ — ​ ​ 17,964 ​ ​ 23,523 ​ ​ — ​ ​ 23,523 General and administrative ​ 7,023 ​ — ​ 7,023 ​ 9,837 ​ — ​ 9,837 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — ​ ​ 11,122 ​ ​ — ​ ​ 11,122 Total operating expenses ​ 27,100 ​ — ​ 27,100 ​ 47,383 ​ — ​ 47,383 Loss from operations ​ (26,971) ​ — ​ (26,971) ​ (45,678) ​ — ​ (45,678) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other income (expense) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ 3 ​ — ​ 3 ​ 50 ​ — ​ 50 Interest expense ​ ​ (1,695) ​ ​ — ​ ​ (1,695) ​ ​ (2,699) ​ ​ — ​ ​ (2,699) Unrealized gain on warrant liability ​ ​ — ​ ​ 8,435 ​ ​ 8,435 ​ ​ — ​ ​ 22,171 ​ ​ 22,171 Total other income (expense), net ​ ​ (1,692) ​ ​ 8,435 ​ ​ 6,743 ​ ​ (2,649) ​ ​ 22,171 ​ ​ 19,522 Loss before benefit from income taxes ​ ​ (28,663) ​ ​ 8,435 ​ ​ (20,228) ​ ​ (48,327) ​ ​ 22,171 ​ ​ (26,156) Benefit from income taxes ​ ​ 4,675 ​ ​ — ​ ​ 4,675 ​ ​ 4,675 ​ ​ — ​ ​ 4,675 Net loss ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share (basic and diluted) ​ $ (6.29) ​ $ 2.21 ​ $ (4.08) ​ $ (2.91) ​ $ 1.48 ​ $ (1.43) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-average common shares (basic and diluted) ​ ​ 3,816,569 ​ 3,816,569 ​ 3,816,569 ​ ​ 14,998,534 ​ 14,998,534 ​ 14,998,534 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Comprehensive loss: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) Other comprehensive income: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unrealized (loss) gain on marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Comprehensive loss ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) ​ ​ Statements of Changes in Stockholders’ Equity (Unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock ​ ​ Common Stock ​ Additional ​ Accumulated ​ ​ ​ Total ​ ​ Number of ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ Shares Amount ​ Shares * Amount Capital * Income Deficit Equity As Previously Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2021 ​ — ​ $ — ​ ​ 3,034,901 ​ $ — ​ $ 396,388 ​ $ — ​ $ (387,117) ​ $ 9,271 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 764 ​ ​ — ​ ​ — ​ ​ 764 Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 25,623 ​ ​ — ​ ​ 348 ​ ​ — ​ ​ — ​ ​ 348 Issuance of series A and B convertible preferred stock in a registered direct offering (Note 8) ​ 4,850 ​ ​ 4,850 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 4,850 Registered direct financing costs, inclusive of warrants ​ — ​ ​ (965) ​ ​ — ​ ​ — ​ ​ 244 ​ ​ — ​ ​ — ​ ​ (721) Conversion of series A convertible preferred stock ​ (2,425) ​ ​ (897) ​ ​ 303,125 ​ ​ — ​ ​ 897 ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 1,773 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with registered direct offering ​ — ​ ​ (2,101) ​ ​ — ​ ​ — ​ ​ 2,101 ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (11,769) ​ ​ (11,769) Balance March 31, 2022 ​ 2,425 ​ $ 887 ​ ​ 3,365,422 ​ $ — ​ $ 400,742 ​ $ — ​ $ (398,886) ​ $ 2,743 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2021 ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (9,183) ​ ​ — ​ ​ 3,827 ​ ​ (5,356) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of series A and B convertible preferred stock in a registered direct offering (Note 8) ​ — ​ ​ (4,850) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (4,850) Registered direct financing costs, inclusive of warrants ​ — ​ ​ 965 ​ ​ — ​ ​ — ​ ​ (244) ​ ​ — ​ ​ — ​ ​ 721 Conversion of series A convertible preferred stock ​ — ​ ​ 897 ​ ​ — ​ ​ — ​ ​ (897) ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with registered direct offering ​ — ​ ​ 2,101 ​ ​ — ​ ​ — ​ ​ (2,101) ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 1,384 ​ ​ 1,384 Total Adjustment March 31, 2022 ​ — ​ $ (887) ​ ​ — ​ $ — ​ $ (12,425) ​ $ — ​ $ 5,211 ​ $ (8,101) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance December 31, 2021 ​ — ​ $ — ​ ​ 3,034,901 ​ $ — ​ $ 387,205 ​ $ — ​ $ (383,290) ​ $ 3,915 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 764 ​ ​ — ​ ​ — ​ ​ 764 Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 25,623 ​ ​ — ​ ​ 348 ​ ​ — ​ ​ — ​ ​ 348 Issuance of series A and B convertible preferred stock in a registered direct offering (Note 8) ​ 4,850 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Registered direct financing costs, inclusive of warrants ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Conversion of series A convertible preferred stock ​ (2,425) ​ ​ — ​ ​ 303,125 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 1,773 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Warrants issued in connection with registered direct offering ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (10,385) ​ ​ (10,385) Balance March 31, 2022 ​ 2,425 ​ $ — ​ ​ 3,365,422 ​ $ — ​ $ 388,317 ​ $ — ​ $ (393,675) ​ $ (5,358) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Statements of Changes in Stockholders’ Equity (Unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock ​ ​ Common Stock ​ Additional ​ Accumulated ​ ​ ​ Total ​ ​ Number of ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ Shares Amount ​ Shares * Amount Capital * Income Deficit Equity As Previously Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance March 31, 2022 ​ 2,425 ​ $ 887 ​ ​ 3,365,422 ​ $ — ​ $ 400,742 ​ $ — ​ $ (398,886) ​ $ 2,743 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 669 ​ ​ — ​ ​ — ​ ​ 669 Fractional shares retired as a result of reverse split ​ — ​ ​ — ​ ​ (10) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 8,687,502 ​ ​ 1 ​ ​ 12,225 ​ ​ — ​ ​ — ​ ​ 12,226 Conversion of series B convertible preferred stock ​ (2,425) ​ ​ (887) ​ ​ 303,125 ​ ​ — ​ ​ 887 ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 4,118 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (12,219) ​ ​ (12,219) Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 414,523 ​ $ — ​ $ (411,105) ​ $ 3,419 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance March 31, 2022 ​ — ​ ​ (887) ​ ​ — ​ ​ — ​ ​ (12,425) ​ ​ — ​ ​ 5,211 ​ ​ (8,101) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Fractional shares retired as a result of reverse split ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Conversion of series B convertible preferred stock ​ — ​ ​ 887 ​ ​ — ​ ​ — ​ ​ (887) ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 7,051 ​ ​ 7,051 Balance June 30, 2022 ​ — ​ $ — ​ ​ — ​ $ — ​ $ (13,312) ​ $ — ​ $ 12,262 ​ $ (1,050) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance March 31, 2022 ​ 2,425 ​ $ — ​ ​ 3,365,422 ​ $ — ​ $ 388,317 ​ $ — ​ $ (393,675) ​ $ (5,358) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 669 ​ ​ — ​ ​ — ​ ​ 669 Fractional shares retired as a result of reverse split ​ — ​ ​ — ​ ​ (10) ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to at-the market stock sales, net of expenses ​ — ​ ​ — ​ ​ 8,687,502 ​ ​ 1 ​ ​ 12,225 ​ ​ — ​ ​ — ​ ​ 12,226 Conversion of series B convertible preferred stock ​ (2,425) ​ ​ — ​ ​ 303,125 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Vesting of RSUs ​ — ​ ​ — ​ ​ 4,118 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (5,168) ​ ​ (5,168) Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 401,211 ​ $ — ​ $ (398,843) ​ $ 2,369 * Adjustment reflected as a result of the 1 . Statements of Changes in Stockholders’ Equity (Unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Preferred Stock ​ ​ Common Stock ​ Additional ​ ​ Accumulated ​ ​ ​ Total ​ ​ Number of ​ ​ ​ ​ ​ Number of ​ ​ ​ ​ Paid-in ​ ​ Other Comprehensive ​ Accumulated ​ Stockholders' ​ Shares Amount ​ Shares * Amount Capital * ​ Income Deficit Equity As Previously Reported ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 414,523 ​ ​ $ — ​ $ (411,105) ​ $ 3,419 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 536 ​ ​ ​ — ​ ​ — ​ ​ 536 Issuance of common stock pursuant to a public offering, net of expenses ​ — ​ ​ — ​ ​ 26,666,666 ​ ​ 3 ​ ​ 21,968 ​ ​ ​ — ​ ​ — ​ ​ 21,971 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ (19,666) ​ ​ (19,666) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance September 30, 2022 ​ — ​ ​ — ​ ​ 39,026,823 ​ $ 4 ​ $ 437,027 ​ ​ $ — ​ $ (430,771) ​ $ 6,260 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjustment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance June 30, 2022 ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (13,312) ​ ​ ​ — ​ ​ 12,262 ​ ​ (1,050) Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ — ​ ​ — Issuance of common stock pursuant to a public offering, net of expenses ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (21,971) ​ ​ ​ — ​ ​ — ​ ​ (21,971) Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ 13,736 ​ ​ 13,736 Balance September 30, 2022 ​ — ​ ​ — ​ ​ — ​ $ — ​ $ (35,283) ​ ​ $ — ​ $ 25,998 ​ $ (9,285) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As Restated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance June 30, 2022 ​ — ​ $ — ​ ​ 12,360,157 ​ $ 1 ​ $ 401,211 ​ ​ $ — ​ $ (398,843) ​ $ 2,369 Share-based compensation - stock options and RSUs ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 536 ​ ​ ​ — ​ ​ — ​ ​ 536 Issuance of common stock pursuant to a public offering, net of expenses ​ — ​ ​ — ​ ​ 26,666,666 ​ ​ 3 ​ ​ (3) ​ ​ ​ — ​ ​ — ​ ​ — Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ — ​ ​ (5,930) ​ ​ (5,930) Balance September 30, 2022 ​ — ​ ​ — ​ ​ 39,026,823 ​ $ 4 ​ $ 401,744 ​ ​ $ — ​ $ (404,773) ​ $ (3,025) * Adjustment reflected as a result of the 1 ​ Statements of Cash Flows ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Six Months Ended ​ Nine Months Ended ​ ​ March 31, 2022 (unaudited) ​ June 30, 2022 (unaudited) ​ September 30, 2022 (unaudited) ​ As Previoulsy Reported Adjustment As Restated As Previoulsy Reported Adjustment As Restated ​ As Previoulsy Reported Adjustment As Restated Cash flows from operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (11,769) ​ $ 1,384 ​ $ (10,385) ​ $ (23,988) ​ $ 8,435 ​ $ (15,553) ​ $ (43,652) ​ $ 22,171 ​ $ (21,481) Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Noncash inventory reserve ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Depreciation ​ 527 ​ — ​ 527 ​ 1,057 ​ — ​ 1,057 ​ 1,255 ​ — ​ 1,255 Amortization ​ 61 ​ — ​ 61 ​ 124 ​ — ​ 124 ​ 188 ​ — ​ 188 Loss on disposition of assets ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ ​ ​ — ​ ​ — ​ ​ 11,122 ​ ​ — ​ ​ 11,122 Noncash stock-based compensation ​ 764 ​ — ​ 764 ​ 1,433 ​ — ​ 1,433 ​ 1,969 ​ — ​ 1,969 Noncash amortization of deferred financing costs ​ ​ 419 ​ ​ — ​ ​ 419 ​ ​ 797 ​ ​ — ​ ​ 797 ​ ​ 1,635 ​ ​ — ​ ​ 1,635 Unrealized gain on warrants ​ ​ — ​ ​ (1,384) ​ ​ (1,384) ​ ​ — ​ ​ (8,435) ​ ​ (8,435) ​ ​ ​ ​ ​ (22,171) ​ ​ (22,171) Changes in operating assets and liabilities: ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts receivable ​ ​ (132) ​ ​ — ​ ​ (132) ​ ​ (554) ​ ​ — ​ ​ (554) ​ ​ (2,178) ​ ​ — ​ ​ (2,178) Income taxes receivable ​ ​ (4,675) ​ ​ ​ ​ ​ (4,675) ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ — Inventory ​ ​ (1,727) ​ ​ — ​ ​ (1,727) ​ ​ (1,374) ​ ​ — ​ ​ (1,374) ​ ​ (831) ​ ​ — ​ ​ (831) Prepaid expenses and other assets ​ ​ 707 ​ ​ — ​ ​ 707 ​ ​ 1,267 ​ ​ — ​ ​ 1,267 ​ ​ (1,551) ​ ​ — ​ ​ (1,551) Accounts payable and accrued expenses ​ 1,095 ​ — ​ 1,095 ​ 3,643 ​ — ​ 3,643 ​ (2,213) ​ — ​ (2,213) Lease liability ​ ​ (21) ​ ​ — ​ ​ (21) ​ ​ (90) ​ ​ — ​ ​ (90) ​ ​ (132) ​ ​ — ​ ​ (132) Net cash used in operating activities ​ (14,751) ​ — ​ (14,751) ​ (17,685) ​ — ​ (17,685) ​ (34,388) ​ — ​ (34,388) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from investing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Purchases of marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Sales and maturities of marketable securities ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Acquisition of property and equipment ​ (126) ​ — ​ (126) ​ (133) ​ — ​ (133) ​ (133) ​ — ​ (133) Net cash (used in) provided by investing activities ​ (126) ​ — ​ (126) ​ (133) ​ — ​ (133) ​ (133) ​ — ​ (133) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash flows from financing activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Proceeds from issuance of preferred stock in registered direct offering, net of offering costs ​ ​ 4,129 ​ ​ — ​ ​ 4,129 ​ ​ 4,129 ​ ​ — ​ ​ 4,129 ​ ​ 4,129 ​ ​ — ​ ​ 4,129 Proceeds from issuance of common stock in public offering, net of offering costs ​ ​ — ​ ​ — ​ ​ — ​ ​ ​ ​ ​ — ​ ​ — ​ ​ 21,971 ​ ​ — ​ ​ 21,971 Proceeds from At-the-Market sales of common stock, net of offering costs ​ ​ 348 ​ ​ — ​ ​ 348 ​ ​ 12,573 ​ ​ — ​ ​ 12,573 ​ ​ 12,573 ​ ​ — ​ ​ 12,573 Proceeds from issuance of long-term debt ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Repayments of long-term debt ​ ​ (5,000) ​ ​ — ​ ​ (5,000) ​ ​ (5,000) ​ ​ — ​ ​ (5,000) ​ ​ (17,150) ​ ​ — ​ ​ (17,150) Debt financing costs paid ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Proceeds from exercise of stock options ​ — ​ — ​ — ​ — ​ — ​ — ​ — ​ — ​ — Net cash provided by financing activities ​ ​ (523) ​ ​ — ​ ​ (523) ​ ​ 11,702 ​ ​ — ​ ​ 11,702 ​ ​ 21,523 ​ ​ — ​ ​ 21,523 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net (decrease) increase in cash and cash equivalents ​ (15,400) ​ — ​ (15,400) ​ (6,116) ​ — ​ (6,116) ​ (12,998) ​ — ​ (12,998) Cash and cash equivalents, beginning of period ​ 19,143 ​ — ​ 19,143 ​ 19,143 ​ — ​ 19,143 ​ 19,143 ​ — ​ 19,143 Cash and cash equivalents, end of period ​ $ 3,743 ​ $ — ​ $ 3,743 ​ $ 13,027 ​ $ — ​ $ 13,027 ​ $ 6,145 ​ $ — ​ $ 6,145 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental cash flow information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest paid ​ $ 452 ​ $ — ​ $ 452 ​ $ 898 ​ $ — ​ $ 898 ​ $ 1,078 ​ $ — ​ $ 1,078

Organization and Description _2

Organization and Description of Business (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Nature of Operations
Accumulated deficit	$ 408,702	$ 404,773	$ 398,843	$ 393,675	$ 383,290
Cash, cash equivalents and marketable securities	5,200
Working capital deficit	$ 2,000

Restatement of Previously Iss_3

Restatement of Previously Issued Financial Statements - Impact on Balance Sheet (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Current assets:
Cash and cash equivalents	$ 5,246	$ 19,143	$ 6,145	$ 13,027	$ 3,743
Accounts receivable, net	3,377	1,533	3,711	2,087	1,665
Inventory, net	1,332	966	1,797	2,340	2,693
Prepaid expenses and other current assets	1,403	2,283	3,834	1,016	1,576
Total current assets	11,358	23,925	15,487	18,470	14,352
Property and equipment, net	177	12,447	203	11,524	12,047
Right of use asset	695	949	761	825	888
Other non-current assets	2,012	2,012	2,012	2,012	2,012
Total assets	14,242	39,333	18,463	32,831	29,299
Current liabilities:
Long-term debt, current portion	1,426	16,833	1,318	12,630	12,252
Accounts payable	7,734	8,707	4,906	12,036	9,537
Accrued expenses	3,908	3,563	5,152	3,877	3,828
Lease liability, current portion	319	175	277	239	231
Total current liabilities	13,387	29,278	11,653	28,782	25,848
Lease liabilities, long-term	466	784	550	630	708
Warrant liability	5,934	5,356	9,285	1,050	8,101
Total liabilities	19,787	35,418	21,488	30,462	34,657
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021
Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued and outstanding at December 31, 2022 and December 31, 2021, respectively	4		4	1
Additional paid-in capital	403,153	387,205	401,744	401,211	388,317
Accumulated deficit	(408,702)	(383,290)	(404,773)	(398,843)	(393,675)
Total stockholders' equity	(5,545)	3,915	(3,025)	2,369	(5,358)	$ 49,328	$ 45,745
Total liabilities and stockholders' equity	$ 14,242	$ 39,333	18,463	32,831	29,299
Reverse stock split conversion ratio	0.025	0.025
Error Correction, Accounting for Warrants | As Previously Reported
Current assets:
Cash and cash equivalents		$ 19,143	6,145	13,027	3,743
Accounts receivable, net		1,533	3,711	2,087	1,665
Inventory, net		966	1,797	2,340	2,693
Prepaid expenses and other current assets		2,283	3,834	1,016	1,576
Total current assets		23,925	15,487	18,470	14,352
Property and equipment, net		12,447	203	11,524	12,047
Right of use asset		949	761	825	888
Other non-current assets		2,012	2,012	2,012	2,012
Total assets		39,333	18,463	32,831	29,299
Current liabilities:
Long-term debt, current portion		16,833	1,318	12,630	12,252
Accounts payable		8,707	4,906	12,036	9,537
Accrued expenses		3,563	5,152	3,877	3,828
Lease liability, current portion		175	277	239	231
Total current liabilities		29,278	11,653	28,782	25,848
Lease liabilities, long-term		784	550	630	708
Total liabilities		30,062	12,203	29,412	26,556
Stockholders' equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021					887
Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued and outstanding at December 31, 2022 and December 31, 2021, respectively			4	1
Additional paid-in capital		396,388	437,027	414,523	400,742
Accumulated deficit		(387,117)	(430,771)	(411,105)	(398,886)
Total stockholders' equity		9,271	6,260	3,419	2,743	$ 49,328
Total liabilities and stockholders' equity		39,333	18,463	32,831	29,299
Error Correction, Accounting for Warrants | Error Correction, Adjustment
Current liabilities:
Warrant liability		5,356	9,285	1,050	8,101
Total liabilities		5,356	9,285	1,050	8,101
Stockholders' equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021					(887)
Additional paid-in capital		(9,183)	(35,283)	(13,312)	(12,425)
Accumulated deficit		3,827	25,998	12,262	5,211
Total stockholders' equity		$ (5,356)	$ (9,285)	$ (1,050)	$ (8,101)

Restatement of Previously Iss_4

Restatement of Previously Issued Financial Statements - Impact on Balance Sheet - Other (Details) - $ / shares	Dec. 31, 2022	Jan. 07, 2022	Jan. 06, 2022	Dec. 31, 2021	Jan. 06, 2020
Restatement of Previously Issued Financial Statements
Preferred stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Preferred stock, authorized (in shares)	10,000,000			10,000,000
Preferred stock, issued (in shares)	4,850			0
Preferred stock, outstanding (in shares)	0			0
Common stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Common stock, authorized (in shares)	300,000,000	300,000,000	150,000,000	300,000,000	300,000,000
Common stock, issued (in shares)	42,970,134			3,034,901
Common stock, outstanding (in shares)	42,970,134			3,034,901

Restatement of Previously Iss_5

Restatement of Previously Issued Financial Statements - Impact on Statement of Operations and Comprehensive Loss (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues, net	$ 3,002	$ 2,126	$ 1,761	$ 3,887	$ 6,888	$ 10,884	$ 4,101	$ 749
Cost of product revenues	1,425	2,231	1,527	3,758	5,183	6,836	10,718	282
Gross profit (loss)	1,577	(105)	234	129	1,705	4,048	(6,617)	467
Operating expenses:
Research and development	788	856	1,257	2,113	2,901	3,253	6,246	13,500
Selling and marketing	5,560	7,411	10,553	17,964	23,523	30,369	43,444	23,285
General and administrative	2,815	3,026	3,997	7,023	9,837	11,860	14,698	12,735
Loss on disposition of assets	11,122				11,122	11,122
Total operating expenses	20,285	11,293	15,807	27,100	47,383	56,604	64,388	49,520
Loss from operations	(18,708)	(11,398)	(15,573)	(26,971)	(45,678)	(52,556)	(71,005)	(49,053)
Other income (expense)
Interest income	46	2	1	3	50	80	25	309
Interest expense	(1,004)	(823)	(872)	(1,695)	(2,699)	(3,131)	(3,914)	(3,109)
Unrealized gain on warrant liability	13,736	7,051	1,384	8,435	22,171	25,520	3,827
Total other income (expense), net	12,778	6,230	513	6,743	19,522	22,469	(62)	(2,800)
Loss before benefit from income taxes	(5,930)	(5,168)	(15,060)	(20,228)	(26,156)	(30,087)	(71,067)	(51,853)
Benefit from income taxes			4,675	4,675	4,675	4,675
Net loss	$ (5,930)	$ (5,168)	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Net loss per share (basic) (in dollars per share)	$ (0.16)	$ (1.15)	$ (3.33)	$ (4.08)	$ (1.43)	$ (1.18)	$ (29.28)	$ (24.40)
Net loss per share (diluted) (in dollars per share)	$ (0.16)	$ (1.15)	$ (3.33)	$ (4.08)	$ (1.43)	$ (1.18)	$ (29.28)	$ (24.40)
Weighted-average common shares (basic) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534	21,610,947	2,426,821	2,117,077
Weighted-average common shares (diluted) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534	21,610,947	2,426,821	2,117,077
Comprehensive loss:
Net loss	$ (5,930)	$ (5,168)	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Other comprehensive income:
Unrealized (loss) gain on marketable securities							(3)	3
Comprehensive loss	(5,930)	(5,168)	(10,385)	(15,553)	(21,481)	$ (25,412)	(71,070)	$ (51,850)
Error Correction, Accounting for Warrants | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues, net	3,002	2,126	1,761	3,887	6,888		4,101
Cost of product revenues	1,425	2,231	1,527	3,758	5,183		10,718
Gross profit (loss)	1,577	(105)	234	129	1,705		(6,617)
Operating expenses:
Research and development	788	856	1,257	2,113	2,901		6,246
Selling and marketing	5,560	7,411	10,553	17,964	23,523		43,444
General and administrative	2,815	3,026	3,997	7,023	9,837		14,698
Loss on disposition of assets	11,122				11,122
Total operating expenses	20,285	11,293	15,807	27,100	47,383		64,388
Loss from operations	(18,708)	(11,398)	(15,573)	(26,971)	(45,678)		(71,005)
Other income (expense)
Interest income	46	2	1	3	50		25
Interest expense	(1,004)	(823)	(872)	(1,695)	(2,699)		(3,914)
Total other income (expense), net	(958)	(821)	(871)	(1,692)	(2,649)		(3,889)
Loss before benefit from income taxes	(19,666)	(12,219)	(16,444)	(28,663)	(48,327)		(74,894)
Benefit from income taxes			4,675	4,675	4,675
Net loss	$ (19,666)	$ (12,219)	$ (11,769)	$ (23,988)	$ (43,652)		$ (74,894)
Net loss per share (basic) (in dollars per share)	$ (0.53)	$ (2.71)	$ (3.78)	$ (6.29)	$ (2.91)		$ (30.86)
Net loss per share (diluted) (in dollars per share)	$ (0.53)	$ (2.71)	$ (3.78)	$ (6.29)	$ (2.91)		$ (30.86)
Weighted-average common shares (basic) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Weighted-average common shares (diluted) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Comprehensive loss:
Net loss	$ (19,666)	$ (12,219)	$ (11,769)	$ (23,988)	$ (43,652)		$ (74,894)
Other comprehensive income:
Unrealized (loss) gain on marketable securities							(3)
Comprehensive loss	(19,666)	(12,219)	(11,769)	(23,988)	(43,652)		(74,897)
Error Correction, Accounting for Warrants | Error Correction, Adjustment
Other income (expense)
Unrealized gain on warrant liability	13,736	7,051	1,384	8,435	22,171		3,827
Total other income (expense), net	13,736	7,051	1,384	8,435	22,171		3,827
Loss before benefit from income taxes	13,736	7,051	1,384	8,435	22,171		3,827
Net loss	$ 13,736	$ 7,051	$ 1,384	$ 8,435	$ 22,171		$ 3,827
Net loss per share (basic) (in dollars per share)	$ 0.37	$ 1.56	$ 0.44	$ 2.21	$ 1.48		$ 1.58
Net loss per share (diluted) (in dollars per share)	$ 0.37	$ 1.56	$ 0.44	$ 2.21	$ 1.48		$ 1.58
Weighted-average common shares (basic) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Weighted-average common shares (diluted) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Comprehensive loss:
Net loss	$ 13,736	$ 7,051	$ 1,384	$ 8,435	$ 22,171		$ 3,827
Other comprehensive income:
Comprehensive loss	$ 13,736	$ 7,051	$ 1,384	$ 8,435	$ 22,171		$ 3,827

Restatement of Previously Iss_6

Restatement of Previously Issued Financial Statements - Impact on Statement of Changes in Stockholders' Equity (Details) $ in Thousands		1 Months Ended			3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jul. 06, 2022 shares	Jul. 31, 2022 USD ($) shares	Oct. 31, 2021 shares	Mar. 31, 2021 shares	Sep. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares	Mar. 31, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares	Sep. 30, 2022 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Increase (decrease) in stockholders' equity
Balance		$ 2,369			$ 2,369	$ (5,358)	$ 3,915	$ 3,915	$ 3,915	$ 3,915	$ 49,328	$ 45,745
Share-based compensation - stock options and RSUs						669	764			2,492	3,338	2,818
Issuance of common stock upon exercise of options											75	610
Warrants issued in connection with long-term debt											1,080	3,570
Unrealized net gain on marketable securities											(3)	3
Net loss					(5,930)	(5,168)	(10,385)	(15,553)	(21,481)	(25,412)	(71,067)	(51,853)
Balance					(3,025)	$ 2,369	$ (5,358)	$ 2,369	$ (3,025)	$ (5,545)	$ 3,915	$ 49,328
Reverse stock split conversion ratio										0.025	0.025
Common stock
Increase (decrease) in stockholders' equity
Balance		$ 1			$ 1
Balance (in shares) | shares		12,360,157			12,360,157	3,365,422	3,034,901	3,034,901	3,034,901	3,034,901	2,189,100	1,745,264
Issuance of common stock upon exercise of options (in shares) | shares											3,160	12,586
Vesting of RSUs (in shares) | shares						4,118	1,773			6,555	3,096
Balance					$ 4	$ 1		$ 1	$ 4	$ 4
Balance (in shares) | shares					39,026,823	12,360,157	3,365,422	12,360,157	39,026,823	42,970,134	3,034,901	2,189,100
Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Balance		$ 401,211			$ 401,211	$ 388,317	$ 387,205	$ 387,205	$ 387,205	$ 387,205	$ 361,548	$ 306,115
Share-based compensation - stock options and RSUs					536	669	764			2,492	3,338	2,818
Issuance of common stock upon exercise of options											75	610
Warrants issued in connection with long-term debt											1,080	3,570
Balance					401,744	401,211	388,317	401,211	401,744	403,153	387,205	361,548
Accumulated Other Comprehensive Income
Increase (decrease) in stockholders' equity
Balance											3
Unrealized net gain on marketable securities											(3)	3
Balance												3
Accumulated Deficit
Increase (decrease) in stockholders' equity
Balance		$ (398,843)			(398,843)	(393,675)	(383,290)	(383,290)	(383,290)	(383,290)	(312,223)	(260,370)
Net loss						(5,168)	(10,385)			(25,412)	(71,067)	(51,853)
Balance						(398,843)	(393,675)	(398,843)		(408,702)	(383,290)	(312,223)
Public offering
Increase (decrease) in stockholders' equity
Issuance of common stock										3	$ 11,898	$ 48,435
Issuance of common stock (in shares) | shares	7,518,334	7,518,334
Public offering | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock										$ 3
Issuance of common stock (in shares) | shares	19,148,332	19,148,332	666,666							26,666,666	666,666	431,250
Public offering | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock											$ 11,898	$ 48,435
At-the-market sales
Increase (decrease) in stockholders' equity
Issuance of common stock						12,226	$ 348			$ 13,457	$ 9,266
At-the-market sales | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock					$ 3	$ 1				$ 1
Issuance of common stock (in shares) | shares				172,879	26,666,666	8,687,502	25,623			12,655,773	172,879
At-the-market sales | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock					$ (3)	$ 12,225	$ 348			$ 13,456	$ 9,266
Error Correction, Accounting for Warrants | As Previously Reported
Increase (decrease) in stockholders' equity
Balance		$ 3,419			3,419	2,743	9,271	9,271	9,271	$ 9,271	49,328
Share-based compensation - stock options and RSUs						669	764				3,338
Issuance of common stock						12,226
Issuance of common stock upon exercise of options											75
Warrants issued in connection with long-term debt											1,080
Unrealized net gain on marketable securities											(3)
Net loss					(19,666)	(12,219)	(11,769)	(23,988)	(43,652)		(74,894)
Balance					6,260	$ 3,419	$ 2,743	$ 3,419	$ 6,260		$ 9,271	$ 49,328
Error Correction, Accounting for Warrants | As Previously Reported | Common stock
Increase (decrease) in stockholders' equity
Balance		$ 1			$ 1
Balance (in shares) | shares		12,360,157			12,360,157	3,365,422	3,034,901	3,034,901	3,034,901	3,034,901	2,189,100
Issuance of common stock						$ 1
Issuance of common stock (in shares) | shares						8,687,502
Issuance of common stock upon exercise of options (in shares) | shares											3,160
Vesting of RSUs (in shares) | shares						4,118	1,773				3,096
Balance					$ 4	$ 1		$ 1	$ 4
Balance (in shares) | shares					39,026,823	12,360,157	3,365,422	12,360,157	39,026,823		3,034,901	2,189,100
Error Correction, Accounting for Warrants | As Previously Reported | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Balance		$ 414,523			$ 414,523	$ 400,742	$ 396,388	$ 396,388	$ 396,388	$ 396,388	$ 361,548
Share-based compensation - stock options and RSUs					536	669	764				3,338
Issuance of common stock						12,225
Issuance of common stock upon exercise of options											75
Warrants issued in connection with long-term debt											1,080
Balance					437,027	414,523	400,742	414,523	437,027		396,388	$ 361,548
Error Correction, Accounting for Warrants | As Previously Reported | Accumulated Other Comprehensive Income
Increase (decrease) in stockholders' equity
Balance											3
Unrealized net gain on marketable securities											(3)
Balance												3
Error Correction, Accounting for Warrants | As Previously Reported | Accumulated Deficit
Increase (decrease) in stockholders' equity
Balance		(411,105)			(411,105)	(398,886)	(387,117)	(387,117)	(387,117)	(387,117)	(312,223)
Net loss						(12,219)	(11,769)				(74,894)
Balance						(411,105)	(398,886)	(411,105)			(387,117)	$ (312,223)
Error Correction, Accounting for Warrants | As Previously Reported | Public offering
Increase (decrease) in stockholders' equity
Issuance of common stock											$ 21,081
Error Correction, Accounting for Warrants | As Previously Reported | Public offering | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock (in shares) | shares											666,666
Error Correction, Accounting for Warrants | As Previously Reported | Public offering | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock											$ 21,081
Error Correction, Accounting for Warrants | As Previously Reported | At-the-market sales
Increase (decrease) in stockholders' equity
Issuance of common stock							$ 348				$ 9,266
Error Correction, Accounting for Warrants | As Previously Reported | At-the-market sales | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock					$ 3
Issuance of common stock (in shares) | shares					26,666,666		25,623				172,879
Error Correction, Accounting for Warrants | As Previously Reported | At-the-market sales | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock					$ 21,968		$ 348				$ 9,266
Error Correction, Accounting for Warrants | Error Correction, Adjustment
Increase (decrease) in stockholders' equity
Balance		(1,050)			(1,050)	(8,101)	$ (5,356)	$ (5,356)	$ (5,356)	$ (5,356)
Balance (in shares) | shares							(5,356,000)	(5,356,000)	(5,356,000)	(5,356,000)
Net loss					13,736	7,051	$ 1,384	$ 8,435	$ 22,171		3,827
Balance					(9,285)	(1,050)	(8,101)	(1,050)	(9,285)		$ (5,356)
Balance (in shares) | shares											(5,356,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Balance		(13,312)			(13,312)	(12,425)	$ (9,183)	$ (9,183)	$ (9,183)	$ (9,183)
Balance (in shares) | shares							(9,183,000)	(9,183,000)	(9,183,000)	(9,183,000)
Balance					(35,283)	(13,312)	$ (12,425)	$ (13,312)	$ (35,283)		$ (9,183)
Balance (in shares) | shares											(9,183,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Accumulated Deficit
Increase (decrease) in stockholders' equity
Balance		$ 12,262			12,262	5,211	$ 3,827	$ 3,827	$ 3,827	$ 3,827
Balance (in shares) | shares							3,827,000	3,827,000	3,827,000	3,827,000
Net loss						7,051	$ 1,384				$ 3,827
Balance						$ 12,262	$ 5,211	$ 12,262			$ 3,827
Balance (in shares) | shares											3,827,000
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Public offering
Increase (decrease) in stockholders' equity
Issuance of common stock											$ (9,183)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Public offering | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock											$ (9,183)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | At-the-market sales | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock					$ (21,971)

Restatement of Previously Iss_7

Restatement of Previously Issued Financial Statements - Impact on Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash inventory reserve					5,323
Depreciation	527	1,057	1,255	1,280	2,064	105
Amortization	61	124	188	254	159	171
Noncash stock-based compensation	764	1,433	1,969	2,493	3,338	2,818
Noncash amortization of deferred financing costs	419	797	1,635	1,969	1,661	1,341
Unrealized gain on warrants	(1,384)	(8,435)	(22,171)	(25,520)	(3,827)
Changes in operating assets and liabilities:
Accounts receivable	(132)	(554)	(2,178)	(1,844)	(668)	(865)
Inventory	(1,727)	(1,374)	(831)	(366)	(6,289)
Prepaid expenses and other assets	707	1,267	(1,551)	880	(967)	(2,485)
Accounts payable and accrued expenses	1,095	3,643	(2,213)	(628)	5,202	3,641
Lease liability	(21)	(90)	(132)	(175)	(131)	(184)
Net cash used in operating activities	(14,751)	(17,685)	(34,388)	(35,947)	(65,202)	(47,311)
Cash flows from investing activities:
Purchases of marketable securities						(54,837)
Sales and maturities of marketable securities					39,729	14,500
Acquisition of property and equipment	(126)	(133)	(133)	(133)	(269)	(353)
Net cash provided by investing activities	(126)	(133)	(133)	(133)	39,460	(40,690)
Cash flows from financing activities:
Proceeds from issuance of common stock in public offering, net of offering costs			21,971	21,936	21,081	48,434
Proceeds from exercise of stock options					75	610
Net cash provided by financing activities	(523)	11,702	21,523	22,183	30,422	67,985
Net (decrease) increase in cash and cash equivalents	(15,400)	(6,116)	(12,998)	(13,897)	4,680	(20,016)
Cash and cash equivalents, beginning of period	19,143	19,143	19,143	19,143	14,463	34,479
Cash and cash equivalents, end of period	3,743	13,027	6,145	5,246	19,143	14,463
Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt					1,080	3,570
Operating right-of-use assets obtained in exchange for new operating lease liabilities					969
Supplemental cash flow information
Interest paid	452	898	1,078	1,162	2,383	2,099
As Previously Reported | Error Correction, Accounting for Warrants
Cash flows from operating activities:
Net loss	(11,769)	(23,988)	(43,652)		(74,894)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash inventory reserve					5,323
Depreciation	527	1,057	1,255		2,064
Amortization	61	124	188		159
Noncash stock-based compensation	764	1,433	1,969		3,338
Noncash amortization of deferred financing costs	419	797	1,635		1,661
Changes in operating assets and liabilities:
Accounts receivable	(132)	(554)	(2,178)		(668)
Inventory	(1,727)	(1,374)	(831)		(6,289)
Prepaid expenses and other assets	707	1,267	(1,551)		(967)
Accounts payable and accrued expenses	1,095	3,643	(2,213)		5,202
Lease liability	(21)	(90)	(132)		(131)
Net cash used in operating activities	(14,751)	(17,685)	(34,388)		(65,202)
Cash flows from investing activities:
Sales and maturities of marketable securities					39,729
Acquisition of property and equipment	(126)	(133)	(133)		(269)
Net cash provided by investing activities	(126)	(133)	(133)		39,460
Cash flows from financing activities:
Proceeds from issuance of common stock in public offering, net of offering costs			21,971		21,081
Proceeds from exercise of stock options					75
Net cash provided by financing activities	(523)	11,702	21,523		30,422
Net (decrease) increase in cash and cash equivalents	(15,400)	(6,116)	(12,998)		4,680
Cash and cash equivalents, beginning of period	19,143	19,143	19,143	19,143	14,463
Cash and cash equivalents, end of period	3,743	13,027	6,145		19,143	$ 14,463
Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt					1,080
Operating right-of-use assets obtained in exchange for new operating lease liabilities					969
Supplemental cash flow information
Interest paid	452	898	1,078		2,383
Error Correction, Adjustment | Error Correction, Accounting for Warrants
Cash flows from operating activities:
Net loss	1,384	8,435	22,171		3,827
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized gain on warrants	(1,384)	(8,435)	(22,171)		(3,827)
Public offering
Cash flows from financing activities:
Proceeds from issuance of preferred stock in registered direct offering, net of offering costs	4,129	4,129	4,129	4,128
Public offering | As Previously Reported | Error Correction, Accounting for Warrants
Cash flows from financing activities:
Proceeds from issuance of preferred stock in registered direct offering, net of offering costs	4,129	4,129	4,129
At-the-market sales
Cash flows from financing activities:
Proceeds from At-the-Market sales of common stock, net of offering costs	348	12,573	12,573	$ 13,494	9,266
At-the-market sales | As Previously Reported | Error Correction, Accounting for Warrants
Cash flows from financing activities:
Proceeds from At-the-Market sales of common stock, net of offering costs	$ 348	$ 12,573	$ 12,573		$ 9,266

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Inventory (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Summary of Significant Accounting Policies
Inventory reserve	$ 5.3

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2022
Loss on disposition of assets	$ (11,122)	$ (11,122)	$ (11,122)
Corium Agreement [Member]
Minimum material purchase requirements	$ 11,100
Loss on disposition of assets			$ (11,100)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies
Advertising costs	$ 8.2	$ 13.8	$ 5.5

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Deferred Financing Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Interest expense [Member]
Deferred Financing Costs
Amortization of deferred financing costs	$ 342,000	$ 277,000	$ 231,000

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) customer	Dec. 31, 2021 USD ($) customer	Dec. 31, 2020 USD ($)
Concentration of risk, financial assets
Financial instruments with off-balance sheet risk of accounting loss, assets						$ 0
Concentration risk, financial liabilities
Financial instruments with off-balance sheet risk of accounting loss, liabilities						0
Total revenue	$ 3,002	$ 2,126	$ 1,761	$ 3,887	$ 6,888	$ 10,884	$ 4,101	$ 749
Customer Concentration Risk | Sales Revenue
Concentration risk, financial liabilities
Number of major customers | customer						4	3
Customer Concentration Risk | Sales Revenue | Customer One
Concentration risk, financial liabilities
Total revenue						$ 2,900	$ 1,300
Customer Concentration Risk | Sales Revenue | Customer Two
Concentration risk, financial liabilities
Total revenue						2,700	1,300
Customer Concentration Risk | Sales Revenue | Customer Three
Concentration risk, financial liabilities
Total revenue						$ 2,600	$ 1,200
Concentration risk, percentage						93%
Customer Concentration Risk | Sales Revenue | Customer Four
Concentration risk, financial liabilities
Total revenue						$ 1,200
Concentration risk, percentage						86%
Customer Concentration Risk | Accounts Receivable
Concentration risk, financial liabilities
Number of major customers | customer						4
Customer Concentration Risk | Accounts Receivable | Customer One
Concentration risk, financial liabilities
Concentration risk, percentage						28%
Customer Concentration Risk | Accounts Receivable | Customer Two
Concentration risk, financial liabilities
Concentration risk, percentage						29%
Customer Concentration Risk | Accounts Receivable | Customer Three
Concentration risk, financial liabilities
Concentration risk, percentage						25%
Customer Concentration Risk | Accounts Receivable | Customer Four
Concentration risk, financial liabilities
Concentration risk, percentage						15%

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Co-Payment Assistance (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable, Beginning Balance	$ 1,040
Allowances for current period sales	10,325
Payments & credits	(6,039)
Accounts Receivable, Ending Balance	5,326
Customer credits, discounts And allowances
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable, Beginning Balance	371
Allowances for current period sales	5,891
Payments & credits	(3,268)
Accounts Receivable, Ending Balance	2,994
Rebates and co-pay assistance
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Accounts Receivable, Beginning Balance	669
Allowances for current period sales	4,434
Payments & credits	(2,771)
Accounts Receivable, Ending Balance	$ 2,332

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Warrants (Details) - shares	Dec. 31, 2022	Jul. 31, 2022	Jul. 06, 2022	Apr. 30, 2022	Mar. 31, 2022	Oct. 31, 2021	Feb. 28, 2021	Feb. 29, 2020
Warrants
Common stock that can be purchased with warrants (in shares)				212,188
Common stock that can be purchased with warrants (in shares)					1,242,813	333,333
Public offering
Warrants
Common stock that can be purchased with warrants (in shares)		54,666,665
Common stock that can be purchased with warrants (in shares)		38,296,664	7,518,334			333,333
Warrants | Public offering
Warrants
Common stock that can be purchased with warrants (in shares)		15,036,668
Warrants | Perceptive Credit Agreement
Warrants
Common stock that can be purchased with warrants (in shares)		11,250			11,250	11,250
Perceptive Warrants | Perceptive Credit Agreement
Warrants
Common stock that can be purchased with warrants (in shares)								35,000
Common stock that can be purchased with warrants (in shares)	35,000					35,000	11,250

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Income Taxes (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Uncertainty in tax positions
Uncertain tax positions	$ 0

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Segment Information (Details)	12 Months Ended
	Dec. 31, 2022 segment
Segment Information
Number of operating segments	1
Number of reporting segments	1

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	56,905,528	647,053	251,972
Common stock warrants
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	56,501,249	379,583	35,000
Unvested restricted stock units
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	6,461	8,325	3,995
Common stock options
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	397,818	259,145	212,977

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value by Hierarchy Level (Details) - Recurring - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Level 1
Assets:
Cash and cash equivalents	$ 5,246	$ 19,143
Total assets at fair value	5,246	19,143
Level 3
Liabilities:
Warrant Liability	5,934	5,356
Total liabilities at fair value	$ 5,934	$ 5,356

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Valuation Assumptions (Details) - Option pricing model	Dec. 31, 2022 Y USD ($)	Dec. 31, 2021 Y USD ($)
Option Volatility
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input		136.4
Risk free interest rate
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input	4.2	1.1
Fair value
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input | $	0.23	31.63
Expected life
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input | Y		4.98
Preferred Warrants [Member] | Strike price
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input | $	(10.40)
Common stock warrants | Strike price
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input | $	0.90	34.08
Maximum | Option Volatility
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input	137.4
Maximum | Expected life
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input | Y	4.5
Minimum | Option Volatility
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input	136.8
Minimum | Expected life
Significant assumptions used in valuation of the Company's warrants
Warrants, Measurement Input | Y	4.3

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Warrants (Details) - Warrants - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 5,356	$ 0
Warrants issued	26,098	9,183
Change in fair value	(25,520)	(3,827)
Ending balance	$ 5,934	$ 5,356

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses
Prepaid insurance	$ 628				$ 775
Other	775				1,508
Total prepaid expenses and other current assets	$ 1,403	$ 3,834	$ 1,016	$ 1,576	$ 2,283

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Property and Equipment
Property and equipment, gross	$ 253	$ 14,597
Less: accumulated depreciation	(76)	(2,150)
Property and equipment, net	177	12,447	$ 203	$ 11,524	$ 12,047
Office equipment
Property and Equipment
Property and equipment, gross	$ 132	$ 7
Estimated Life (in years)	5 years	5 years
Computer equipment
Property and Equipment
Property and equipment, gross	$ 121	$ 113
Estimated Life (in years)	3 years	3 years
Manufacturing equipment
Property and Equipment
Property and equipment, gross	$ 14,300	$ 14,477
Estimated Life (in years)	7 years	7 years

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Accrued Liabilities
Gross to net accruals	$ 2,332				$ 670
Accrued compensation	833				2,086
Accrued professional fees and other	743				807
Total accrued liabilities	$ 3,908	$ 5,152	$ 3,877	$ 3,828	$ 3,563

Leases - Summary (Details)

Leases - Summary (Details)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) lease	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Leases
Number of finance leases | lease				0
Number of operating leases | lease				1
Lessee, Operating Lease, Existence of Option to Extend [true false]				true
Renewal term				5 years
Operating lease expense | $				$ 355,000	$ 180,000
Operating lease expense information:
Cash paid for amounts included in measurement of lease liabilities | $	$ 21,000	$ 90,000	$ 132,000	$ 175,000	$ 131,000	$ 184,000
Weighted-average remaining lease term (years)				2 years 3 months
Weighted-average discount rate				11.80%

Leases - Maturity of lease liab

Leases - Maturity of lease liabilities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Operating Leases
2023	$ 391
2024	397
2025	101
Total	889
Less: Interest	(104)
Present value of lease liability	$ 785

Credit Agreement and Guaranty_2

Credit Agreement and Guaranty (Details)

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jul. 25, 2022 USD ($)

Jul. 08, 2022 USD ($)

Jan. 07, 2022 USD ($)

Feb. 10, 2020 USD ($) $ / shares Y item

Dec. 31, 2023 USD ($)

Mar. 31, 2022 USD ($) $ / shares shares

Jun. 30, 2022 USD ($)

Sep. 30, 2022 USD ($)

Dec. 31, 2022 USD ($) Y shares

Dec. 31, 2020 USD ($)

Jul. 31, 2022 $ / shares shares

Mar. 22, 2022 shares

Dec. 31, 2021 USD ($) Y

Oct. 31, 2021 $ / shares shares

Sep. 30, 2021 $ / shares

Feb. 28, 2021 shares

Feb. 26, 2021 $ / shares

Feb. 10, 2021 $ / shares

Credit Agreement and Guaranty

Amount borrowed

$ 20,000,000

Repayments of debt

$ 5,000,000

$ 5,000,000

$ 17,150,000

$ 17,375,000

Interest rate (as a percent)

14.38%

Percentage of annual interest rate

3%

Common stock that can be purchased with warrants (in shares) | shares

1,242,813

333,333

Proceeds from warrant exercises

$ 20,000,000

Perceptive Credit Agreement

Credit Agreement and Guaranty

Outstanding line of credit

$ 0

Repayments of debt

$ 5,000,000

$ 5,000,000

Prepayment of outstanding principal

$ 7,000,000

Monthly principal payments

$ 75,000

Minimum cash covenants

$ 3,000,000

Revenue generated under debt

$ 87,100,000

$ 62,600,000

Perceptive Credit Agreement | Perceptive Warrants

Credit Agreement and Guaranty

Exercise price of warrants (in dollars per share) | $ / shares

$ 114.80

Common stock that can be purchased with warrants (in shares) | shares

35,000

35,000

11,250

Number of warrants issued | item

2

Beneficial ownership percentage

19.99%

Facility fee percentage

1%

Perceptive Credit Agreement | First Seven Lakhs Shares

Credit Agreement and Guaranty

Exercise price of warrants (in dollars per share) | $ / shares

$ 149.60

$ 105.52

$ 14.90

$ 141.60

$ 186.80

$ 186.80

Common stock that can be purchased with warrants (in shares) | shares

17,500

17,500

17,500

17,500

17,500

Perceptive Credit Agreement | Remaining Seven Lakhs Shares

Credit Agreement and Guaranty

Exercise price of warrants (in dollars per share) | $ / shares

$ 186.80

$ 86.61

$ 12.37

$ 115.20

149.60

$ 149.60

Common stock that can be purchased with warrants (in shares) | shares

17,500

17,500

17,500

17,500

Perceptive Credit Agreement | Warrants

Credit Agreement and Guaranty

Exercise price of warrants (in dollars per share) | $ / shares

$ 69.13

$ 10.03

$ 90.80

$ 114.80

$ 114.80

Common stock that can be purchased with warrants (in shares) | shares

11,250

11,250

11,250

Senior secured delayed draw term loan facility | Perceptive Credit Agreement

Credit Agreement and Guaranty

Maximum borrowing capacity

$ 35,000,000

Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche One

Credit Agreement and Guaranty

Amount borrowed

5,000,000

Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Two

Credit Agreement and Guaranty

Amount borrowed

15,000,000

Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Three

Credit Agreement and Guaranty

Amount borrowed

$ 15,000,000

LIBOR | Perceptive Credit Agreement

Credit Agreement and Guaranty

Variable interest rate margin (as a percent)

10.25%

Interest rate for the base rate

1.50%

Prepayment Occur on or Before February, 10, 2022 | Perceptive Credit Agreement

Credit Agreement and Guaranty

Prepayment premium percentage

4%

Prepayment Occur on or Before February, 10, 2023 | Perceptive Credit Agreement

Credit Agreement and Guaranty

Prepayment premium percentage

2%

Two Thousand Twenty Perceptive Warrants [Member]

Credit Agreement and Guaranty

Fair value of warrants

$ 3,600,000

Two Thousand Twenty One Perceptive Warrants [Member]

Credit Agreement and Guaranty

Fair value of warrants

$ 1,100,000

Option pricing model | Risk free interest rate

Credit Agreement and Guaranty

Warrants, Measurement Input

4.2

1.1

Option pricing model | Expected life

Credit Agreement and Guaranty

Warrants, Measurement Input | Y

4.98

Option pricing model | Fair value

Credit Agreement and Guaranty

Warrants, Measurement Input

0.23

31.63

Option pricing model | Maximum | Expected life

Credit Agreement and Guaranty

Warrants, Measurement Input | Y

4.5

Option pricing model | Minimum | Expected life

Credit Agreement and Guaranty

Warrants, Measurement Input | Y

4.3

Option pricing model | Common stock warrants | Strike price

Credit Agreement and Guaranty

Warrants, Measurement Input

0.90

34.08

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Volatility

Credit Agreement and Guaranty

Warrants, Measurement Input

0.700

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Risk free interest rate

Credit Agreement and Guaranty

Warrants, Measurement Input | item

0.0147

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Expected life

Credit Agreement and Guaranty

Warrants, Measurement Input | Y

7

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Fair value

Credit Agreement and Guaranty

Warrants, Measurement Input | $ / shares

160.40

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Maximum | Perceptive Warrants | Strike price

Credit Agreement and Guaranty

Warrants, Measurement Input | $ / shares

186.80

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Minimum | Perceptive Warrants | Strike price

Credit Agreement and Guaranty

Warrants, Measurement Input | $ / shares

149.60

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Warrants | Volatility

Credit Agreement and Guaranty

Warrants, Measurement Input

1.035

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Warrants | Risk free interest rate

Credit Agreement and Guaranty

Warrants, Measurement Input | item

0.0115

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Warrants | Expected life

Credit Agreement and Guaranty

Warrants, Measurement Input | Y

7

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Warrants | Strike price

Credit Agreement and Guaranty

Warrants, Measurement Input | item

114.80

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Credit Agreement | Expected life

Credit Agreement and Guaranty

Warrants, Measurement Input | Y

7

Credit Agreement and Guaranty -

Credit Agreement and Guaranty - Carrying Amount Of term Loan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Credit Agreement and Guaranty
Notes payable	$ 2,625,000	$ 20,000,000
Debt issuance costs	(209,000)	(550,000)
Warrant discount	(990,000)	(2,617,000)
Total	1,426,000	16,833,000
Less, current portion	1,426,000	16,833,000	$ 1,318,000	$ 12,630,000	$ 12,252,000
Warrants and debt issue costs	$ 1,969,000	$ 1,661,000

Stockholders' Equity - Amended

Stockholders' Equity - Amended and Restated Certificate of Incorporation (Details)	12 Months Ended
	Dec. 31, 2022 class shares	Jan. 07, 2022 shares	Jan. 06, 2022 shares	Dec. 31, 2021 shares	Jan. 06, 2020 shares
Stockholders' Equity
Common stock, authorized (in shares) | shares	300,000,000	300,000,000	150,000,000	300,000,000	300,000,000
Board of Directors, number of classes	3
Term of Board member	3 years
Number of classes elected at each annual meeting	1
Minimum
Stockholders' Equity
Affirmative vote of all then-outstanding shares of capital stock for removal of directors (as a percent)	75%

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Aug. 22, 2022

Jul. 06, 2022

Apr. 27, 2022

Apr. 25, 2022

Apr. 04, 2022

Mar. 15, 2022

Mar. 14, 2022

Jan. 10, 2022

Jul. 31, 2022

Oct. 31, 2021

Mar. 31, 2021

Sep. 30, 2022

Jun. 30, 2022

Mar. 31, 2022

Sep. 30, 2022

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Mar. 22, 2022

Sep. 30, 2021

Feb. 28, 2021

Feb. 26, 2021

Feb. 10, 2021

Oct. 02, 2020

Feb. 10, 2020

Sale of stock

Common stock that can be purchased with warrants (in shares)

333,333

1,242,813

Stock stated value

$ 0.0001

$ 0.0001

Maximum

Sale of stock

Proceeds from issuance of common stock in public offering, net of offering costs

$ 75

Common stock

Sale of stock

Conversion of convertible preferred stock (in shares)

303,125

Perceptive Warrants | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

35,000

35,000

11,250

Exercise price of warrants (in dollars per share)

$ 114.80

First Seven Lakhs Shares | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

17,500

17,500

17,500

17,500

17,500

Exercise price of warrants (in dollars per share)

$ 14.90

$ 141.60

$ 105.52

$ 186.80

$ 186.80

$ 149.60

Remaining Seven Lakhs Shares | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

17,500

17,500

17,500

17,500

Exercise price of warrants (in dollars per share)

$ 12.37

$ 115.20

$ 86.61

149.60

$ 149.60

$ 186.80

Warrants | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

11,250

11,250

11,250

Exercise price of warrants (in dollars per share)

$ 10.03

$ 90.80

$ 69.13

$ 114.80

$ 114.80

Series A-1 warrants

Sale of stock

Warrant Exercisable Term

5 years

Series A-2 warrants

Sale of stock

Exercisable term

13 months

Series B Warrants

Sale of stock

Conversion of stock shares converted

303,125

2020 Shelf Registration Statement

Sale of stock

Aggregate amount of securities issuable

$ 200

2022 Preferred Stock Offering

Sale of stock

Common stock that can be purchased with warrants (in shares)

30,313

Proceeds from issuance of common stock in public offering, net of offering costs

$ 4.1

Exercise price of warrants (in dollars per share)

$ 10

Conversion price

$ 8

Preferred Stock, convertible, shares issuable

606,250

Exercisable term

6 months

Stock stated value

$ 1,000

Warrants and rights outstanding, term

5 years

Duration From Offering To Anniversary Of Closing

180 days

2022 Preferred Stock Offering | Series A Warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

212,188

606,250

Exercise price of warrants (in dollars per share)

$ 10.40

$ 10.40

Exercisable term

6 months

Warrants and rights outstanding, term

5 years

Warrant Exercisable Term

5 years

2022 Preferred Stock Offering | Series B Warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

606,250

Exercise price of warrants (in dollars per share)

$ 10.40

Exercisable term

6 months

Warrants and rights outstanding, term

1 year 6 months

At-the-market sales | Common stock

Sale of stock

Issuance of common stock (in shares)

172,879

26,666,666

8,687,502

25,623

12,655,773

172,879

Proceeds from issuance of common stock in public offering, net of offering costs

$ 9.3

At-the-market sales | Common stock | Maximum

Sale of stock

Commission percentage

3%

Authorized value for shares issuance

$ 50

Public offering

Sale of stock

Issuance of common stock (in shares)

7,518,334

7,518,334

Common stock that can be purchased with warrants (in shares)

7,518,334

38,296,664

333,333

Share price (in dollars per share)

$ 0.90

Proceeds from issuance of common stock in public offering, net of offering costs

$ 22

Public offering | Common stock

Sale of stock

Issuance of common stock (in shares)

19,148,332

19,148,332

666,666

26,666,666

666,666

431,250

Common stock that can be purchased with one-half of warrant (in shares)

1

Share price (in dollars per share)

$ 0.8999

$ 34

Proceeds from issuance of common stock in public offering, net of offering costs

$ 22

$ 21.1

Public offering | Warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

15,036,668

Public offering | Pre-funded warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

7,518,334

2022 ATM

Sale of stock

Issuance of common stock (in shares)

8,687,502

3,942,648

Proceeds from issuance of common stock in public offering, net of offering costs

$ 12.2

$ 0.9

2022 ATM | Common stock

Sale of stock

Issuance of common stock (in shares)

25,623

Proceeds from issuance of common stock in public offering, net of offering costs

$ 0.3

2022 ATM | Common stock | Maximum

Sale of stock

Commission percentage

3%

Authorized value for shares issuance

$ 50

2022 ATM | New Warrant [Member]

Sale of stock

Warrant Exercisable Term

6 months

H.C. Wainwright & Co., LLC, Sales Agent [Member]

Sale of stock

Common stock that can be purchased with warrants (in shares)

1,333,333

Commission percentage

7%

3%

Exercise price of warrants (in dollars per share)

$ 1.125

H.C. Wainwright & Co., LLC, Sales Agent [Member] | Common stock

Sale of stock

Issuance of common stock (in shares)

12,841,000

Series A Preferred Stock

Sale of stock

Conversion of stock shares converted

2,425

Series A Preferred Stock | 2022 Preferred Stock Offering

Sale of stock

Issuance of common stock (in shares)

2,425

Series B Preferred Stock

Sale of stock

Issuance of common stock (in shares)

2,425

Series B Preferred Stock | 2022 Preferred Stock Offering

Sale of stock

Issuance of common stock (in shares)

2,425

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Options Summary (Details) - Common stock options	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Minimum
Equity Incentive Plans
Exercise prices of options granted through the end of the year (in dollars per share)	$ 0.20
Maximum
Equity Incentive Plans
Exercise prices of options granted through the end of the year (in dollars per share)	$ 430
1997 Plan and 2008 Plan
Equity Incentive Plans
Expiration period	10 years
Vesting period	4 years
2014 Incentive Compensation Plan
Equity Incentive Plans
Shares available for grant | shares	314,398

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity Incentive Plans
Total stock-based compensation expense	$ 764	$ 1,433	$ 1,969	$ 2,493	$ 3,338	$ 2,818
Common stock options
Equity Incentive Plans
Total stock-based compensation expense				$ 2,493	$ 3,338	$ 2,818
Assumptions used to compute employee stock based compensation under the Black-Scholes option pricing model
Expected dividend yield (as a percent)				0%	0%	0%
Expected life (in years)				6 years 3 months	6 years 3 months	6 years 3 months
Unrecorded deferred stock-based compensation
Unrecorded deferred stock-based compensation balance related to stock options				$ 3,300
Weighted-average amortization period over which cost is expected to be recognized				2 years 9 months 18 days
Weighted average grant date fair value of options granted (in dollars per share)				$ 3.29
Common stock options | Cost of goods sold
Equity Incentive Plans
Total stock-based compensation expense				$ 133	$ 271	$ 14
Common stock options | Research and development
Equity Incentive Plans
Total stock-based compensation expense				372	490	651
Common stock options | Selling and marketing
Equity Incentive Plans
Total stock-based compensation expense				155	148	108
Common stock options | General and administrative
Equity Incentive Plans
Total stock-based compensation expense				$ 1,833	$ 2,429	$ 2,045
Common stock options | Minimum
Assumptions used to compute employee stock based compensation under the Black-Scholes option pricing model
Risk-free interest rate (as a percent)				1.71%	66%	0.40%
Expected volatility (as a percent)				107%	105%	65%
Common stock options | Maximum
Assumptions used to compute employee stock based compensation under the Black-Scholes option pricing model
Risk-free interest rate (as a percent)				4.22%	1.51%	1.68%
Expected volatility (as a percent)				118%	106%	106%
Unvested restricted stock units
Unrecorded deferred stock-based compensation
Unrecorded deferred stock-based compensation balance related to stock options				$ 68,000,000
Weighted-average amortization period over which cost is expected to be recognized				8 months 12 days

Equity Incentive Plans - Stoc_2

Equity Incentive Plans - Stock Option Activity (Details) - Common stock options - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Options
Options outstanding at beginning of year (in shares)	259,145	212,946
Options granted (in shares)	187,454	64,528
Options exercised (in shares)		(3,159)
Options cancelled/forfeited (in shares)	(48,781)	(15,170)
Options outstanding at end of year (in shares)	397,818	259,145	212,946
Options exercisable at end of year (in shares)	182,667
Vested and expected to vest at end of year (in shares)	397,818
Weighted Average Exercise Price
Options outstanding at beginning of year (in dollars per share)	$ 113.33	$ 125.29
Options granted (in dollars per share)	3.97	105
Options exercised (in dollars per share)		23.80
Options cancelled/forfeited (in dollars per share)	97.44	264.46
Options outstanding at end of year (in dollars per share)	63.75	$ 113.33	$ 125.29
Options exercisable at end of year (in dollars per share)	$ 113.54
Weighted Average Remaining Contractual Life (Years)
Options outstanding	7 years 8 months 12 days	6 years 1 month 6 days	6 years 3 months 18 days
Options exercisable	5 years 8 months 12 days
Aggregate Intrinsic Value
Options outstanding at the end of the year (in dollars)	$ 6
Vested and expected to vest at end of year	$ 6
Estimated stock price (in dollars per share)	$ 0.23

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock (Details) - Unvested restricted stock units - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Shares
Restricted stock outstanding at beginning of year (in shares)	8,325	3,988
Granted (in shares)	4,690	7,433
Vested (in shares)	(6,554)	(3,096)
Restricted stock outstanding at end of year (in shares)	6,461	8,325	3,988
Weighted Average Grant Date Fair Value
Granted (in dollars per share)	$ 1.05	$ 67.27
Vested (in dollars per share)	$ 76.30	$ 112.73
Aggregate Intrinsic Value
Intrinsic value of vested shares	$ 2	$ 163	$ 458
Executive officers
Shares
Granted (in shares)		1,774
Vesting period		1 year
Directors
Shares
Granted (in shares)	4,690	5,659
Directors | Minimum
Shares
Vesting period	1 year	1 year
Directors | Maximum
Shares
Vesting period		3 years

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2018
Federal | Net Operating Losses
Income Taxes
Net operating loss carryforwards	$ 390.6	$ 188.9
Indefinite net operating loss carryforward	201.7
Federal | Research and Development.
Income Taxes
Tax credit carryforwards	6.4
State | Net Operating Losses
Income Taxes
Net operating loss carryforwards	79.9
State | Research and Development.
Income Taxes
Tax credit carryforwards	$ 0.9

Income Taxes - Deferred Taxes (

Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 87,216	$ 81,102
Research credit carryforward	7,071	7,943
Stock options and other	2,297	2,114
Total gross deferred tax assets	96,584	91,159
Valuation allowance for deferred tax assets	(96,584)	(91,159)
Net deferred tax assets	0	0
Valuation allowance
Increase (decrease) in the valuation allowance	$ 5,400	$ 14,400

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of U.S. statutory income tax rate to effective tax rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate
Federal income tax at statutory rate (as a percent)	21%	21%	21%
State income tax benefit, net of federal benefit (as a percent)	0.10%	0.20%	1%
Unrealized gain on warrants	18.80%	1.10%
Research and development tax credits (as a percent)	0.10%	0.20%	0.70%
Other (as a percent)	(5.60%)	(2.20%)	(2.00%)
Increase to valuation allowance (as a percent)	(18.50%)	(20.30%)	(20.70%)
Effective income tax rate (as a percent)	15.90%	0%	0%

Income Taxes - Sale of New Jers

Income Taxes - Sale of New Jersey Net Operating Losses (Details) - New Jersey - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Jan. 31, 2021	Jan. 31, 2018	Dec. 31, 2022	Mar. 31, 2022
Sale of New Jersey Net Operating Losses
Net proceeds from sale of NOL and tax credit			$ 4.7
Sale of unused NOLs
Sale of New Jersey Net Operating Losses
Maximum lifetime benefit under the Program	$ 20	$ 15
Sale of unused NOLs | Minimum
Sale of New Jersey Net Operating Losses
Allowable sale of unused tax benefits as a percentage of total value		80%
Net Operating Losses
Sale of New Jersey Net Operating Losses
NOLs				$ 44.3
Research and Development.
Sale of New Jersey Net Operating Losses
NOLs				$ 1

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2020	Dec. 31, 2022
Commitments and Contingencies
Future purchase commitments		$ 238.2
Corium Agreement [Member]
Commitments and Contingencies
Quarterly minimum volume amount of product to be ordered	$ 5.6
Additional fee payable as a percentage of transfer price for units ordered	25%
Percentage of additional fee as penalty percent		25%
Reminder 2022		$ 5.3
2023		7
2024 and Each Year Thereafter		$ 22.5

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) - Balance Sheets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Current assets:
Cash and cash equivalents	$ 5,246	$ 19,143	$ 6,145	$ 13,027	$ 3,743
Accounts receivable, net	3,377	1,533	3,711	2,087	1,665
Income taxes receivable					4,675
Inventory, net	1,332	966	1,797	2,340	2,693
Prepaid expenses and other current assets	1,403	2,283	3,834	1,016	1,576
Total current assets	11,358	23,925	15,487	18,470	14,352
Property and equipment, net	177	12,447	203	11,524	12,047
Right of use asset	695	949	761	825	888
Other non-current assets	2,012	2,012	2,012	2,012	2,012
Total assets	14,242	39,333	18,463	32,831	29,299
Current liabilities:
Long-term debt, current portion	1,426	16,833	1,318	12,630	12,252
Accounts payable	7,734	8,707	4,906	12,036	9,537
Accrued expenses	3,908	3,563	5,152	3,877	3,828
Lease liability, current portion	319	175	277	239	231
Total current liabilities	13,387	29,278	11,653	28,782	25,848
Lease liabilities, long-term	466	784	550	630	708
Warrant liability	5,934	5,356	9,285	1,050	8,101
Total liabilities	19,787	35,418	21,488	30,462	34,657
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021
Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued and outstanding at December 31, 2022 and December 31, 2021, respectively	4		4	1
Additional paid-in capital	403,153	387,205	401,744	401,211	388,317
Accumulated deficit	(408,702)	(383,290)	(404,773)	(398,843)	(393,675)
Total stockholders' equity	(5,545)	3,915	(3,025)	2,369	(5,358)	$ 49,328	$ 45,745
Total liabilities and stockholders' equity	$ 14,242	$ 39,333	18,463	32,831	29,299
Reverse stock split conversion ratio	0.025	0.025
As Previously Reported | Error Correction, Accounting for Warrants
Current assets:
Cash and cash equivalents		$ 19,143	6,145	13,027	3,743
Accounts receivable, net		1,533	3,711	2,087	1,665
Income taxes receivable					4,675
Inventory, net		966	1,797	2,340	2,693
Prepaid expenses and other current assets		2,283	3,834	1,016	1,576
Total current assets		23,925	15,487	18,470	14,352
Property and equipment, net		12,447	203	11,524	12,047
Right of use asset		949	761	825	888
Other non-current assets		2,012	2,012	2,012	2,012
Total assets		39,333	18,463	32,831	29,299
Current liabilities:
Long-term debt, current portion		16,833	1,318	12,630	12,252
Accounts payable		8,707	4,906	12,036	9,537
Accrued expenses		3,563	5,152	3,877	3,828
Lease liability, current portion		175	277	239	231
Total current liabilities		29,278	11,653	28,782	25,848
Lease liabilities, long-term		784	550	630	708
Total liabilities		30,062	12,203	29,412	26,556
Stockholders' equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021					887
Common stock, $.0001 par value, 300,000,000 shares authorized, 42,970,134 and 3,034,901 issued and outstanding at December 31, 2022 and December 31, 2021, respectively			4	1
Additional paid-in capital		396,388	437,027	414,523	400,742
Accumulated deficit		(387,117)	(430,771)	(411,105)	(398,886)
Total stockholders' equity		9,271	6,260	3,419	2,743	$ 49,328
Total liabilities and stockholders' equity		39,333	18,463	32,831	29,299
Error Correction, Adjustment | Error Correction, Accounting for Warrants
Current liabilities:
Warrant liability		5,356	9,285	1,050	8,101
Total liabilities		5,356	9,285	1,050	8,101
Stockholders' equity
Preferred stock, $.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2022 and no shares issued and outstanding at December 31, 2021					(887)
Additional paid-in capital		(9,183)	(35,283)	(13,312)	(12,425)
Accumulated deficit		3,827	25,998	12,262	5,211
Total stockholders' equity		$ (5,356)	$ (9,285)	$ (1,050)	$ (8,101)

Quarterly Financial Informati_4

Quarterly Financial Information (Unaudited) - Balance Sheets - Other (Details) - $ / shares	Dec. 31, 2022	Jan. 07, 2022	Jan. 06, 2022	Dec. 31, 2021	Jan. 06, 2020
Quarterly Financial Information (Unaudited)
Preferred stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Preferred stock, authorized (in shares)	10,000,000			10,000,000
Preferred stock, issued (in shares)	4,850			0
Preferred stock, outstanding (in shares)	0			0
Common stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Common stock, authorized (in shares)	300,000,000	300,000,000	150,000,000	300,000,000	300,000,000
Common stock, issued (in shares)	42,970,134			3,034,901
Common stock, outstanding (in shares)	42,970,134			3,034,901

Quarterly Financial Informati_5

Quarterly Financial Information (Unaudited) - Statements of Operations and Comprehensive Loss (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues, net	$ 3,002	$ 2,126	$ 1,761	$ 3,887	$ 6,888	$ 10,884	$ 4,101	$ 749
Cost of product revenues	1,425	2,231	1,527	3,758	5,183	6,836	10,718	282
Gross profit (loss)	1,577	(105)	234	129	1,705	4,048	(6,617)	467
Operating expenses:
Research and development	788	856	1,257	2,113	2,901	3,253	6,246	13,500
Selling and marketing	5,560	7,411	10,553	17,964	23,523	30,369	43,444	23,285
General and administrative	2,815	3,026	3,997	7,023	9,837	11,860	14,698	12,735
Loss on disposition of assets	11,122				11,122	11,122
Total operating expenses	20,285	11,293	15,807	27,100	47,383	56,604	64,388	49,520
Loss from operations	(18,708)	(11,398)	(15,573)	(26,971)	(45,678)	(52,556)	(71,005)	(49,053)
Other income (expense)
Interest income	46	2	1	3	50	80	25	309
Interest expense	(1,004)	(823)	(872)	(1,695)	(2,699)	(3,131)	(3,914)	(3,109)
Unrealized gain on warrant liability	13,736	7,051	1,384	8,435	22,171	25,520	3,827
Total other income (expense), net	12,778	6,230	513	6,743	19,522	22,469	(62)	(2,800)
Loss before benefit from income taxes	(5,930)	(5,168)	(15,060)	(20,228)	(26,156)	(30,087)	(71,067)	(51,853)
Benefit from income taxes			4,675	4,675	4,675	4,675
Net loss	$ (5,930)	$ (5,168)	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Net loss per share (basic) (in dollars per share)	$ (0.16)	$ (1.15)	$ (3.33)	$ (4.08)	$ (1.43)	$ (1.18)	$ (29.28)	$ (24.40)
Net loss per share (diluted) (in dollars per share)	$ (0.16)	$ (1.15)	$ (3.33)	$ (4.08)	$ (1.43)	$ (1.18)	$ (29.28)	$ (24.40)
Weighted-average common shares (basic) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534	21,610,947	2,426,821	2,117,077
Weighted-average common shares (diluted) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534	21,610,947	2,426,821	2,117,077
Comprehensive loss:
Net loss	$ (5,930)	$ (5,168)	$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Other comprehensive income:
Unrealized (loss) gain on marketable securities							(3)	3
Comprehensive loss	(5,930)	(5,168)	(10,385)	(15,553)	(21,481)	$ (25,412)	(71,070)	$ (51,850)
Error Correction, Accounting for Warrants | As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Revenues, net	3,002	2,126	1,761	3,887	6,888		4,101
Cost of product revenues	1,425	2,231	1,527	3,758	5,183		10,718
Gross profit (loss)	1,577	(105)	234	129	1,705		(6,617)
Operating expenses:
Research and development	788	856	1,257	2,113	2,901		6,246
Selling and marketing	5,560	7,411	10,553	17,964	23,523		43,444
General and administrative	2,815	3,026	3,997	7,023	9,837		14,698
Loss on disposition of assets	11,122				11,122
Total operating expenses	20,285	11,293	15,807	27,100	47,383		64,388
Loss from operations	(18,708)	(11,398)	(15,573)	(26,971)	(45,678)		(71,005)
Other income (expense)
Interest income	46	2	1	3	50		25
Interest expense	(1,004)	(823)	(872)	(1,695)	(2,699)		(3,914)
Total other income (expense), net	(958)	(821)	(871)	(1,692)	(2,649)		(3,889)
Loss before benefit from income taxes	(19,666)	(12,219)	(16,444)	(28,663)	(48,327)		(74,894)
Benefit from income taxes			4,675	4,675	4,675
Net loss	$ (19,666)	$ (12,219)	$ (11,769)	$ (23,988)	$ (43,652)		$ (74,894)
Net loss per share (basic) (in dollars per share)	$ (0.53)	$ (2.71)	$ (3.78)	$ (6.29)	$ (2.91)		$ (30.86)
Net loss per share (diluted) (in dollars per share)	$ (0.53)	$ (2.71)	$ (3.78)	$ (6.29)	$ (2.91)		$ (30.86)
Weighted-average common shares (basic) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Weighted-average common shares (diluted) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Comprehensive loss:
Net loss	$ (19,666)	$ (12,219)	$ (11,769)	$ (23,988)	$ (43,652)		$ (74,894)
Other comprehensive income:
Unrealized (loss) gain on marketable securities							(3)
Comprehensive loss	(19,666)	(12,219)	(11,769)	(23,988)	(43,652)		(74,897)
Error Correction, Accounting for Warrants | Error Correction, Adjustment
Other income (expense)
Unrealized gain on warrant liability	13,736	7,051	1,384	8,435	22,171		3,827
Total other income (expense), net	13,736	7,051	1,384	8,435	22,171		3,827
Loss before benefit from income taxes	13,736	7,051	1,384	8,435	22,171		3,827
Net loss	$ 13,736	$ 7,051	$ 1,384	$ 8,435	$ 22,171		$ 3,827
Net loss per share (basic) (in dollars per share)	$ 0.37	$ 1.56	$ 0.44	$ 2.21	$ 1.48		$ 1.58
Net loss per share (diluted) (in dollars per share)	$ 0.37	$ 1.56	$ 0.44	$ 2.21	$ 1.48		$ 1.58
Weighted-average common shares (basic) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Weighted-average common shares (diluted) (in shares)	36,997,836	4,510,219	3,115,211	3,816,569	14,998,534		2,426,821
Comprehensive loss:
Net loss	$ 13,736	$ 7,051	$ 1,384	$ 8,435	$ 22,171		$ 3,827
Other comprehensive income:
Comprehensive loss	$ 13,736	$ 7,051	$ 1,384	$ 8,435	$ 22,171		$ 3,827

Quarterly Financial Informati_6

Quarterly Financial Information (Unaudited) - Statements of Changes in Stockholders' Equity (Details)			1 Months Ended			3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Jul. 06, 2022 shares	Apr. 04, 2022 shares	Jul. 31, 2022 USD ($) shares	Oct. 31, 2021 shares	Mar. 31, 2021 shares	Sep. 30, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares	Mar. 31, 2022 USD ($) shares	Jun. 30, 2022 USD ($) shares	Sep. 30, 2022 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Increase (decrease) in stockholders' equity
Balance			$ 2,369,000			$ 2,369,000	$ (5,358,000)	$ 3,915,000	$ 3,915,000	$ 3,915,000	$ 3,915,000	$ 49,328,000	$ 45,745,000
Share-based compensation - stock options and RSUs							669,000	764,000			2,492,000	3,338,000	2,818,000
Issuance of common stock upon exercise of options												75,000	610,000
Unrealized net gain on marketable securities												(3,000)	3,000
Net loss						(5,930,000)	(5,168,000)	(10,385,000)	(15,553,000)	(21,481,000)	(25,412,000)	(71,067,000)	(51,853,000)
Balance						(3,025,000)	$ 2,369,000	$ (5,358,000)	$ 2,369,000	$ (3,025,000)	$ (5,545,000)	$ 3,915,000	$ 49,328,000
Reverse stock split conversion ratio											0.025	0.025
Preferred Stock
Increase (decrease) in stockholders' equity
Balance (in shares) | shares							2,425
Balance (in shares) | shares								2,425
Common stock
Increase (decrease) in stockholders' equity
Balance			$ 1,000			$ 1,000
Balance (in shares) | shares			12,360,157			12,360,157	3,365,422	3,034,901	3,034,901	3,034,901	3,034,901	2,189,100	1,745,264
Fractional shares retired as a result of reverse split | shares							(10)				(11)
Issuance of common stock upon exercise of options (in shares) | shares												3,160	12,586
Conversion of convertible preferred stock (in shares) | shares		303,125
Vesting of RSUs (in shares) | shares							4,118	1,773			6,555	3,096
Balance						$ 4,000	$ 1,000		$ 1,000	$ 4,000	$ 4,000
Balance (in shares) | shares						39,026,823	12,360,157	3,365,422	12,360,157	39,026,823	42,970,134	3,034,901	2,189,100
Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Balance			$ 401,211,000			$ 401,211,000	$ 388,317,000	$ 387,205,000	$ 387,205,000	$ 387,205,000	$ 387,205,000	$ 361,548,000	$ 306,115,000
Share-based compensation - stock options and RSUs						536,000	669,000	764,000			2,492,000	3,338,000	2,818,000
Issuance of common stock upon exercise of options												75,000	610,000
Balance						401,744,000	401,211,000	388,317,000	401,211,000	401,744,000	403,153,000	387,205,000	361,548,000
Accumulated Other Comprehensive Income
Increase (decrease) in stockholders' equity
Balance												3,000
Unrealized net gain on marketable securities												(3,000)	3,000
Balance													3,000
Accumulated Deficit
Increase (decrease) in stockholders' equity
Balance			$ (398,843,000)			(398,843,000)	(393,675,000)	(383,290,000)	(383,290,000)	(383,290,000)	(383,290,000)	(312,223,000)	(260,370,000)
Net loss							(5,168,000)	(10,385,000)			(25,412,000)	(71,067,000)	(51,853,000)
Balance							(398,843,000)	$ (393,675,000)	(398,843,000)		$ (408,702,000)	(383,290,000)	(312,223,000)
Series A Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock (in shares) | shares								(2,425)			(2,425)
Series A Convertible Preferred Stock | Common stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock (in shares) | shares								303,125			303,125
Series B Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock							$ (2,425)
Conversion of convertible preferred stock (in shares) | shares											(2,425)
Series B Convertible Preferred Stock | Common stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock (in shares) | shares							303,125				303,125
Series A and B Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock (in shares) | shares								4,850			4,850
Public offering
Increase (decrease) in stockholders' equity
Issuance of common stock											$ 3,000	$ 11,898,000	$ 48,435,000
Issuance of common stock (in shares) | shares	7,518,334		7,518,334
Public offering | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock											$ 3,000
Issuance of common stock (in shares) | shares	19,148,332		19,148,332	666,666							26,666,666	666,666	431,250
Public offering | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock												$ 11,898,000	$ 48,435,000
At-the-market sales
Increase (decrease) in stockholders' equity
Issuance of common stock							$ 12,226,000	$ 348,000			$ 13,457,000	$ 9,266,000
At-the-market sales | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock						$ 3,000	$ 1,000				$ 1,000
Issuance of common stock (in shares) | shares					172,879	26,666,666	8,687,502	25,623			12,655,773	172,879
At-the-market sales | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock						$ (3,000)	$ 12,225,000	$ 348,000			$ 13,456,000	$ 9,266,000
Error Correction, Accounting for Warrants | As Previously Reported
Increase (decrease) in stockholders' equity
Balance			$ 3,419,000			3,419,000	2,743,000	9,271,000	9,271,000	9,271,000	$ 9,271,000	49,328,000
Share-based compensation - stock options and RSUs							669,000	764,000				3,338,000
Issuance of common stock							12,226,000
Issuance of common stock upon exercise of options												75,000
Registered direct financing costs, inclusive of warrants								(721,000)
Unrealized net gain on marketable securities												(3,000)
Net loss						(19,666,000)	(12,219,000)	(11,769,000)	(23,988,000)	(43,652,000)		(74,894,000)
Balance						6,260,000	3,419,000	2,743,000	$ 3,419,000	$ 6,260,000		$ 9,271,000	$ 49,328,000
Error Correction, Accounting for Warrants | As Previously Reported | Preferred Stock
Increase (decrease) in stockholders' equity
Balance							$ 887,000
Balance (in shares) | shares							2,425
Registered direct financing costs, inclusive of warrants								(965,000)
Warrants issued in connection with registered direct offering								(2,101,000)
Balance								$ 887,000
Balance (in shares) | shares								2,425
Error Correction, Accounting for Warrants | As Previously Reported | Common stock
Increase (decrease) in stockholders' equity
Balance			$ 1,000			$ 1,000
Balance (in shares) | shares			12,360,157			12,360,157	3,365,422	3,034,901	3,034,901	3,034,901	3,034,901	2,189,100
Fractional shares retired as a result of reverse split | shares							(10)
Issuance of common stock							$ 1,000
Issuance of common stock (in shares) | shares							8,687,502
Issuance of common stock upon exercise of options (in shares) | shares												3,160
Vesting of RSUs (in shares) | shares							4,118	1,773				3,096
Balance						$ 4,000	$ 1,000		$ 1,000	$ 4,000
Balance (in shares) | shares						39,026,823	12,360,157	3,365,422	12,360,157	39,026,823		3,034,901	2,189,100
Error Correction, Accounting for Warrants | As Previously Reported | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Balance			$ 414,523,000			$ 414,523,000	$ 400,742,000	$ 396,388,000	$ 396,388,000	$ 396,388,000	$ 396,388,000	$ 361,548,000
Share-based compensation - stock options and RSUs						536,000	669,000	764,000				3,338,000
Issuance of common stock							12,225,000
Issuance of common stock upon exercise of options												75,000
Registered direct financing costs, inclusive of warrants								244,000
Warrants issued in connection with registered direct offering								2,101,000
Balance						437,027,000	414,523,000	400,742,000	414,523,000	437,027,000		396,388,000	$ 361,548,000
Error Correction, Accounting for Warrants | As Previously Reported | Accumulated Other Comprehensive Income
Increase (decrease) in stockholders' equity
Balance												3,000
Unrealized net gain on marketable securities												(3,000)
Balance													3,000
Error Correction, Accounting for Warrants | As Previously Reported | Accumulated Deficit
Increase (decrease) in stockholders' equity
Balance			(411,105,000)			(411,105,000)	(398,886,000)	(387,117,000)	(387,117,000)	(387,117,000)	(387,117,000)	(312,223,000)
Net loss							(12,219,000)	(11,769,000)				(74,894,000)
Balance							(411,105,000)	(398,886,000)	(411,105,000)			(387,117,000)	$ (312,223,000)
Error Correction, Accounting for Warrants | As Previously Reported | Series A Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								$ (897,000)
Conversion of convertible preferred stock (in shares) | shares								(2,425)
Error Correction, Accounting for Warrants | As Previously Reported | Series A Convertible Preferred Stock | Common stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock (in shares) | shares								303,125
Error Correction, Accounting for Warrants | As Previously Reported | Series A Convertible Preferred Stock | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								$ 897,000
Error Correction, Accounting for Warrants | As Previously Reported | Series B Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock							$ (887,000)
Conversion of convertible preferred stock (in shares) | shares							(2,425)
Error Correction, Accounting for Warrants | As Previously Reported | Series B Convertible Preferred Stock | Common stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock (in shares) | shares							303,125
Error Correction, Accounting for Warrants | As Previously Reported | Series B Convertible Preferred Stock | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock							$ 887,000
Error Correction, Accounting for Warrants | As Previously Reported | Series A and B Convertible Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								4,850,000
Error Correction, Accounting for Warrants | As Previously Reported | Series A and B Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								$ 4,850,000
Conversion of convertible preferred stock (in shares) | shares								4,850
Error Correction, Accounting for Warrants | As Previously Reported | Public offering
Increase (decrease) in stockholders' equity
Issuance of common stock												$ 21,081,000
Error Correction, Accounting for Warrants | As Previously Reported | Public offering | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock (in shares) | shares												666,666
Error Correction, Accounting for Warrants | As Previously Reported | Public offering | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock												$ 21,081,000
Error Correction, Accounting for Warrants | As Previously Reported | At-the-market sales
Increase (decrease) in stockholders' equity
Issuance of common stock								$ 348,000				$ 9,266,000
Error Correction, Accounting for Warrants | As Previously Reported | At-the-market sales | Common stock
Increase (decrease) in stockholders' equity
Issuance of common stock						$ 3,000
Issuance of common stock (in shares) | shares						26,666,666		25,623				172,879
Error Correction, Accounting for Warrants | As Previously Reported | At-the-market sales | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock						$ 21,968,000		$ 348,000				$ 9,266,000
Error Correction, Accounting for Warrants | Error Correction, Adjustment
Increase (decrease) in stockholders' equity
Balance			(1,050,000)			(1,050,000)	(8,101,000)	$ (5,356,000)	$ (5,356,000)	$ (5,356,000)	$ (5,356,000)
Balance (in shares) | shares								(5,356,000)	(5,356,000)	(5,356,000)	(5,356,000)
Registered direct financing costs, inclusive of warrants								$ 721,000
Net loss						13,736,000	7,051,000	1,384,000	$ 8,435,000	$ 22,171,000		3,827,000
Balance						(9,285,000)	(1,050,000)	(8,101,000)	(1,050,000)	(9,285,000)		$ (5,356,000)
Balance (in shares) | shares												(5,356,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Preferred Stock
Increase (decrease) in stockholders' equity
Balance							(887,000)
Registered direct financing costs, inclusive of warrants								965,000
Warrants issued in connection with registered direct offering								2,101,000
Balance								(887,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Balance			(13,312,000)			(13,312,000)	(12,425,000)	$ (9,183,000)	$ (9,183,000)	$ (9,183,000)	$ (9,183,000)
Balance (in shares) | shares								(9,183,000)	(9,183,000)	(9,183,000)	(9,183,000)
Registered direct financing costs, inclusive of warrants								$ (244,000)
Warrants issued in connection with registered direct offering								(2,101,000)
Balance						(35,283,000)	(13,312,000)	(12,425,000)	$ (13,312,000)	$ (35,283,000)		$ (9,183,000)
Balance (in shares) | shares												(9,183,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Accumulated Deficit
Increase (decrease) in stockholders' equity
Balance			$ 12,262,000			12,262,000	5,211,000	$ 3,827,000	$ 3,827,000	$ 3,827,000	$ 3,827,000
Balance (in shares) | shares								3,827,000	3,827,000	3,827,000	3,827,000
Net loss							7,051,000	$ 1,384,000				$ 3,827,000
Balance							12,262,000	5,211,000	$ 12,262,000			$ 3,827,000
Balance (in shares) | shares												3,827,000
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Series A Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								897,000
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Series A Convertible Preferred Stock | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								(897,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Series B Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock							887,000
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Series B Convertible Preferred Stock | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock							$ (887,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Series A and B Convertible Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								(4,850,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Series A and B Convertible Preferred Stock | Preferred Stock
Increase (decrease) in stockholders' equity
Conversion of convertible preferred stock								$ (4,850,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Public offering
Increase (decrease) in stockholders' equity
Issuance of common stock												$ (9,183,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | Public offering | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock												$ (9,183,000)
Error Correction, Accounting for Warrants | Error Correction, Adjustment | At-the-market sales | Additional Paid in Capital.
Increase (decrease) in stockholders' equity
Issuance of common stock						$ (21,971,000)

Quarterly Financial Informati_7

Quarterly Financial Information (Unaudited) - Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss		$ (10,385)	$ (15,553)	$ (21,481)	$ (25,412)	$ (71,067)	$ (51,853)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash inventory reserve						5,323
Depreciation		527	1,057	1,255	1,280	2,064	105
Amortization		61	124	188	254	159	171
Loss on disposition of assets	$ 11,122			11,122	11,122
Noncash stock-based compensation		764	1,433	1,969	2,493	3,338	2,818
Noncash amortization of deferred financing costs		419	797	1,635	1,969	1,661	1,341
Unrealized gain on warrants		(1,384)	(8,435)	(22,171)	(25,520)	(3,827)
Changes in operating assets and liabilities:
Accounts receivable		(132)	(554)	(2,178)	(1,844)	(668)	(865)
Income taxes receivable		(4,675)
Inventory		(1,727)	(1,374)	(831)	(366)	(6,289)
Prepaid expenses and other assets		707	1,267	(1,551)	880	(967)	(2,485)
Accounts payable and accrued expenses		1,095	3,643	(2,213)	(628)	5,202	3,641
Lease liability		(21)	(90)	(132)	(175)	(131)	(184)
Net cash used in operating activities		(14,751)	(17,685)	(34,388)	(35,947)	(65,202)	(47,311)
Cash flows from investing activities:
Purchases of marketable securities							(54,837)
Sales and maturities of marketable securities						39,729	14,500
Acquisition of property and equipment		(126)	(133)	(133)	(133)	(269)	(353)
Net cash provided by investing activities		(126)	(133)	(133)	(133)	39,460	(40,690)
Cash flows from financing activities:
Proceeds from issuance of common stock in public offering, net of offering costs				21,971	21,936	21,081	48,434
Proceeds from Issuance of Long-term Debt							20,000
Repayments of long-term debt		(5,000)	(5,000)	(17,150)	(17,375)
Debt financing costs paid							(1,059)
Proceeds from exercise of stock options						75	610
Net cash provided by financing activities		(523)	11,702	21,523	22,183	30,422	67,985
Net (decrease) increase in cash and cash equivalents		(15,400)	(6,116)	(12,998)	(13,897)	4,680	(20,016)
Cash and cash equivalents, beginning of period	13,027	19,143	19,143	19,143	19,143	14,463	34,479
Cash and cash equivalents, end of period	6,145	3,743	13,027	6,145	5,246	19,143	14,463
Supplemental cash flow information
Interest paid		452	898	1,078	1,162	2,383	2,099
As Previously Reported | Error Correction, Accounting for Warrants
Cash flows from operating activities:
Net loss		(11,769)	(23,988)	(43,652)		(74,894)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash inventory reserve						5,323
Depreciation		527	1,057	1,255		2,064
Amortization		61	124	188		159
Loss on disposition of assets	11,122			11,122
Noncash stock-based compensation		764	1,433	1,969		3,338
Noncash amortization of deferred financing costs		419	797	1,635		1,661
Changes in operating assets and liabilities:
Accounts receivable		(132)	(554)	(2,178)		(668)
Income taxes receivable		(4,675)
Inventory		(1,727)	(1,374)	(831)		(6,289)
Prepaid expenses and other assets		707	1,267	(1,551)		(967)
Accounts payable and accrued expenses		1,095	3,643	(2,213)		5,202
Lease liability		(21)	(90)	(132)		(131)
Net cash used in operating activities		(14,751)	(17,685)	(34,388)		(65,202)
Cash flows from investing activities:
Sales and maturities of marketable securities						39,729
Acquisition of property and equipment		(126)	(133)	(133)		(269)
Net cash provided by investing activities		(126)	(133)	(133)		39,460
Cash flows from financing activities:
Proceeds from issuance of common stock in public offering, net of offering costs				21,971		21,081
Repayments of long-term debt		(5,000)	(5,000)	(17,150)
Proceeds from exercise of stock options						75
Net cash provided by financing activities		(523)	11,702	21,523		30,422
Net (decrease) increase in cash and cash equivalents		(15,400)	(6,116)	(12,998)		4,680
Cash and cash equivalents, beginning of period	13,027	19,143	19,143	19,143	19,143	14,463
Cash and cash equivalents, end of period	$ 6,145	3,743	13,027	6,145		19,143	$ 14,463
Supplemental cash flow information
Interest paid		452	898	1,078		2,383
Error Correction, Adjustment | Error Correction, Accounting for Warrants
Cash flows from operating activities:
Net loss		1,384	8,435	22,171		3,827
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized gain on warrants		(1,384)	(8,435)	(22,171)		(3,827)
Public offering
Cash flows from financing activities:
Proceeds from issuance of preferred stock in registered direct offering, net of offering costs		4,129	4,129	4,129	4,128
Public offering | As Previously Reported | Error Correction, Accounting for Warrants
Cash flows from financing activities:
Proceeds from issuance of preferred stock in registered direct offering, net of offering costs		4,129	4,129	4,129
At-the-market sales
Cash flows from financing activities:
Proceeds from At-the-Market sales of common stock, net of offering costs		348	12,573	12,573	$ 13,494	9,266
At-the-market sales | As Previously Reported | Error Correction, Accounting for Warrants
Cash flows from financing activities:
Proceeds from At-the-Market sales of common stock, net of offering costs		$ 348	$ 12,573	$ 12,573		$ 9,266

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent event - Series C Preferred Stock [Member]	Jan. 25, 2023 Vote $ / shares
Subsequent Event [Line Items]
Preferred Stock, Dividends Per Share, Declared | $ / shares	$ 0.001
Preferred Stock, Votes Per Whole Share | Vote	1,000,000